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ABSTRACT 
 
The development of safe and effective antipyretic and anti-inflammatory drugs remains an 
important focus of the pharmacological industry. Despite reports that rectal thermometry 
causes stress-induced hyperthermia in rodents, it remains the most commonly used method for 
measuring core body temperature during antipyretic drug-testing. The impact of the stress-
induced hyperthermia on the accuracy and reliability of thermal responses reported in 
pharmacological studies investigating the efficacy of antipyretic drugs remains unclear. 
Additionally, the sickness response to Brewer’s yeast, the pyrogen recommended for inducing 
fever during antipyretic testing, remains largely uncharacterised and its mechanisms unknown.  
 
I used intra-abdominally implanted temperature-sensitive radiotelemeters to measure changes 
in the abdominal temperature of both normothermic and febrile rats injected with Brewer’s 
yeast, and exposed to rectal temperature measurement at hourly intervals for five hours. My 
results show that rectal temperature measurement is associated with a reproducible, non-
decremental rise in abdominal temperature (0.6 - 0.8 °C) in normothermic rats. The 
hyperthermia was muted in febrile rats and was not blunted by the common habituation 
procedure. A comparison of temperatures measured using rectal thermometry with those 
measured using biotelemetry showed that rectal temperatures recorded using a thermocouple 
probe could be up to 0.5 °C lower or 0.7 °C greater than abdominal temperatures recorded 
using an abdominally implanted telemeter. The differences in thermal responses exhibited by 
normothermic vs febrile rats, coupled with the under- or overestimation of core body 
temperatures when one uses thermocouple probes supports my hypothesis that the procedure 
of rectal thermometry may affect the accuracy of thermal responses observed during antipyretic 
drug-testing.   
 
Having examined the methods used for temperature measurement, my second objective was to 
characterise the sickness response to the recommended and commonly used pyrogen for 
antipyretic screening; Saccharomyces cerevisiae (Brewer’s yeast). I measured the change in 
abdominal temperature, nocturnal activity, food intake and body mass gain in male Sprague 
Dawley rats injected subcutaneously with one of three doses of Brewer’s yeast (0.4, 0.2 and 4 
g/kg). I further characterised the spatiotemporal activation of inflammatory mediators in the 
periphery (tumor necrosis factor alpha and interleukin (IL)-6) and in the brain (nuclear factor 
 vii 
(NF) for interleukin 6, NF-kB, cyclooxygenase-2 (COX-2) and the signal transducer and 
activator of transcription (STAT)-3 in the vascular organ of the lamina terminalis (OVLT). 
Lastly, I measured the expression of hypothalamic inflammatory genes including: cytokines 
(IL-1b, IL-6, TNF-a), enzymes (COX-2 and microsomal prostaglandin synthase (mPGES)) 
and regulators of transcription factors (NF-kB inhibitor alpha (IkBa) and suppressor of 
cytokine signalling 3 (SOCS3)). My results show that Brewer’s yeast dose-dependently 
induces fever, lethargy, anorexia and body mass stunting. However, the sickness response to 
the high dose of Brewer’s yeast; the dose commonly used during antipyretic screening, was 
associated with an initial short-lived hypothermia, lengthy fevers, excessive peripheral and 
central inflammation and the development of an abscess.  
 
My last objective was to investigate if zymosan, a cell wall moiety of Brewer’s yeast could be 
used as an alternative pyrogen during antipyretic drug testing. Using the same methods as 
outlined for my second study, I therefore characterised the sickness responses and activation 
of inflammatory mediators associated with subcutaneous injection of two doses of zymosan 
(300 mg/kg and 30 mg/kg). My results show that zymosan dose-dependently induces fever, 
lethargy, anorexia and body mass stunting and that zymosan activates the same suite of 
inflammatory mediators as Brewer’s yeast albeit on a more moderate scale. Thus, zymosan 
could be used as a pyrogen for simulating fungal infections during antipyretic drug testing.  
 
In conclusion, the studies undertaken as part of my PhD have shown that among the methods 
and models currently recommended for use during antipyretic drug testing, rectal thermometry 
is associated with stress and hyperthermia which can potentially affect the accuracy and 
reliability of observations and conclusions drawn on the efficacy of test drugs. Additionally, at 
the recommended doses, Brewer’s yeast induces fever and sickness behaviours albeit with 
undesirable animal welfare challenges such as hypothermia, excessive inflammation and a 
lengthy sickness response due to the development of an abscess. However, zymosan is suitable 
for use as alternative to Brewer’s yeast as it is capable of inducing fever, sickness behaviours 
and inflammation of a moderate magnitude, which would allow pharmacological interventions 
without inducing animal suffering related to an excessive and prolonged inflammation.  
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PREFACE 
 
Humans are constantly and unavoidably exposed to various disease-causing microorganisms, 
which include bacteria, viruses, fungi and protozoa. In order to improve our chances of 
survival, we have an in-built immune system, which fights these microorganisms. Natural and 
non-specific barriers including the skin, mucous membranes and various secretions such as 
earwax, tears and stomach acid strategically fight the entry of these potentially harmful 
microorganisms at all possible points of entry. In the event that these barriers are breached, the 
microorganisms encounter a second line of defence comprising a group of proteins and 
phagocytic cells that are activated to neutralize the invading pathogen and, most importantly, 
to inform the body about the presence of these unwanted and potentially life-threatening 
invaders. Normally, a local inflammatory response is triggered, which is characterised by pain, 
redness, heat and swelling at the site of infection. Through specialized inflammatory mediators, 
the immune system also communicates with the brain, the higher command-centre for 
controlling body function and behaviour, to adjust bodily function in accordance with the 
presence of the unwanted pathogens.  
 
Upon receiving input from the immune system, the brain initiates a set of physiological, 
metabolic and behavioural responses which commonly include fever and sickness behaviour 
(a collection of non-specific signs of sickness including tiredness, loss of motivation, anorexia 
and depression-like behaviour). Although fever and sickness behaviour are generally regarded 
as beneficial, an excessively prolonged and exaggerated sickness response may negatively 
impact on our quality of life and often drives us to seek relief, usually in the form of antipyretic 
drugs. Since antiquity, mankind has used antipyretic plants such as the willow to deal with 
inflammation, fever and sickness. Today, several highly effective antipyretic drugs have been 
developed, albeit with some exhibiting undesirable side effects. Pharmaceutical companies and 
scientists, therefore, continue to search for safe but effective drugs and, most importantly, for 
better methods and models of testing antipyretic drugs.  
 
The main aim of this thesis was therefore to systematically characterise and validate the current 
methods and models that are used in testing antipyretic drugs. In Chapter 1, I review literature 
on the studies that have thus far described the methods and pyrogens used in testing the efficacy 
and mechanisms of action of antipyretic drugs. In Chapter 2, I compare the two methods 
commonly used for measuring temperature during antipyretic testing; rectal thermometry and 
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biotelemetry. Chapter 3 investigates the sickness and inflammatory responses induced by 
subcutaneously injecting rats with Brewer’s yeast, the pyrogen that is recommended for use 
during antipyretic drug testing. In Chapter 4, I investigate whether zymosan, a moiety of 
Brewer’s yeast can be used as an alternative pyrogen to the highly potent Brewer’s yeast. The 
experimental findings presented in my thesis chapters, limitations of my study and 
recommendations for future studies are summarized and discussed in the concluding chapter, 
Chapter 5.  
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1. CHAPTER ONE - INTRODUCTION 
 
 
 
 
 
  
 2 
The innate immune system comprises of physical and chemical barriers and specialized, 
non-specific phagocytic cells (e.g. macrophages, natural killer cells, neutrophils and 
dendritic cells) which are the body’s first line of defence and resistance against invading 
pathogens (Parham, 2014). Activation of the innate immune system is often accompanied 
by an inflammatory response and an increase in the circulating levels of chemical 
messengers e.g. cytokines, leukotrienes and prostaglandins, which are mediators of the 
body’s defensive response to infection. Circulating inflammatory mediators activate 
changes in the chemical milieu of the brain which trigger the development of 
physiological responses e.g. fever as well as behavioural responses such as lethargy, 
depression, loss of appetite, pain, somnolence which are collectively known as sickness 
behaviour (Kelley et al., 2003, Kent et al., 1988, Dantzer, 2004). Fever and sickness 
behaviour collectively form the sickness response or sickness syndrome, which is a 
crucial part of the host immune defence against infection (Hart, 1988).  
 
Although now known to be a strategic and necessary part of the body’s defence against 
invading pathogens, the sickness response is often paradoxically associated with 
discomfort and a temporary reduction in the quality of life and productivity that most 
would rather do without. Common practice is to therefore prescribe antipyretic and anti-
inflammatory drugs that reduce the magnitude of the inflammatory response and attenuate 
the fever and sickness behaviour. Most antipyretic and anti-inflammatory drugs inhibit 
the production of various inflammatory mediators such as prostaglandins (Vane and 
Botting, 2003, Vane, 1971, Anderson, 2008). Other mechanisms include inhibiting non-
prostaglandin dependent processes such as neutrophil migration, inhibiting the 
production of other inflammatory mediators (e.g. cytokines) and enhancing the 
production of anti-inflammatory signals [see Aronoff and Neilson (2001) for review].  
 
Over the past century, the demand for antipyretic drugs such as aspirin and paracetamol, 
as common household drugs, has significantly grown and the pharmaceutical industry 
continues searching for new drugs that will be cheaper and more effective. Despite recent 
technological advances, the methods and models used for testing antipyretic drugs have 
not changed much over the past almost 100 years and the mechanisms underlying the 
sickness response induced by the pyrogen recommended for inducing fever during 
antipyretic testing remain largely uncharacterised.  
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This introductory chapter summarizes the development of fever and sickness behaviour 
following infection and the use of antipyretic drugs to alleviate the maladaptive symptoms 
of this sickness response. I then review the current methods and models used in testing 
antipyretic drugs and reveal gaps in our knowledge, which will be addressed by the 
experiments described in this thesis. 
 
1.1 The classical mechanisms known to mediate fever and sickness behaviours 
 
1.1.1 Pathogen recognition 
 
The entry of an exogenous pyrogen into the body is immediately detected by non-specific, 
phagocytic cells of the innate immune system. These cells express pattern recognition 
receptors (PRRs), e.g. toll like receptors (TLRs) and C-type lectin receptors (CLRs), 
which allow for the identification of structures that are conserved in microbial species, 
commonly known as pathogen associated molecular patterns (PAMPs) and damage 
associated molecular patterns (DAMPs) [see (Takeuchi and Akira, 2010) for review]. 
Different PRRs recognize different molecular patterns on microorganisms e.g. TLR2 
forms heterodimers with TLR1 and TLR6 and distinctly recognizes diacyl and triacyl 
lipoproteins from bacterial, mycoplasma and fungal cells (Takeuchi and Akira, 2010) 
while TLR3 recognizes double-stranded viral RNA (Matsumoto and Seya, 2008) and 
TLR4 recognises the Gram-negative bacterial endotoxin lipopolysaccharide (LPS) as 
well as some viral envelope proteins (Lu et al., 2008, Saito and Gale, 2007). The Dectin 
family, a subgroup of CLRs, recognizes carbohydrate molecules, such as glucans, chitins 
and mannans mostly found in fungal microbial species (Saijo and Iwakura, 2011). The 
response of each PRR has been shown to differ depending on the type of ligand that binds, 
as well the type of immune cell that is activated. In general, stimulation of PRRs activates 
the innate immune system and increases the production of inflammatory mediators, such 
as chemotactic factors, interferons, chemokines, acute phase proteins and, cytokines, 
which play a role in the development of fever and sickness behaviour (Takeuchi and 
Akira, 2010, Akira et al., 2006). 
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1.1.2 Pro-inflammatory cytokines 
 
Cytokines are inducible, pleiotropic polypeptide molecules released by 
immunocompetent cells, whose primary function is to regulate and coordinate immune 
responses (Conti et al., 2004, Striz et al., 2014). Although cytokines have been 
extensively studied, we remain far from knowing the dynamics of the full mechanisms 
underlying their function during an immune response to infection, partly due to the 
conflicting descriptions of their biological effects given in literature [for examples see 
(Kawasaki et al., 1989, Leon et al., 1997, Long et al., 1990b, Roth et al., 1998, Töllner et 
al., 2000b, Shachar and Karin, 2013)]. These conflicting findings could be attributed to 
differences in (1) species used (e.g. rats, mice, rabbits, guinea pigs), (2) the nature of the 
exogenous pyrogens administered (e.g. bacterial vs. viral or fungal, and serotypes of each 
microbe, purity of pyrogens etc.) and (3) the routes of administration or the models of 
inflammation used (e.g. acute vs. chronic, systemic vs. local). Moreover, the experimental 
approach for investigating the function of a cytokine is usually to block its release or its 
function and observe how the immune response is altered. However, it remains a 
challenge to fully delineate the individual contribution of each cytokine to the immune 
response or the hierarchical action of a group of cytokines due to cross-inductions and 
compensatory functions exhibited when the blocked cytokine is absent. Be that as it may, 
research has still managed to unravel some of the functions of individual cytokines and 
because some of these cytokines (interleukin-1b, interleukin-6 and tumor necrosis factor-
alpha) are implicated in the sickness responses discussed in Chapters 3 and 4 of this 
thesis, I will briefly discuss their contribution to the development of febrile responses to 
infectious agents. The common inflammatory mediators and pathways activated by each 
of these three cytokines are summarized in Figure 1.1. 
 
1.1.2.1 Interleukin-1b 
 
Interleukin-1b (IL-1b ) is one of the most extensively studied members of the 11-member 
IL-1 family, and is released by immunocompetent cells such as macrophages and 
microglia during infection (Vitkovic et al., 2000). IL-1b binds to the type I IL-1 Receptor 
(IL-1RI) and initiates the transduction of inflammatory signals through the recruitment 
of the myeloid differentiation primary response protein (MyD88), the IL-1 receptor 
 5 
associated kinase (IRAK), the TNF-a-receptor associated factor (TRAF) and subsequent 
activation of the transcription factor nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFkB) (Malinowsky et al., 1995, Jefferies et al., 2001).  
 
 
Figure 1.1: Intracellular signalling pathways activated by the binding of IL-1b, IL-6 and 
TNF-a to their respective receptors on a target cell. IL-1b binds to a membrane-anchored 
IL-1R (mIL-1R) receptor and TNF-α binds to a membrane-bound TNF (mTNFR) 
receptor. Binding of IL-1b and TNF to their respective receptors leads to the dissociation 
of IkBa from NF-kB and the subsequent translocation of NF-kB into the nucleus where 
it activates transcription of genes encoding inflammatory molecules e.g. cyclooxygenase-
2 (COX-2) and microsomal prostaglandin E synthase (mPGES). IL-6 binds to its 
membrane-bound IL-6 receptor (mIL-6R) or alternatively to a soluble IL-6 receptor (not 
shown) which associates with gp130 and activates Janus Kinase (JAK) and the 
subsequent activation, dimerization and nuclear translocation of the signal transducer and 
activator of transcription (STAT) which in turn activates transcription of inflammatory 
genes. The binding of IL-6 also activates the Ras/Mitogen activated protein kinases 
(MAPK) pathway leading to the activation and nuclear translocation of the nuclear factor 
for IL-6 (NF-IL6) and subsequent transcription of inflammatory genes. Through the 
activation of the JAK/phosphadytil inositol -3 Kinase (PI3K) pathway, IL-6 binding also 
activates NF-kB. 
(Figure 1.1 was generated by Rachael Dangarembizi from basic principles of 
intracellular cytokine signalling) 
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When activated, NF-kB dissociates from its inhibitory regulator IkBa and translocates to 
the nucleus where it promotes the transcription of a number of inflammatory genes e.g. 
cytokines, immunoreceptors, enzymes such as cyclooxygenase-2 as well as its inhibitory 
regulator IkBa (Nadjar et al., 2005, Sun et al., 1993). Because inflammatory signals 
activate NF-kB and promote its translocation into the nucleus and subsequent synthesis 
of IkBa, several studies have shown that staining for nuclear NF-kB and monitoring 
IkBa synthesis can serve as useful tools of measuring neuroinflammation (Laflamme and 
Rivest, 1999, Quan et al., 1997). IL-1b also binds to the type II IL-1 Receptor (IL-1RII) 
but this receptor is now known to be a decoy receptor, believed to negatively regulate the 
function of the cytokine (Mantovani et al., 2001).  
 
The pyrogenic effects of IL-1b have been demonstrated in studies showing that fever is 
attenuated or inhibited in: (1) IL-1b knockout mice injected with turpentine (Horai et al., 
1998, Zheng et al., 1995) or LPS (Kozak et al., 1998), and (2) rats injected with IL-1 
receptor antagonist (IL-ra) after injection of the viral mimic, polyinosinic: polycytidylic 
acid (poly I:C) (Fortier et al., 2004, Luheshi et al., 1996) or LPS (Bluthé et al., 1992, 
Long et al., 1990b). Central administration of IL-1b has similarly been shown to mediate 
the development of sickness behaviours e.g. decreased social exploration and anorexia 
(Bluthé et al., 2000b, Bluthe et al., 1994, Harden et al., 2008). Moreover, antagonism of 
IL-1b function, by either administering an antagonist (IL-ra) or by knocking out IL-1RI 
receptors in mice attenuated the development of IL-1b and LPS-induced sickness 
behaviours (Bluthé et al., 1995, Bluthé et al., 1997, Bluthé et al., 1992, Ching et al., 2007, 
Kent et al., 1992). 
 
1.1.2.2 Tumor necrosis factor-alpha 
 
Tumor necrosis factor-alpha (TNF-a) is a potent cytokine that is released by various cells 
such as macrophages, Kupffer cells, eosinophils, natural killer cells and glial cells (Tracey 
and Cerami, 1993). TNF-a, which shares the same biological effects as, and is sometimes 
called cachectin, exists as a membrane-bound prohormone (26 kDa) that can be 
proteolitically cleaved by the metalloproteinase TNF-a-converting enzyme (TACE) into 
smaller monomers (17 kDa) in the presence of inflammatory stimuli (Black, 2002, Jue et 
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al., 1990). Three monomers associate to form a non-covalently bound trimer, which is the 
predominant active form of TNF-a during systemic inflammation (Tracey and Cerami, 
1993). Two membrane-bound receptor types have been identified for TNF-a; p55 (type 
I TNFR) and p75 (type II TNFR) (Tartaglia and Goeddel, 1992). Additionally, another 
soluble TNF receptor (sTNFR), believed to be cleaved from the membrane-bound 
receptors (Nophar et al., 1990) is also found in serum and exhibits neutralizing or 
antagonistic effects on TNF-a (Aderka et al., 1992, Engelmann et al., 1989). TNF-a 
binding is also associated with the activation and translocation of NF-kB, and the 
resultant induction of inflammatory gene transcription (Heller and Kronke, 1994).  
 
The role of TNF-a in mediating fever has been the subject of much debate and still 
remains unresolved because TNF-a appears to exhibit both pyrogenic and cryogenic 
properties. The pyrogenic effects of TNF-a have been demonstrated in several studies 
that have shown that: (1) peripheral and central administration of  human recombinant 
TNF-a induced fever in rabbits (Morimoto et al., 1989, Nakamura et al., 1988, Dinarello 
et al., 1986), and (2) neutralization of TNF-a activity by administration of TNF-a 
antiserum or TNF-a monoclonal antibodies attenuated the magnitude of the febrile 
response to LPS and turpentine (Cooper et al., 1994, Luheshi et al., 1997, Nagai et al., 
1988). Contrary to these findings, other studies supporting the cryogenic effects of TNF-
α have shown that: (1) neutralizing TNF-a activity using TNF-a antiserum or its 
inhibitory soluble receptor (sTNFR) exacerbated the febrile response to LPS in rats and 
mice (Kozak et al., 1995, Long et al., 1990a, Töllner et al., 2000a), and (2) TNF-a double 
receptor knockout mice developed similar or even greater fevers than wild-type mice 
when challenged with a high dose of LPS (Leon et al., 1997). Consistent with these 
cryogenic effects, TNF-a has been implicated in mediating hypothermia during sepsis 
(Derijk and Berkenbosch, 1994, Kozak et al., 1995, Leon, 2004, Töllner et al., 2000a), a 
regulated response that is believed to improve the chances of survival in life-threatening 
states of infection (Romanovsky and Szekely, 1998). 
 
Both peripheral and central administration of recombinant human TNF-α was shown to 
induce depression of social exploration and body mass gain in mice (Bluthe et al., 1994). 
Similarly, blockage of TNF-α though central administration of sTNFR-binding protein 
attenuated the depressive effects of LPS in IL-1RI knockout mice (Bluthé et al., 2000b). 
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These findings tend to support the involvement of TNF-α in mediating sickness 
behaviours. Contrary to these findings however are reports that TNF-α knockout mice 
developed similar sickness behaviours to those noted with wild type mice after 
intraperitoneal LPS administration (Leon et al., 1997). Other studies have similarly 
shown that blockage of endogenously released TNF-α had no effect on nocturnal activity 
and minimal effects on LPS-induced anorexia (Töllner et al., 2000a, Harden et al., 2006).  
 
In light of these conflicting findings, it is difficult to consistently explain the mechanisms 
by which TNF-α induces fever and sickness behaviour. What appears clear from most 
studies, however, is that TNF-α is released at critical phases during the sickness response 
and may mediate the sickness response through central rather than peripheral 
mechanisms. 
 
1.1.2.3 Interleukin-6 
 
 
Interleukin-6 (IL-6) (initially called interferon b2/B cell differentiation factor/B cell 
stimulation factor) is a glycoprotein (20-30 kDa) secreted by various types of cells 
including monocytes, fibroblasts, endothelial cells, Kupffer cells, glial cells and neurons 
(Naka et al., 2002). IL-6 exerts its biological effects by binding to either a membrane-
anchored receptor (mIL-6R) or a soluble form of the IL-6 receptor (sIL-6R) obtained 
from proteolytic cleavage of mIL-6R (Rose-John et al., 2006, Müllberg et al., 1994). 
Unlike most soluble receptors that compete with their membrane bound counterparts, sIL-
6R has been shown to facilitate IL-6 effects on cells that do not express the membrane-
bound form (Jones and Rose-John, 2002). The binding of IL-6 to both receptors induces 
their association with a ubiquitously expressed, membrane-bound signal transducer 
gp130. The signal transducer gp130 homodimerises and is phosphorylated on its 
cytoplasmic site by tyrosine kinases of the Janus Kinase (JAK) family. The 
phosphorylation of gp130 facilitates the docking of signal transducers and activators of 
transcription (STATs), mainly STAT3 (Heinrich et al., 1998, Heinrich et al., 2003). 
Subsequent to binding, STAT3 is phosphorylated, dimerises and translocates to the 
nucleus where it is activated, through further phosphorylation, to regulate transcription 
of target genes which include pro-inflammatory cytokines, rate limiting enzymes for 
prostaglandin production as well as regulatory molecules for the JAK/STAT pathway 
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(Heinrich et al., 1998, Heinrich et al., 2003). IL-6R association with gp130 binding has 
also been shown to induce activation of other kinase families, such as the Ras kinases, 
mitogen activated protein kinases (MAPK) and phosphatidylinositol (PI)-3 kinase, with 
subsequent activation of the positive transcription factor, nuclear factor for IL-6 (NF-IL6) 
in addition to NF-kB (Akira et al., 1995). Activation and nuclear translocation of NF-IL6 
has been associated with the transcription of inflammatory genes and acute phase proteins 
during infection (Damm et al., 2011, Schneiders et al., 2015a, Akira et al., 1990).   
 
There is abundant experimental evidence supporting the involvement of IL-6 in mediating 
fever (Dinarello et al., 1991a, LeMay et al., 1990, Lenczowski et al., 1999, Blatteis et al., 
1990, Hübschle et al., 2001, Harden et al., 2008). These studies and more have shown 
that central and peripheral administration of IL-6 induces fever in different species of 
experimental animals. Other studies also showed that IL-6 deficient mice were unable to 
develop fever in response to LPS, IL-1b, or TNF-a (Chai et al., 1996, Sundgren-
Andersson et al., 1998). IL-6 is clearly a key and necessary component of the febrile 
response during infection because neutralizing circulating IL-6 was shown to completely 
abolish the development of fever in rats injected with LPS (Harden et al., 2006). Both 
TNF-a and IL-1b induce IL-6 release and this cytokine may possibly mediate their 
pyrogenic effects.  
 
Evidence supporting the involvement of IL-6 in mediating sickness behaviour has been 
provided by several studies that have shown that central or peripheral administration of 
IL-6 decreased food intake and motor activity (Plata-Salamán, 1999, Plata-Salamán et al., 
1988, Schöbitz et al., 1995, Harden et al., 2008). The deletion of the IL-6 gene was also 
shown to decrease the depressive effects of LPS on social exploration and food intake in 
mice (Bluthé et al., 2000a), while blockage of IL-6 using antisera abolished the sickness 
behaviours associated with LPS administration (Harden et al., 2006, Harden et al., 2011).   
 
Once synthesized and released by immunocompetent cells in the periphery, cytokines 
serve as part of the communication medium between the immune system and the brain, 
which ultimately orchestrates fever and sickness behaviour. 
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1.2 Immune-to-brain communication 
 
As discussed earlier, neural cells, glial cells and endothelial cells of the brain vasculature 
are some of the cells that express receptors for cytokines. Until a few decades ago, the 
idea that the mobile scavenging cells of the immune system could communicate with a 
static, “isolated” central nervous system was unimaginable and heretical; from the 
perspectives of both the neuroscientists and the immunologists [see Quan and Banks 
(2007) for review]. However, experimental evidence that has progressively been 
generated by neuroimmunologists has now shown that the immune system does 
communicate with the brain and that there are a number of ways through which this 
communication occurs. The four principal ways (illustrated in Figure 1.2) include: (1) 
transport of cytokines across the blood brain barrier; (2) entry of cytokines through areas 
lacking the blood brain barrier; (3) binding of cytokines to receptors on the brain 
vasculature, and (4) direct stimulation of vagal afferents by cytokines and other molecules 
in the periphery (Banks et al., 1989, Hashimoto et al., 1991, Matsumura and Kobayashi, 
2004). Subsequently, neurons and glial cells in the hypothalamus and other nuclei of the 
brain are then activated by secondary mediators produced locally e.g. prostaglandin E2 or 
through neural signalling. These four principal modes through which the immune system 
communicates with the brain are discussed further.  
1.2.1 Transport of cytokines across the blood brain barrier 
 
The physicochemical characteristics of cytokines make it very difficult for them to 
traverse the restrictive and protective blood brain barrier (BBB) e.g. they are hydrophilic 
while the BBB favours transport of lipophilic substances. They are also generally large, 
charged molecules hence diffusion across the non-polar membranes of the BBB would 
be too slow, if at all possible. Based on these reasons the possibility that cytokines could 
cross the BBB was initially excluded (Breder et al., 1988), but subsequently Banks and 
colleagues provided the first experimental evidence that radiolabelled cytokines 
administered in the periphery could be transported across the BBB through a specific 
carrier-mediated transport system (Banks et al., 1989). The studies that followed 
confirmed the existence of transport systems for cytokines including: IL-1b, TNF-a, and 
IL-6. These studies showed that the transport system is highly specific and saturable and 
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that it could be bidirectional or unidirectional (Banks and Kastin, 1991, Banks et al., 1989, 
Banks et al., 1994, Banks et al., 1991, Gutierrez et al., 1993, Quan and Banks, 2007). 
 
 
 
Figure 1.2: Immune-to-brain communication during infection  
(1) Cytokines released by immunocompetent cells in the periphery are transported across 
the blood brain barrier (BBB) through specialized, cytokine transport systems. (2) 
Cytokines can enter through areas with an incomplete BBB e.g. the vascular organ of the 
lamina terminalis (OVLT). (3) Cytokines can bind to cytokine receptors expressed on 
endothelial cells of the BBB and induce the production of prostaglandins within the brain. 
(4) Peripheral signals transmitted directly to the brain through neural afferents. Brain 
responses are subsequently mediated by the local production of secondary mediators such 
as prostaglandin E2 (PGE2) as well as by synaptic communications.  
 
(Figure 1.2 was generated by Rachael Dangarembizi from basic principles of immune-to-
brain signalling) 
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1.2.2 Entry of cytokines through circumventricular organs that lack a BBB 
 
In addition to being transported across the blood brain barrier, cytokines may also be 
transported through circumventricular organs (CVOs); highly vascularized areas of the 
brain that lack a blood brain barrier and are in close contact with the cerebrovascular 
system (Roth et al., 2004). The capillaries in the CVOs are fenestrated, thereby permitting 
drainage of plasma and substances that are usually restricted by the BBB from entering 
the brain. CVOs were traditionally believed to only take part in homeostatic and 
endocrine functions, but research has now shown that they are also key components of 
immune-to-brain communication (Saper and Breder, 1994). These special areas are 
however delimited from the rest of the brain through the tight junctions of ependymal 
cells. It has been proposed that cytokines in the circulation most likely enter the 
perivascular space passively and interact with specific receptors located on the surface of 
glial cells, perivascular macrophages or endothelial cells. These cells may synthesize 
small lipophilic secondary mediators e.g. PGE2 which can diffuse to other brain areas. 
Alternatively, the CVOs could communicate with other brain areas through neural 
projections (Roth et al., 2004, Watkins et al., 1995b). 
 
One of the CVOs, the organum vasculosum laminae terminalis or vascular organ of the 
lamina terminalis (OVLT), has received much attention as a potential port of entry for 
cytokines during infection and inflammation due to its proximity to and intimate neural 
connects with the hypothalamus. The OVLT also expresses receptors for IL-1b, TNF-a 
and IL-6, further affirming that it is involved in communication between the immune 
system and the brain. IL-1 conjugated to colloidal gold was injected into rabbits to induce 
fever, and using electron microscopy the gold particles were observed in the endothelium 
of the OVLT (Hashimoto et al., 1991). Through immunohistochemistry and real-time 
polymerase chain reaction (RT-PCR), several studies have shown the activation and 
nuclear translocation of transcription factors (NF-kB, STAT3 and NF-IL6) and the 
subsequent expression of their target genes in the OVLT following a peripheral immune 
challenge (Damm et al., 2011, Hübschle et al., 2001, Rummel et al., 2011, Rummel et al., 
2004). 
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1.2.3 Binding of cytokines to receptors on the brain vasculature 
 
Besides its obvious role of regulating entry of substances into the brain, the BBB is now 
recognized as an active component of immune-to-brain communication. Endothelial cells 
of the brain vasculature express receptors for IL-1b, TNF-a and IL-6 (Bebo and 
Linthicum, 1995, Konsman et al., 2004, Vallières and Rivest, 1997) and have also been 
shown to release various inflammatory molecules including cytokines and prostaglandins 
(Matsumura and Kobayashi, 2004). To further support the involvement of the BBB in 
relaying communication from the periphery to the brain during infection, studies have 
shown a brain specific vascular induction of COX-2 and mPGES during LPS induced 
fever (Inoue et al., 2002) and that a selective deletion of COX-2 and mPGES in 
endothelial cells attenuated the inflammatory response and fever associated with a 
peripheral immune challenge (Wilhelms et al., 2014). 
 
1.2.4 Direct stimulation of vagal afferents 
 
The observations that fever can occur within minutes of an immune challenge and in the 
absence of detectable levels of cytokines in the circulation have led to the view that a 
neural pathway may also be involved in immune-to-brain communication (Watkins et al., 
1995b, Campisi et al., 2003). In support of the vagus nerve (one of the main nerves that 
innervate the thoraco-abdominal area) being involved in mediating fever and sickness 
behaviour are the findings that: (1) vagal neurons express IL-1R mRNA and the 
prostaglandin E2 receptor 3 (EP3) (Ek et al., 1998), and (2) LPS and IL-1b first produces 
cFos expression in the nucleus of the solitary tract (Brady et al., 1994, Wan et al., 1994), 
the predominant projection area of vagal afferents, and that this activation can be 
abrogated by vagotomy (Wan et al., 1994).  
 
Vagotomy in rats and mice has emerged as one of the prominent ways of investigating 
the role of vagal afferents in mediating fever and sickness and most studies show that 
vagotomy attenuates the fever and sickness behaviour (Bluthe et al., 1996, Hansen and 
Krueger, 1997, Sehic and Blatteis, 1996, Watkins et al., 1995a) or at least the early part 
of it (Romanovsky et al., 1997, Romanovsky, 2004). However, subdiaphragmatic 
vagotomy attenuated fever and sickness only at low doses of LPS (Romanovsky et al., 
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1997) and when injected via the intraperitoneal route. In addition to vagal transfer, 
cutaneous afferent sensory nerves have also been shown to participate in the induction of 
fever following subcutaneous administration of LPS (Ross et al., 2000). 
 
Having discussed the four ways by which the immune system communicates with the 
brain, we will now discuss how communications from the immune system once they get 
to the brain eventually lead to the development of fever and sickness behaviour.   
     
1.3  PGE2 synthesis and effects on brain areas that mediate fever and the 
sickness response   
 
According to the current concepts of the development of fever, prostaglandin E2 is the 
ultimate mediator that plays the critical role of stimulating the brain areas that mediate 
the febrile response (Ivanov and Romanovsky, 2004, Oka, 2004, Nilsberth et al., 2009). 
The biosynthesis of PGE2 (summarized in Figure 1.3) begins with the synthesis of 
arachidonic acid from membrane phospholipids catalysed by phospholipase A2 (PLA2) 
and endocannabinoids catalysed by the recently discovered monoacylglycerol lipase 
(MAGL) (Sanchez-Alavez et al., 2015). The PLA2 superfamily is comprised of 19 
members that fall under four subclasses. Of these four, only two have been linked with 
inflammation associated PGE2 synthesis: cytosolic PLA2 (cPLA2) and secretory PLA2 
(sPLA2). The transcription of cPLA2 and sPLA2, particularly that of sPLA2-IIA, is 
upregulated in response to inflammatory stimuli (Ivanov and Romanovsky, 2004, Kudo 
and Murakami, 2002). Recently, an additional PLA-independent, arachidonic acid 
production pathway was described, in which the endocannabinoid 2-
arachidonoylglycerol (2-AG) is hydrolysed by MAGL (Sanchez-Alavez et al., 2015).  
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Figure 1.3: Biosynthesis of Prostaglandin (PG) E2  
Step 1: Arachidonic acid synthesis from membrane phospholipids is catalysed by 
cytosolic or secretory phospholipase A2 (cPLA2 or sPLA2) or monoacylgycerol lipase 
(MAGL). Step 2: PGH2 synthesis, a two-step reaction catalysed by cyclooxygenases (1 
and 2). Step 3: PGE2 synthesis catalysed by microsomal or cytosolic PGE synthase 
(mPGES or cPGES). Solid arrows represent the main PGE2 pathway and hashed arrows 
represent the alternative pathways, which produce other products e.g. leukotrienes, 
thromboxanes and other prostaglandins.  
(Figure 1.3 was modified from Ivanov and Romanovsky (2004)).  
 
Once synthesized, arachidonic acid is converted to prostaglandin H2 (PGH2) by 
cyclooxygenases (COX). Two isozymes of COX have been characterised which share 
63% of their sequence and both catalyse the same steps in prostanoid synthesis (Vane et 
al., 1998). One isomer is constitutively expressed (COX-1) while the expression of the 
other (COX-2) is induced by inflammatory stimuli (Smith et al., 2000). COX-1 is the 
house-keeping variant of the enzyme whose physiological functions include, for example, 
the production of prostaglandins for the maintenance of the integrity of the mucosal 
epithelium (Vane et al., 1998). COX-1 has also been implicated in the development of 
LPS-induced hypothermia (Steiner et al., 2009). COX-2 on the other hand is the variant 
mostly induced by inflammatory molecules such as IL-1b, IL-6, TNF-α, bacterial 
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endotoxin, and other pyrogenic molecules (Ivanov et al., 2002). COX-2 has, therefore, 
received much attention both as a marker for inflammation and as a therapeutic target for 
alleviating inflammation and fever. Finally, PGH2 is converted to PGE2 (and other 
bioactive products e.g. PGF2, PGD2, thromboxane and prostacyclin) by prostaglandin E 
synthases (PGE synthase). One inducible, membrane-bound form of PGE synthase 
(microsomal PGES/mPGES), is upregulated, like COX-2, in response to inflammatory 
stimuli (Ivanov et al., 2002, Murakami et al., 2000, Mancini et al., 2001). Microsomal 
prostaglandin synthase-1 is an essential and rate-limiting enzyme in PGE2 synthesis 
during fever, as shown by the absence of fever in mice lacking mPGES (Engblom et al., 
2003, Wilhelms et al., 2014).  
 
Evidence in support of the intermediary role of PGE2 in fever and some sickness 
behaviours includes findings that there is a rise in plasma levels of PGE2 that parallels the 
development of fever after administration of an exogenous or endogenous pyrogen 
(Morimoto et al., 1992). Similar to the rise in plasma, others have reported a rise in levels 
of PGE2 in the ventricular cerebrospinal fluid (CSF) and in the interstitial fluid around the 
hypothalamic preoptic area (Bernheim et al., 1980) that follow an immune challenge. 
Furthermore, inhibition of PGE2 synthesis blocked fever and sickness behaviour 
(Scammell et al., 1998) while mice deficient in type 1 and type 3 prostaglandin E 
receptors did not develop fever after an immune challenge (Oka et al., 2003). 
 
There are four subtypes of prostaglandin E2 receptors namely; EP1, EP2, EP3 and EP4 
(Sugimoto and Narumiya, 2007). Of the four subtypes, the EP3 receptor mediates PGE2-
induced fever and sickness behaviour although EP1 and EP4 receptors may also play a 
part (Oka et al., 2003). The EP3 receptor is expressed in key areas of the brain involved 
in mediating fever and sickness behaviour (Matsumura et al., 1992, Nakamura et al., 
1999, Sugimoto et al., 1994). EP3 receptors are abundantly expressed in areas that receive 
immune-related signals from the periphery such as the nucleus of the solitary tract, which 
receives vagal inputs during infection, and the anterior wall of the third ventricle (OVLT 
region) which receives humoral signals during infection (Matsumura et al., 1992, Ek et 
al., 2000). The expression of EP3 receptors was also detected in brain areas that control 
sleep and wakefulness, namely the raphe nuclei and the locus coeruleus (LC) (Matsumura 
et al., 1992, Ek et al., 2000). Additionally, brain areas that mediate pain sensation and 
suppression have also been shown to express EP3 receptors and these include the 
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parabrachial nucleus, thalamus, raphe nuclei, LC and the periaqueductal grey (PAG) 
(Matsumura et al., 1992, Ek et al., 2000). Lastly, the highest intensity of EP3 receptor 
immunoreactivity was reported in areas that mediate thermoregulatory responses namely 
median preoptic nucleus (MnPO), medial preoptic area (mPOA), the dorsomedial 
hypothalamus (DMH) and the medullary raphe pallidus (Nakamura et al., 1999). The 
evidence presented above affirms the importance of EP3 receptors in mediating PGE2 
induced fever and sickness behaviour. Further affirmation comes from studies done using 
EP3 receptor knockout mice, which showed that mice lacking the EP3 receptors could not 
develop fever (Lazarus et al., 2007, Oka et al., 2003, Ushikubi et al., 1998). 
 
As mentioned earlier, the strongest expression of EP3 was detected on the cell bodies and 
processes of neurons of the MnPO and the mPOA (Nakamura et al., 1999, Nakamura et 
al., 2000). Most of the EP3 expressing neurons in the preoptic region produce gamma 
amino butyric acid (GABA) (Nakamura et al., 2002) and project to the DMH (Nakamura 
et al., 2005b) and rostral raphe pallidus (rRPa) (Nakamura et al., 2002), the two areas that 
stimulate sympathetic activation of thermal effectors which generate heat during the 
febrile response (Nakamura et al., 2004, Nakamura et al., 2009). The effects of PGE2 on 
EP3 receptors in the peri-OVLT area are inhibitory and resemble the effects of 
microinjecting GABAA antagonists (bicuculline and gabazine) i.e. increased 
thermogenesis, tachycardia and cutaneous vasoconstriction (Osaka, 2008). The binding 
of PGE2 to EP3 receptor expressing neurons in the preoptic area is thought to deactivate 
their tonic inhibition of the downstream sympathoexcitatory neurons in the DMH and 
rRPa (Nakamura et al., 2009). Disinhibition of the DMH and rRPa in turn stimulates the 
sympathetic preganglionic neurons of the intermediolateral cell column of the spinal cord 
ultimately leading to an increase in sympathetic activity in the thermoregulatory effector 
organs for non-shivering thermogenesis such as intercapsular brown adipose tissue 
(BAT) and the rat-tail artery (Nakamura et al., 2004). The MnPO, DMH and rRPa also 
activate shivering thermogenesis (Nakamura and Morrison, 2011). Microinjection of 
muscimol, a GABAA agonist in each of these regions was shown to inhibit cold defensive 
and febrile shivering (Nakamura and Morrison, 2011). In addition to stimulating 
sympathetically driven thermoregulatory responses, the DMH projects neural signals to 
the paraventricular nucleus (PVN), which in turn activates the hypothalamic-pituitary-
adrenal (HPA) axis for production of thermogenic glucocorticoids (DiMicco et al., 2006). 
Ultimately, the rise in temperature during fever is effected through both autonomic and 
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endocrine thermogenic mechanisms; an increase in brown adipose tissue (BAT) 
metabolism (Jepson et al., 1988, Morrison, 2003), increased cutaneous vasoconstriction 
to reduce heat loss (Rathner et al., 2008, Nakamura et al., 2009), increased muscle 
contraction (shivering) (Nakamura and Morrison, 2011), and a host of other heat 
conserving behavioural changes which include postural and environmental preferences.  
 
Prostaglandin effects on other brain areas likewise mediate other sickness behaviours for 
example the binding of PGD2 to prostaglandin D1 (DP1) receptors activates the nucleus 
accumbens and the ventrolateral preoptic nucleus which then inhibits the arousal system 
(tuberomammilary nucleus, dorsal raphe and the LC) [see Saper et al. (2012) for review]. 
Anorexia may be mediated by PGE2 activation of the arcuate nucleus and subsequent 
inhibition of the areas that promote feeding (DMH, PVN, and lateral hypothalamic area) 
[see (Saper et al., 2012) for review]. 
 
In addition to the activity of PGE2 as a central mediator of fever, several studies have also 
reported the involvement of other mediators including opioids (Blatteis and Romanovsky, 
1994, Blatteis et al., 1991), substance P (Blatteis e al., 1994, Szelenyi et al., 2005) and 
endothelin-1 (Fabricio et al., 2005).  
 
Having now reviewed the mechanisms underlying the development of the sickness 
response as a host defence strategy against infection, it is important for us to briefly 
discuss other biological effects of fever and sickness behaviours that may potentially be 
undesirable and prompt intervention.  
 
1.4 The maladaptive side of fever and the sickness behaviours  
 
“Humanity has but three great enemies: Fever, famine and war; of these by far the 
greatest, by far the most terrible, is fever”, was a witty remark from William Osler (Osler, 
1896) who voiced his apprehension, shared by many past and present physicians, on 
dealing with fever and the debilitating nature of sickness in patients with infectious 
diseases. Fever, often accompanied by other non-specific sickness behaviours, is part of 
the conserved brain-mediated sickness response that is associated with infection and has 
been regarded as the hallmark for disease. Writings dating back to the historic times of 
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Hippocrates, when the foundations of modern day science and medicine were laid, are all 
consistent in their description of the changes in body temperature and the accompanying 
sickness symptoms that are associated with disease (Atkins, 1982). The debate of whether 
or not fever is beneficial to the host began during these ancient times and remains even 
until today.  
 
A rise in body temperature during infection is believed to create a hostile environment 
for invading pathogens within which their function is impaired, while at the same time 
optimizing the function of the host’s immune cells (Kluger, 1991). Fever is therefore 
regarded as a preserved, natural means of fighting pathogens and increasing the chances 
of survival of the host. In accordance with this tenet, experiments done to demonstrate 
the importance of fever in host immune defence showed that survival in lizards infected 
with bacteria was improved by allowing them to develop and defend the febrile state, 
while increased mortality was observed in infected lizards that were injected with an 
antipyretic (Kluger et al., 1975, Bernheim and Kluger, 1976). These reports were later 
qualified by further studies that showed that high body temperatures increase the 
recruitment and migration of immune cells to strategic locations in the body e.g. lymphoid 
tissue, where they can effectively fight infections (Evans et al., 2000, Chen et al., 2006). 
Although these and other studies have demonstrated the benefits of fever in the host’s 
defence against an invading pathogen, the high temperatures and accompanying sickness 
behaviours that follow infections are generally a great source of discomfort and may even 
threaten survival in certain vulnerable groups of people. For example, temperatures above 
38 °C have been associated with febrile seizures and convulsions in children aged 
between six months and five years (Knudsen, 2000), although this applies only to a subset 
of this population. Another example where the risks associated with fever may outweigh 
its physiological benefits is in patients with cardiovascular and pulmonary diseases; the 
increased metabolic demands associated with fever may cause inimical cardiopulmonary 
outcomes (Mackowiak and Plaisacne, 1998). Similarly, fever is detrimental in cases of 
neurological injury and severe sepsis (Ntaios et al., 2015, Thompson, 2015) and currently, 
the antipyretic arsenal the available to mitigate the cost of fever in these conditions is 
insufficient (Sultar et al., 2004, Greenberg, 2010). Additionally, with the aid of various 
antibiotic regimens, the biological value of fever as a defence against microbes may not 
be as critical as in earlier times and thus the use of antipyretic drugs, such as aspirin, to 
alleviate the discomfort associated with illness is common practice. Even guidelines of 
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the World Health Organization (WHO) for the clinical management of uncomplicated 
self-limiting influenza indicate that ‘‘supportive care can be provided as needed, such as 
antipyretics (e.g. paracetamol or acetaminophen) for fever or pain’’ (Programme, 2009). 
1.5 Antipyretics 
 
The history of the use of substances that reduce fever (antipyretics) dates back to ancient 
times when natural products were used to treat the fever, pain and sickness that 
accompanied most diseases. Early Egyptian inscriptions dating back to as early as 1500 
BC reported the use of willow tree leaves in the treatment of inflammation and fever. An 
extract from the Ebers Papyrus reads:  
 
“wound is inflamed…[there is] a concentration of heat; the lips of that wound are 
reddened and that man is hot in consequence…then you must make cooling substances 
for him to draw the heat out…leaves of the willow” (Mann, 2000).  
 
Interestingly, the description given in this extract fits that of inflammation and fever, and 
the recommended remedy forms the basis for use of the modern day pharmacologic 
antipyretic drug, aspirin. An abridged history of antipyretic drug discovery is summarised 
in Table 1.1. In the mid-to-late 20th century, the mechanisms underlying the antipyretic 
properties of antipyretic products were elucidated by Sir John Vane and his colleagues 
who showed that aspirin and other related antipyretics, collectively known as non-
steroidal anti-inflammatory drugs (NSAIDs), are inhibitors of cyclooxygenases and 
therefore disrupt prostaglandin synthesis (Ferreira et al., 1971, Vane, 1971, Flower and 
Vane, 1974). Aspirin and related drugs may also attenuate inflammation and fever by 
other mechanisms which include:(1) inhibition of leukocyte adhesion and migration 
through endothelial cells (Hofbauer et al., 1998, Kapiotis et al., 1996) (2) inhibition of 
pro-inflammatory cytokine synthesis through arresting NF-kB translocation and 
stabilising IkBa (Shackelford et al., 1997, Housby et al., 1999, Pierce et al., 1996) and 
(3) increasing production of endogenous antipyretics and anti-inflammatory mediators 
such as adenosine (Cronstein et al., 1994).
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Table 1.1: Abridged history of antipyretics 
Historical period 
(Dates if available) 
Description/Developments References 
Sumerian era 
(3500 BC) 
Sumerian tablets describe the use of willow (Salix spp) leaves for 
rheumatic fever 
(Jack, 1997, Mahdi, 2010) 
Early Egyptian Kingdom 
(circa 1500 BC) 
Ebers Papyrus - willow (Salix spp) leaves for treating 
inflammation, fever and pain.  
(Rainsford, 2016) 
(Mann, 2000) 
Hippocratic era 
(circa 2400 years ago) 
Hippocrates – willow bark for pain (Gross et al., 1948) 
(Levesque and Lafont, 2000) 
Roman Empire 
 (AD 30-60) 
Aulus Cornelius Celsus –willow leaves used for relieving pain 
and inflammation 
(Rainsford, 2016) 
Early Chinese Kingdoms Use of Poplus alba L and Salix babylonica L for treating 
rheumatic fever, colds and wounds 
(Gross et al., 1948) 
(Levesque and Lafont, 2000) 
Middle ages 
(circa 1486) 
1759-1760 
1763 
 
 
Use of willow bark and leaves for wounds and ulcers. 
Use of Salix genera leaves for treating fevers 
Reverend Edward Stone-first clinical trial of salicylate containing 
preparations for treating fever 
 
(Levesque and Lafont, 2000) 
(Levesque and Lafont, 2000) 
(Stone, 1763) 
 22 
19th century 
1828-1838 
 
1875-early 1890’s 
 
1899 
 
Extraction, isolation, purification of salicylates and salicylic acid 
 
Full experimental reports of the antipyretic effects of salicylic 
acid 
Release of commercial acetylsalicylic acid (aspirin) as an 
antipyretic drug 
 
(Hedner and Everts, 1998, Mackowiak, 
2000) 
(Rainsford, 2016, Maclagan, 1876) 
 
20th century 
 
Continued development of other antipyretic drugs e.g. antifebrin, 
phenacitin, acetaminophen, fenamates, indomethacin 
Elucidation of mechanisms of antipyretic drugs 
(Mackowiak, 2000, Rodnan and Benedek, 
1970) 
(Vane and Botting, 2003, Vane and 
Botting, 1997, Vane and Botting, 1998) 
Present day Continued research on developing cheap, safe and effective 
antipyretics with minimal side effects  
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As discussed earlier (see section 1.3), there are two isoforms of COX; the constitutive 
and physiological COX-1, and the inducible and pathological COX-2. The first NSAIDs 
used as antipyretics exhibited inhibitory effects on both isoforms and some (e.g. aspirin, 
indomethacin and ibuprofen) showed a much greater inhibitory effect against COX-1 than 
COX-2 resulting in undesirable side effects, such as gastric mucosa damage, gastric 
bleeding and renal damage (Mitchell et al., 1993, Dunn and Zambraski, 1980, Singh, 
1998). It appeared that drugs with greater COX-2:COX-1 activity would act as better anti-
inflammatory and antipyretic drugs with minimal side effects.  Thus around the late 90’s 
the pharmaceutical industry started to produce selective COX-2 inhibitors, such as 
celecoxib and rofecoxib (Jüni et al., 2002, Masferrer et al., 1994). However, these 
selective COX-2 inhibitors also exhibit undesirable side effects. By blocking the 
production of PGI2, the selective COX-2 inhibitors are thought to disrupt the antagonistic 
effects of PGI2 on Thromboxane A2 (TXA2), a potent vasoconstrictor and inducer of 
platelet aggregation (Dogné et al., 2005). A PGI2/ TXA2 imbalance is associated with an 
increased risk of acute myocardial infarction, thrombosis, atherosclerosis and other 
cardiovascular complications (Leval et al., 2004). Apart from the cyclooxygenase related 
side effects, other antipyretics have also been associated with other undesirable effects. 
For example, there have been cases of acetaminophen-related hepatotoxicity reported in 
patients taking acetaminophen with alcohol, in patients taking acetaminophen together 
with other medications that promote the function of cytochrome P450, as well as in cases 
of chronic or acute overdose (McClain et al., 1988).   
 
The side effects associated with the use of the conventional NSAIDs have fuelled the 
quest for cheaper, safer and more effective antipyretic and anti-inflammatory drugs. With 
hundreds of articles published just over the past decade, research on natural products 
exhibiting antipyretic and anti-inflammatory effects appears be an ever-expanding field. 
Rodents are commonly used as animal models for antipyretic testing.  
 
1.6 In vivo protocol commonly used for testing antipyretics 
 
The efficacy of an antipyretic agent is usually determined by measuring the ability of 
the agent to suppress fever. An accurate determination of a drug’s ability to suppress 
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fever is therefore contingent on an accurate method for measuring body temperature 
(thermometry). 
 
1.6.1 Choice of thermometry methods 
 
Generally, the choice of a good thermometry method is governed by the purpose of 
temperature measurement and the nature of the study. For pharmacognostic and 
pharmacological studies there are a few basic properties that would be desirable when 
one considers choosing a thermometry method. A good thermometry method should: (1) 
have a high level of accuracy and sensitivity to changes in temperature and should allow 
reasonable assessment of the temporal effects of the drug being tested, (2) have minimal 
artefacts and interference, and (3) cause minimal distress and/or discomfort to both the 
experimental subjects and the researcher as these may cause errors and inaccurate 
deductions. To date, the two most commonly used thermometry methods in 
pharmacognostic and pharmacological studies are biotelemetry and rectal thermometry.  
 
1.6.1.1 Biotelemetry 
 
Biotelemetry is a technique that allows for remote measurement of a number of 
physiological parameters in free-moving, conscious animals in their natural environment 
(Kramer et al., 2001). The telemetry system comprises a telemeter, which is surgically 
implanted into the abdomen of the animal, and sends amplitude modulated radio waves 
to a receiver that is usually placed underneath the animal’s cage (Kramer and Kinter, 
2003). The receiver then sends all the data to an in-house data acquisition and processing 
system, which consolidates the data and provides meaningful output (Kramer and Kinter, 
2003). For example, if the physiological parameter being measured is temperature, the 
frequency of the radio waves sent by the calibrated temperature-sensitive radiotelemeter 
to the receiver is correlated with temperature and converted to degrees Celsius. 
Radiotelemetry systems have made significant advances, with current systems able to 
measure more than 20 physiological parameters which include temperature, locomotor 
activity, heart rate, blood pressure, blood velocity and respiratory rate (Kramer and 
Kinter, 2003).  
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In studies investigating the efficacy of antipyretic drugs, biotelemetry offers the following 
advantages: (1) an ability to monitor thermal responses round the clock to assess the 
progression of sickness and the duration of action of the drugs being tested (2) minimal 
handling and hence reduced influence of method-related confounding artefacts and (3) an 
ability to measure other important indices of sickness such as reduced locomotor activity 
(Gegout-Pottie et al., 1999). Studies investigating the postsurgical impact of telemeter 
implantation on growth, feeding and drinking patterns in rodents, have reported no 
adverse effects in rats (Leon et al., 2004). Mice have however been noted to show 
decreases in body weight, locomotion and eating for up 14 days post-surgery (Baumans 
et al., 2001). The adverse effects reported in mice may have been related to the small 
animal body-to-transmitter (B:T) size ratio (Baumans et al., 2001). Current designs of 
smaller transmitters that have been recently developed may, however, reduce this 
problem.  
 
The major drawback of using telemetry is the high set-up and maintenance costs and the 
unavoidable need for surgical implantation of the telemeters (Kramer and Kinter, 2003, 
Kramer et al., 2001). Due to these limitations, many researchers undertaking 
pharmacological studies have chosen to use rectal thermometry to measure changes in 
body temperature.  
  
1.6.1.2 Rectal thermometry 
 
From the 1970s to present day, rectal thermometry has remained the thermometry method 
of choice in pharmacological studies that investigate temperature responses to various 
drugs (see Table 1.2). 
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Table 1.2: Pyrogenic models and thermometry methods used in testing antipyretic drugs from a subset of studies carried 
out in the periods 1970-1980 and 2015-2016 
Anti-inflammatory/Antipyretic 
Compound 
Pyrogen used Thermometric 
method 
Reference 
1970 - 1980 
Aspirin Brewer’s yeast Rectal (Loux et al., 1972) 
Fenclofenac Brewer’s yeast Oesophageal (Atkinson and Leach, 1976) 
Δ9-tetrahydrocannabinol Brewer’s yeast Rectal (Sofia et al., 1973) 
Non-steroidal anti-inflammatory drugs 
(ketoprofen, indomethacin, ibuprofen, 
phenylbutazone and aspirin) 
Lipopolysaccharide Rectal (Tachizawa et al., 1977) 
Mepacrine Brewer’s yeast Rectal (Spagnuolo et al., 1978) 
3,4 disubstituted thiophenes Brewer’s yeast Rectal (Press and Safir, 1980) 
[2-(2, 3-didecanoyloxy)-propyl] 2-
acetyloxybenzoate 
Brewer’s yeast Rectal (Carter et al., 1980) 
5, 8-dioxygenated isoquinoline-4-
carboxylates 
Brewer’s yeast Rectal (Allen Jr and Weiss, 1970) 
Substituted pyridines and diazines Brewer’s yeast Rectal (Fanshawe et al., 1976) 
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2-(3'-trifluoromethylthio-anilino)-
nicotinic acid 
Brewer’s yeast Rectal (Giudicelli and Najer, 
1974) 
2-oxo-phenylbutanoic acid Brewer’s yeast Rectal (Kigasawa et al., 1979) 
Substituted phenylacetic compounds Brewer’s yeast Rectal (Diamond and Santora, 
1974) 
Furan derivatives Brewer’s yeast Rectal (D'alo, 1978) 
Cyclopenta [b] indole-2-carboxylic 
acids 
Brewer’s yeast Rectal (Berger and Corraz, 1977) 
2-[4-(3-methyl-2-thienyl) phenyl] 
propionic acid 
Mycobacterium 
butyricum 
Rectal (Kodama et al., 1980) 
Indomethacin, aspirin and paracetamol Shigella 
dysenteriae 
Rectal (Feldberg et al., 1973) 
2015 - 2016 
Acacia hockii and Kigelia africana Turpentine Rectal (Kamau et al., 2016) 
Kickxia ramosissima Brewer’s yeast Rectal (Jan and Khan, 2016) 
Delonix regia 
 
Brewer’s yeast Rectal (Patra et al., 2016) 
Artermisia herba-alba Brewer’s yeast Rectal (Jaleel et al., 2016) 
Qingkailing Brewer’s yeast Rectal (Qin et al., 2016) 
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H. abbysinica Oliv and L. buchananii Brewer’s yeast Rectal (Nthiga et al., 2016) 
Baicallin Lipopolysaccharide Rectal (Ye et al., 2015) 
Jasminum sambac Brewer’s yeast Rectal (Sengar et al., 2015) 
Stahlianthus involucratus Brewer’s yeast Rectal (Pingsusaen et al., 2015) 
Ocimum sanctum Brewer’s yeast Rectal (Kumar et al., 2015) 
Eupatorium chinense Brewer’s yeast Rectal (Jiang and Xu, 2015) 
Dalbergia saxtalis Brewer’s yeast Rectal (Hassan et al., 2015b) 
Microcos paniculata Brewer’s yeast Rectal (Aziz, 2015) 
Silymarin from Silybum marianum 
 
Brewer’s yeast Rectal (Amin and Arbid, 2015) 
Viola yedoensis Lipopolysaccharide Rectal (Ying-yi et al., 2015) 
Euphorbia helioscopa Brewer’s yeast Rectal (Saleem et al., 2015) 
NOSH Sundilac (AVT-18A) Lipopolysaccharide Rectal (Kashfi et al., 2015) 
Ixora pavetta Andrews Brewer’s yeast Rectal (Mondal et al., 2015) 
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Of the studies undertaking pharmacological antipyretic testing between 1970 and 1980, 
only studies that clearly described the method of temperature measurement and their 
pyrogen and method of inducing fever were included in formulating Table 2. A similar 
criterion was used to obtain recent studies, but due to increases in the volumes of this type 
of work in recent years, a comparable number was obtained within 1 year (2015-2016). 
Comparisons of temperatures measured using rectal thermometry and biotelemetry have 
yielded conflicting findings; with some studies reporting lower and others higher 
temperatures measured using rectal thermometry than those measured using abdominally-
implanted radiotelemeters (Dallmann et al., 2006, Bae et al., 2007, Dilsaver et al., 1992). 
The conflicting findings noted with the use of rectal thermometry and biotelemetry could 
be the result of technical differences, such as the: (1) varying sensitivities of the devices 
used, (2) differences in thermocouple insertion depths used (the farther away from the 
liver, the lower the temperatures are likely to be), or (3) stress-related effects associated 
with the procedure of rectal temperature measurement.  
 
1.6.1.3 Rectal thermometry and stress-induced hyperthermia 
 
The procedure of rectal temperature measurement has been associated with stress-
induced physiological changes, which include a rise in body temperature (stress-induced 
hyperthermia) (Bae et al., 2007, Dallmann et al., 2006, Poole and Stephenson, 1977), an 
increase in circulating levels of corticosterone (Veening et al., 2004) and inflammatory 
cytokines (Hale et al., 2003). Stress-induced hyperthermia is a common physiological 
response exhibited by various species of animals to stressful events, such as handling, 
restraint (Hashimoto et al., 2001, Parrott and Lloyd, 1995, Shibata and Nagasaka, 1982), 
exposure to an open field (Butterweck et al., 2003, Grundmann et al., 2006, Kluger et al., 
1987, Rowsey et al., 2001), separation, disturbance, injection (Van Der Heyden et al., 
1997), exposure to a novel environment and switching of cages (Morimoto et al., 1991, 
Long et al., 1990c). 
 
Regardless of the stressor, researchers have generally agreed that stress-induced 
hyperthermia is an acute response, the magnitude of which depends on the nature of the 
stimulus (Bouwknecht et al., 2007, Vinkers et al., 2008, Parrott and Lloyd, 1995). 
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Although there are many studies that have reported the occurrence of stress-induced 
hyperthermia in normothermic rats, very few studies have investigated the development 
of stress-induced hyperthermia in febrile rats. The few that have, have shown that 
although prominent in normothermic rats, the hyperthermic response to rectal 
temperature measurement appears to be muted in febrile rats (Vinkers et al., 2009). 
During antipyretic drug testing, the efficacy of the antipyretic drug is usually obtained by 
comparisons made between the temperatures of treated febrile rats and their 
normothermic counterparts. The induction of stress-induced hyperthermia in 
normothermic, but not febrile rats could negatively impact the accuracy and reliability of 
results obtained in these studies.  
 
Although not commonly used for pharmacognostic antipyretic testing there are other 
alternatives for temperature measurement e.g. a chronic insertion of the probe in a 
restrained or restricted rat to continuously measure rectal or colonic temperatures. Partial 
obstruction of the rectum and sustained stress-induced hyperthermia resulting from 
restraint, handling and possibly the presence of the thermocouple probe have been 
reportedly associated with this technique (Poole and Stephenson, 1977, Gordon, 1990). 
 
The methods of thermometry described in this section are used to determine thermal 
responses to administration of a fever-causing agent (pyrogen). Thus, as much as it is 
important to use an accurate thermometry method, it is equally important to consider the 
characteristics of the sickness responses induced by one’s pyrogen of choice. 
 
1.6.2 Choice of a pyrogen for in vivo antipyretic testing 
 
In pharmacological studies, an experimental pyrogen maybe considered good if it 
satisfies most or all of the following conditions: (1) a good success rate i.e. an ability to 
induce fever in most or all of the experimental subjects when administered, (2) an ability 
to induce a significant increase in temperature which is reasonably uniform and 
reproducible, (3) an early onset but also a reasonable duration to allow assessment of 
pharmacological effects, and (4) a reasonable sensitivity to antipyretics. Other factors that 
affect the choice of a pyrogen may include availability, cost, storage and other cost or 
logistics-related factors. Although LPS from Escherichia coli is a well-characterised 
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pyrogen for inducing experimental fevers, the pyrogen that is most commonly used in 
testing pharmacognostic antipyretic drugs is live Saccharomyces cerevisiae. In fact, S. 
cerevisiae is recommended for use as an experimental pyrogen in pharmacological 
antipyretic drug-testing guidelines (Thangaraj, 2016, Vogel, 2002)  
 
1.6.2.1 Saccharomyces cerevisiae 
 
Saccharomyces cerevisiae is a saprophytic, unicellular, uninucleate, eukaryotic fungus, 
whose use in the baking (Baker’s yeast) and brewing (Brewer’s yeast) industry dates back 
to antiquity. Recent advances in the field of biotechnology have also extended the use of 
S. cerevisiae as a cloning vector for production of mammalian proteins, such as vaccines, 
interferons, hormones, enzymes and other high value natural products (Kingsman et al., 
1987, Krivoruchko and Nielsen, 2015). S. cerevisiae is also popularly used as a probiotic 
and for treating Clostridium difficile-related diarrhoea (Segarra-Newnham, 2007).  
 
The yeast cell is comprised of a protoplast that is surrounded by a cell wall made up of 
b-1,3 and b-1,6 glucans (30-50%), mannoproteins (40%), chitins, lipids and other 
proteins (Klis et al., 2006, Lipke and Ovalle, 1998). The glycoprotein and polysaccharides 
in yeast cell walls are covalently linked to form macromolecular complexes and the 
glycosylations and linkage patterns vary from species to species and within species (Klis 
et al., 2006, Lipke and Ovalle, 1998). Generally, S. cerevisiae has been regarded as a safe 
commensal. Recently however, virulent strains of yeast have been isolated and implicated 
in invasive fungal infections, which include vaginitis (Sobel et al., 1993) and systemic 
infections predominantly in immunocompromised patients and transplant recipients 
(Popiel et al., 2015, Silva et al., 2011, Aucott et al., 1990, Cimolai et al., 1987). These 
and other studies therefore show that contrary to the common belief that S. cerevisiae is 
safe and non-pathogenic, S. cerevisiae is an emerging opportunistic pathogen, which has 
the ability to invade, proliferate and cause illness (Mccusker, 2006). 
 
The pathogenicity of Brewer’s yeast is due to the presence of the distinctive highly 
glycosylated proteins and polysaccharides on the surface of the yeast’s cell wall that are 
recognized as PAMPs by the innate immune system (Levitz, 2004). The recognition of 
b-1,3 glucans by the CLR Dectin-1 and b-1,6 glucans by complement receptor 3 (CR3) 
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is known to trigger an immune response (Romani, 2011, Levitz, 2010). Dectin-2, langerin 
and the mannose receptor recognise mannans, while mincle receptor recognizes chitin 
(Romani, 2011, Levitz, 2010). O-linked mannans and other yeast cell components such 
as DNA and RNA activate TLRs (mainly TLR2, TLR6 and TLR9) and trigger 
inflammation and subsequently sickness (Romani, 2011).  
 
Despite its extensive use in antipyretic screening studies over the last 40-50 years (see 
Table 1.2), there are very few studies, in refereed literature, that have fully characterised 
the febrile response to Brewer’s yeast injection. Of the few studies that have been done, 
rectal thermometry has been used but as described earlier in section 1.6.1.3 of this thesis, 
rectal temperature measurement has methodological limitations. In addition to inducing 
hyperthermia, rectal temperature measurement is restricted to 30-60 min intervals and 
therefore does not allow the continuous temperature recordings much needed to fully 
describe thermal responses. Moreover, because of its cumbersome and labour-intensive 
nature, rectal thermometry does not easily lend itself for temperature measurements to 
continue over long periods of time. As a result of these methodological limitations, the 
exact characteristics of fever induced by the standard doses of Brewer’s yeast used in 
antipyretic screening studies are largely unknown. Knowing the characteristics of a fever, 
such as latency, amplitude and duration, is critical when testing antipyretics as the drug 
being tested must not be administered for example during the falling phase when 
temperatures are naturally decreasing. Without the data on the characteristics of the 
febrile response to common doses of Brewer’s yeast used in antipyretic testing, it is 
difficult to determine at which point along the course of the fever the pharmacological 
manipulations are being done. Thus, the reliability of the observed antipyretic effects is 
compromised.  
 
In addition to the lack of data describing the characteristics of the febrile response, there 
is also a paucity of data describing the molecular mechanisms subserving fever and 
sickness behaviour responses to Brewer’s yeast administration. From some of the work 
that has been done it appears that Brewer’s yeast may induce an inflammatory response 
similar to that described earlier following LPS administration. For example, some studies 
have shown that administration of COX-inhibitors abrogates Brewer’s yeast-induced 
fever (Loux et al., 1972, Opas et al., 1987), suggesting that Brewer’s yeast-induced fever 
is prostaglandin dependent and cyclooxygenases may play an active role. From studies 
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done on other pathogenic fungi, we already know that activation of TLR2/TLR6 and 
Dectin-1 leads to downstream activation of NF-kB (Saijo and Iwakura, 2011). Thus, 
Brewer’s yeast may activate NF-kB signalling pathways which trigger the production of 
pro-inflammatory cytokines (Gantner et al., 2003). To support the possible involvement 
of pro-inflammatory cytokines in mediating Brewer’s yeast-induced fever, a study done 
in rats showed that intraperitoneal (i.p.) injection of Brewer’s yeast was associated with 
increased concentrations of TNF-a and IL-1b in peritoneal fluid (Ferreira et al., 2012). 
Similarly, injection of mannan components isolated from the cell wall of Brewer’s yeast 
increased serum levels of TNF-a in rats (Ataŏglu et al., 2000). In vitro studies done using 
macrophages have also shown that NF-kB activation and TNF-a production are increased 
in response to stimulation with Brewer’s yeast, or other yeast cell wall components 
(Brown et al., 2003, Gantner et al., 2003, Young et al., 2001). Although these studies 
show the possible involvement of some inflammatory molecules in Brewer’s yeast-
induced fever, they do not provide a full spatiotemporal picture of the activation of the 
mediators in relation to changes in temperatures and other sickness behaviours.  
 
The standard doses of whole S. cerevisiae used to induce fever during antipyretic drug 
testing are very high, ranging between 2 - 4 g/kg (Hassan et al., 2015b, Josa et al., 2001, 
Pingsusaen et al., 2015). The subcutaneous route is the recommended and commonly used 
route of administration of Brewer’s yeast most likely because it mimics a localized 
peripheral infection, is less invasive and is associated with a high success rate unlike that 
noted via the intraperitoneal route. However, subcutaneous administration of high doses 
of Brewer’s yeast during injection of Brewer’s yeast at high doses has been shown to 
induce the development of inflammatory abscesses and granulomas (Todd, 1986). There 
remains therefore the need to develop other effective pyrogens with less side-effects. One 
potential alternative is zymosan, a cell wall moiety of Brewer’s yeast.   
 
1.6.2.2 Zymosan 
 
 
Zymosan is a purified cell wall product of S. cerevisiae that is commonly used as a 
phlogistic agent in animal models of arthritis (Keystone et al., 1977), peritonitis, pleurisy 
(Utsunomiya et al., 1998), oedema, pain and general inflammation. Although zymosan is 
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mainly used in studies investigating the mechanisms of local inflammation, this moiety 
of S. cerevisiae may be a good candidate for simulating fungal infections and testing 
antipyretic agents. Zymosan primarily contains b-glucans and mannans that activate the 
alternative complement pathways and immunocompetent cells such as macrophages, 
neutrophils (Doherty et al., 1985), natural killer cells (Duan et al., 1994), and mast cells. 
Like live yeast, zymosan initiates the inflammatory response by binding to TLR2/TLR6 
and Dectin-1 (Brown et al., 2003, Keystone et al., 1977). Mouse macrophages stimulated 
by zymosan showed redistribution of TLR2 from the cell surface to the phagosome 
(Underhill et al., 1999). Similarly, stimulation of macrophages with radiolabelled 
zymosan showed that the binding of zymosan to Dectin-1 requires the cooperative action 
of TLR2 and its associated immunoreceptor tyrosine-based activation motifs (Brown et 
al., 2003) to initiate an inflammatory response. Zymosan activates the NF-kB and 
JAK/STAT inflammatory signalling pathways (de Hooge et al., 2004a) and is associated 
with an increase in the pro-inflammatory cytokines TNF-a (Utsunomiya et al., 1998, 
Asmuth et al., 1990a), IL-1b (Fantuzzi et al., 1997) and IL-6 (Utsunomiya et al., 1998, 
Asmuth et al., 1990a, Bastos-Pereira et al., 2014). Additionally, zymosan administration 
substantially increases the production of PGE2 (Doherty et al., 1985), eicosanoids (Rao 
et al., 1994), chemoattractants (Utsunomiya et al., 1998) and the migration of neutrophils 
to the site on infection (Ajuebor et al., 1998). Stimulation of primary neuroglial cultures, 
obtained from the OVLT and the MnPO, with zymosan has also been shown to increase 
TNF-α and IL-6 (Bastos-Pereira et al., 2014). The findings from the studies discussed 
above provide evidence that zymosan is a PAMP that elicits an immune response and 
activates similar inflammatory mediators and immune-to-brain communication pathways 
to those mentioned previously with LPS administration (see section 1.1.2). 
 
Studies characterising the inflammatory response to zymosan-induced arthritis in rats, 
(Gegout et al., 1994) have observed a febrile response, albeit short-lived (4h), following 
intra-articular injection of 4 mg/kg zymosan. Moreover, intraperitoneal injection of 10 
mg/kg zymosan in rats also induced a short-lived (4 h) fever of moderate magnitude (1.2 
°C), which was also accompanied by reduced food intake and motor activity on the first 
day after injection (Hubschle et al., 2007, Naoi et al., 2006). The doses of zymosan used 
in the above studies to induce arthritis and peritonitis induced very low-to-moderate 
amplitude, short-duration fevers that may not be desirable for screening antipyretics. 
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However, intraperitoneal injection of greater doses of zymosan (500 mg/kg) resulted in 
sepsis, shock and increased mortality in rats (Fantuzzi et al., 1997). Administration of 
moderate-to-high doses of zymosan could however induce high magnitude, long duration 
fevers that are desirable for evaluating pharmacological agents.  
 
1.6.3 The incorporation of sickness behaviours during pharmacognostic antipyretic 
drug testing 
 
As discussed earlier, fever is often accompanied by other cytokine-mediated sickness 
behaviours, such as lethargy, somnolence, anorexia, general body aches and depression-
like behaviour. However, current guidelines for testing antipyretic drugs only focus on 
the efficacy of test substances in reducing temperature (Thangaraj, 2016) possibly based 
on an assumption that fever and sickness behaviours are mediated largely by common 
pathways; hence drugs that are effective in attenuating fever are most likely capable of 
suppressing sickness behaviours. Research has shown, however, that although both fever 
and sickness behaviours are cytokine-mediated responses to infection, the mechanisms 
underlying their development may be different (Harden et al., 2011, Hübschle et al., 
2006). During illness, sickness behaviours tend to last long after fever has resolved and 
from a clinical point of view, it is these prolonged sickness behaviours that are more 
debilitating and uncomfortable to the patient compared to the slight rise in temperature 
they may experience during fever (Bower et al., 2002, Hewlett et al., 2005). Thus it is 
important to test the efficacy of pharmacognostic drugs not only on the thermal response, 
but so too on the non-thermal responses to infection.  
 
1.7 Thesis Aims 
 
There is a resurgent interest in the search for safe and effective antipyretic drugs to replace 
or complement the conventional NSAIDs, which have various side effects. Researchers 
and pharmacological companies are shifting their focus to natural products with possible 
anti-inflammatory and antipyretic effects. In line with this shift, the field of 
pharmacognosy has grown considerably over the past few decades. The general aim of 
the research described in this thesis is to characterise and validate the standard models of 
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inducing fever and methods of temperature measurement used in pharmacognostic 
antipyretic drug screening studies. 
 
Despite technological advancement and the introduction of computer-based thermometry 
methods that allow remote, real-time measurements of various physiological parameters 
in free moving rats, most studies still use rectal thermometry for monitoring temperature 
changes during antipyretic drug testing (shown by the frequency of use of rectal 
thermometry in a sample of studies given in Table 1.2). Research has shown that the 
handling and restraint associated with rectal temperature measurement is associated with 
stress-related physiological changes including hyperthermia. Stress-induced 
hyperthermia may affect the accuracy and reliability of thermal responses observed 
during antipyretic drug testing. The aim of the experiments described in Chapter 2 of 
this thesis was therefore to characterise the stress-induced hyperthermia associated 
with rectal temperature measurement in normothermic and febrile rats. Fever was 
induced by subcutaneous injection of Brewer’s yeast and changes in core body 
temperature after rectal temperature measurement were monitored using remote-sensing, 
thermosensitive telemeters implanted in the abdomen of each rat. Because some studies 
pre-expose experimental animals to the procedure of rectal temperature measurement for 
a prescribed period of time prior to the experiments, I also sought to investigate if the 
standard prescribed method of habituation blunts or reduces the magnitude of the stress-
induced hyperthermia. I therefore pre-exposed some rats to the procedure of rectal 
temperature measurement and compared their thermal response with that of rats naive to 
the procedure. Lastly, to verify the accuracy of rectal thermometry in measuring core 
body temperature, I compared the temperatures measured using rectal thermocouple 
probes with temperatures measured using intra abdominally implanted radiotelemeters.   
 
Having reviewed the literature describing the recommended Brewer’s yeast model for 
inducing fever in antipyretic drug testing, it became apparent that there is little data 
describing the characteristics of the febrile response induced by administration of the 
standard doses of Brewer’s yeast used in antipyretic drug testing. Without knowledge of 
the fever characteristics, it is difficult to determine the best time for pharmacological 
manipulations and drug testing to reliably conclude if the drug indeed exhibits the desired 
effects. The first aim of the experiments described in Chapter 3 was therefore to 
characterise the febrile response and sickness behaviours associated with 
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subcutaneous injection of the standard doses of Brewer’s yeast used in antipyretic 
drug testing. Using biotelemetry, I characterised the latency, time to peak, amplitude and 
duration of the febrile response to subcutaneous injection of Brewer’s yeast. Previous 
studies done mainly using LPS as a pyrogen have shown that in addition to fever, rats 
also show signs of sickness e.g. lethargy, anorexia and growth-stunting. In addition to 
fever, these behavioural responses are good indices of sickness and may be useful for 
assessing the pharmacological effects of drugs. Thus, I also characterised the 
development of sickness behaviours after subcutaneous injection of Brewer’s yeast. I 
found for the first time that the standard doses of Brewer’s yeast used for inducing fever 
during antipyretic drug testing also induce lethargy, anorexia and growth stunting.    
 
The inflammatory mechanisms accompanying the fever and sickness behaviour 
associated with Brewer’s yeast infection have not been fully elucidated. As a result, of 
the hundreds of studies reporting positive antipyretic effects from natural products, very 
few proffer any mechanistic explanations and are limited to merely screening for the 
presence or absence of antipyretic activity with no knowledge of cellular targets or 
potential antipyretic mechanisms of action. The progression of newly discovered 
antipyretic natural products might be limited by a lack of data on the inflammatory 
pathways activated in the pyrogenic model used for testing them. The second aim of the 
experiments described in Chapter 3 of this thesis was to elucidate the spatiotemporal 
activation of key inflammatory mediators and signalling pathways during Brewer’s 
yeast-induced fever and sickness behaviour. Using biological assays based on the 
growth promoting effects and cytotoxic effects of cytokines, I measured the circulating 
levels of IL-6 and TNF-a at four time points corresponding to the early, peak, plateau 
and falling phase of Brewer’s yeast-induced fever. To measure neuroinflammation, I used 
immunohistochemical staining and examined the activation and translocation of 
transcription factors (STAT3, NF-kB and NF-IL6) in the OVLT. I also measured the 
expression of their target genes in the hypothalamus using Real Time-Polymerase Chain 
Reaction at each of the four phases of fever described above. The methods used for 
measuring neuroinflammation in my experiments are well established methods that have 
been successfully used in other studies to investigate neuroinflammation induced by LPS 
(Damm et al., 2011, Rummel et al., 2011). Using the above-described methods I managed 
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to show, for the first time, the spatiotemporal patterns of activation of inflammatory 
mediators during Brewer’s yeast-induced fever, anorexia and lethargy.  
 
The administration of Brewer’s yeast elicited fever, sickness behaviour and inflammatory 
mediators and therefore qualifies as a valid model for testing antipyretic drugs. Although 
Brewer’s yeast was noted to be a highly effective pyrogen, I observed that the standard 
doses and volumes used during antipyretic drug testing are associated with the development 
of an abscess, pain and suffering/discomfort in the rats. According to the animal ethics 
principle of refinement, procedures and techniques used for collecting data on experimental 
animals should cause minimal (if any) suffering and pain (Fenwick et al., 2009). I tested a 
dose of Brewer’s yeast lower than the standard doses used, but the inflammatory response 
noted with the lower dose was short-lived and therefore undesirable for the purposes of 
testing antipyretic drugs. However, as reviewed earlier in this chapter, zymosan, a cell wall 
product prepared from Brewer’s yeast, is commonly used as an inflammatory agent for 
inducing arthritis, peritonitis and pleurisy and may be a potential alternative for inducing 
fever during antipyretic drug testing. The aim of the experiments described in Chapter 
4 of this thesis was therefore to characterise the fever, sickness behaviour and 
inflammatory mechanisms associated with subcutaneous injection of moderate doses 
of zymosan in rats.  I found that, like Brewer’s yeast, zymosan induces fever and sickness 
behaviour through the activation of peripheral and neuroinflammatory mediators. The 
spatiotemporal characteristics of zymosan-induced neuroinflammatory mediator activation 
was in most cases very similar to that noted with Brewer’s yeast.   
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2. CHAPTER TWO 
 
 
 
 
 
 
 
 
Thermometry methods used during antipyretic testing: Limitations of 
using rectal thermometry 
 
 
 
 
 
 
 
 
 
Data and ideas presented in this chapter have been published in the paper: Dangarembizi, 
R., Erlwanger, K H., Mitchell, D., Hetem, R S., Madziva, M T and Harden, L M. 2017. 
Measurement of body temperature in normothermic and febrile rats: Limitations of using 
rectal thermometry. Physiology and Behaviour 179, 162-167.  
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2.1 Introduction 
 
Rectal temperature recorded using a thermocouple probe inserted into the rectum and 
abdominal temperature recorded using a radiotelemeter implanted into the abdomen 
potentially yield comparable values with regard to core body temperature (Dilsaver et al., 
1992). However, one major disadvantage associated with the measurement of rectal 
temperature in laboratory animals is that the procedure of handling and inserting the 
thermocouple probe is stressful (Veening et al., 2004). The stress initiated by handling 
and inserting the thermocouple probe into the rectum leads to a number of physiological 
changes, which include an increase in body temperature (stress-induced hyperthermia) 
(Bae et al., 2007, Dallmann et al., 2006) as well as an increase in neuroendocrine 
hormones and cytokines (Hale et al., 2003, Veening et al., 2004). While the stress-induced 
hyperthermic response that follows rectal temperature measurement is commonly 
reported in normothermic rats, it appears to be muted or masked in rats with a fever 
(Vinkers et al., 2009). 
 
Despite reports of the procedure causing stress-induced hyperthermia, rectal thermometry 
remains a common technique for measuring antipyresis in rodents in pharmacological, 
especially ethnopharmacological, studies. Body temperature is the key physiological 
indicator used to determine the efficacy of the antipyretic pharmacological agents and 
usually conclusions are drawn from comparisons between the temperatures of treated 
febrile rats and their normothermic counterparts. Because the technique used for 
measuring temperature in these studies appears to cause a prominent increase in body 
temperature in normothermic, but not febrile, rats, it is important to examine the 
characteristics of this hyperthermia and establish whether the use of rectal thermometry 
can impact the accuracy and validity of results.   
 
In an attempt to reduce the stress-induced physiological changes associated with rectal 
temperature measurement, laboratory animals are often habituated to the procedure by 
subjecting them to the procedure of rectal temperature measurement for two-to-three days 
before the start of the experiment (Souza et al., 2002, Tomazetti et al., 2005). Whether 
this protocol indeed habituates the animals to the procedure by blunting the stress-induced 
hyperthermia remains unclear. 
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Thus, using a standardized technique for measuring rectal temperature, this study was 
carried out to investigate the effects of: (1) rectal temperature measurement on 
temperature responses of normothermic and febrile rats, and (2) commonly used 
habituation protocols at attenuating the hyperthermic response associated with the 
procedure of rectal temperature measurement. I used rats that had either been subjected 
to rectal temperature measurements before the experiment (pre-exposed), or rats that were 
naive to rectal temperature measurement and administered either saline or a pyrogenic 
dose of Brewer’s yeast to induce fever. During the plateau phase of the fever rectal 
temperatures were repeatedly measured at hourly intervals in both normothermic and 
febrile rats while monitoring abdominal temperature changes using intra-abdominally-
implanted radiotelemeters. Results obtained in this study show that the procedure of rectal 
temperature measurement produced a robust, consistent hyperthermic response in 
normothermic rats, but not in rats with a fever induced by subcutaneous administration 
of Brewer’s yeast. Pre-exposing normothermic rats to rectal temperature measurements 
on two successive days before the experiment did not affect the magnitude or the duration 
of the hyperthermic response induced by rectal temperature measurements.  
 
2.2 Materials and methods 
 
2.2.1 Animals 
 
Male Sprague-Dawley rats were purchased from the National Health Laboratory Services 
(Johannesburg, South Africa) and housed in the Central Animal Service Unit of the 
University of the Witwatersrand, Johannesburg. Rats were housed individually in acrylic 
cages lined with wood shavings in a temperature-controlled room (22 ± 2 °C) on a 
12h:12h light/dark cycle (lights on at 06:00 clock time). Rats were allowed to acclimate 
to their environment for seven days before surgery. The rats had access to rodent pellets 
and water ad libitum. On the day of injection of the pyrogen, rats had a body mass of 
between 250 and 300 g. All experiments were performed in accordance with the 
regulations of the Animal Ethics Control Committee of the University of the 
Witwatersrand and were approved by its Animal Ethics Screening Committee (ethics 
clearance number 2014/10/C; see Appendix). 
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2.2.2 Abdominal temperature 
 
Abdominal temperature was recorded by remote biotelemetry using temperature-
sensitive radiotelemeters (TA10TA-F40, Data Sciences, St Paul, MN, USA), which had 
been implanted intra-abdominally. Rats were anaesthetized with 80 mg/kg ketamine 
hydrochloride (Anaket-V, Bayer, South Africa) and 20 mg/kg xylazine (Chanazine, 
Bayer, South Africa). After surgery, the rats received a single intramuscular injection of 
an analgesic, buprenorphine (Temgesic®, 0.05 mg/kg Schering-Plough, Johannesburg, 
South Africa) and were given seven days to recover from the surgery before the 
commencement of the experiments outlined below. Transmitter output frequency (Hz) 
was monitored at one-minute intervals by a receiver plate (RPC-1, Data Sciences, St Paul, 
MN, USA) placed beneath the cage of each rat. The frequency received by each plate was 
fed into a peripheral processor connected to a personal computer and converted to degrees 
Celsius. The radiotelemeters were calibrated individually by the manufacturer (Data 
Sciences, St Paul, MN, USA), in a water bath at 35 °C and 39 °C, to an accuracy of 0.1 
°C. 
2.2.3 Rectal temperature  
Rectal temperature measurements were obtained by gently inserting a lubricated 
thermocouple probe (Type T copper/constantan thermocouple probe, external diameter 2 
mm) 40 mm into the rectum of each rat. An insertion depth of 40 mm has been used 
successfully for determining core body temperature in rats (Bae et al., 2007, Kiyatkin and 
Brown, 2005, Kollmar et al., 2007). The polyvinyl chloride-insulated thermocouple probe 
was calibrated against a high-accuracy thermometer (Quat 100, Heraeus, Hanau, 
Germany) in an insulated water bath across a range of temperatures (35, 36, 37, 38, 39 
and 40 °C) to an accuracy of 0.1 °C. To measure rectal temperature, the rat was placed 
with all four paws on a smooth, solid surface and gently held in place by a hand positioned 
over the back, while the tail was lifted and the thermocouple probe was inserted. It took 
time (30 – 120 s) to settle the rats and position them for the insertion of the thermocouple 
probe into the rectum. Once inserted the probe remained in the rectum for 40 s to allow 
temperatures to stabilise (Bae et al., 2007). All rectal temperature measurements were 
performed by one person (Rachael Dangarembizi). 
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2.2.4 Pyrogen 
 
Brewer’s yeast (Sigma Aldrich, St Louis, USA: Lot# SLBC 5519V) was reconstituted in 
sterile, non-pyrogenic 0.9 % saline (Sabax, Johannesburg, South Africa) to a final 
concentration of 20 % (w/v). The yeast solution was injected subcutaneously (s.c.) in the 
dorsum of the neck at a volume of 20 ml/kg (equivalent to 4000 mg/kg) (Hassan et al., 
2015a, Keri et al., 2010). 
 
2.2.5 Experimental procedures 
 
To determine if pre-exposure to the procedure of rectal temperature measurement reduced 
the magnitude of stress-induced hyperthermia, rectal temperatures were measured once a 
day (1-2 hours before the onset of the dark phase), for two days before the start of the 
experiment. These rats were said to be “pre-exposed”, while the other rats that received 
their first rectal temperature measurement only on the day of the experiment were called 
“naive”. Pre-exposed and naive rats received a s.c. injection of either Brewer’s yeast or 
saline.  As additional controls, another group of twelve rats received a s.c. injection of 
Brewer’s yeast, but without subsequent rectal temperature measurements. In an attempt 
to reduce the number of animals used for the study I chose not to include an additional 
group of rats that received saline followed by no rectal temperature measurements 
(referred to in Figure 2.1 and 2.3B as “no rectal probe”), but rather to use abdominal 
temperature recordings from pre-intervention days when the rats were left undisturbed in 
their home cages. The final experimental groups are summarized in Table 2.1. 
 
Injections were administered at 16:00, two hours before the onset of the dark phase. 
Pharmacological antipyretic testing guidelines in rats recommend that the test compound 
or the standard drug be administered 18 hours after injection of the pyrogen and rectal 
temperatures be recorded at regular time intervals of 30-60 minutes for five hours 
thereafter (Thangaraj, 2016, Vogel, 2002). I therefore started all rectal temperature 
measurements 18 hours after injection of Brewer’s yeast and rectal temperature 
measurements were taken once every hour, over a five-hour period (10:00-15:00). 
Following each rectal temperature measurement, the rats were returned to their home 
cages.   
 62 
 
Table 2.1: Summary of experimental interventions and sample size 
Intervention Sample size 
Rectal probe pre-exposed + Brewer’s yeast 9  
(2 rats excluded in final analysis) 
Rectal probe naive + Brewer’s yeast 9 
(1 rat excluded in final analysis) 
Rectal probe pre-exposed + Saline # 8 
Rectal probe naive + Saline # 9 
(1 rat excluded in final analysis) 
No rectal probe + Brewer’s yeast  
(6 of the 12 rats were used for calculating the “baseline” 
average abdominal temperatures of febrile rats as explained 
in the data analysis section). 
12 
# In an attempt to reduce the number of animals used for the study I chose not to include an additional 
group of rats that received saline followed by no rectal temperature measurements  
 
2.2.6 Data analysis 
 
All data were analysed using GraphPad Prism software (version 7.0, GraphPad Software 
Inc, USA). Statistical significance was accepted for P < 0.05. To analyse the fever induced 
by s.c. administration of Brewer’s yeast, the original one-minute abdominal temperature 
recordings were averaged over two hours and the two-hourly means compared by 
repeated measures two-way analysis of variance (ANOVA) with intervention and time as 
main effects. Tukey’s post hoc test was used to detect differences between groups when 
the ANOVA detected significant main effects or interactions.  
 
Pearson’s correlation analyses were performed to calculate the correlation coefficient (r) 
between rectal temperatures recorded using a thermocouple probe and abdominal 
temperatures recorded using a radiotelemeter. A Bland-Altman analysis (Bland and 
Altman, 1986) was performed to determine the level of agreement between the two 
methods of temperature measurement. 
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As mentioned earlier, a group of rats (n = 12) received a s.c. injection of Brewer’s yeast, 
but without subsequent rectal temperature measurements. Six of these rats were used to 
calculate the “baseline” average abdominal temperatures of febrile rats 18 – 23 hours after 
injection of Brewer’s yeast, i.e. during the five-hour experimental period (10:00 – 15:00).  
To determine the effect of rectal temperature measurements on the abdominal 
temperature of febrile rats, I calculated the difference between the abdominal 
temperatures of rats having or not having rectal temperature measurements and the 
baseline average abdominal temperatures calculated as outlined above. Rats were 
excluded from data analysis when temperature responses differed by more than twice the 
standard deviation of the group mean (n = 2 Pre-exposed + Brewer’s yeast; n = 1 Naive 
+ Brewer’s yeast). 
 
To determine the effect of rectal temperature measurements on the abdominal 
temperature of normothermic rats over the five-hour experimental period (10:00 – 15:00), 
I calculated the difference between the abdominal temperatures of a rat having rectal 
temperature measurements following injection of saline or not having rectal temperature 
measurements from the average abdominal temperature of the rat when left undisturbed 
at exactly the same time of the day, on three previous days.  For statistical purposes, the 
one-minute changes in abdominal temperature values, calculated as outlined above, were 
averaged over five minutes for the five-hour experimental period (10:00 – 15:00). The 
five-minutes means were compared by repeated measures two-way ANOVA with 
intervention and time as main effects. Tukey’s post hoc test was used to detect differences 
between groups when the ANOVA detected significant main effects or interactions. Rats 
were excluded from data analysis when temperature responses differed by more than 
twice the standard deviation of the group mean (n = 1 Naive + Saline). 
 
The maximum change in abdominal temperature, after each rectal temperature 
measurement in pre-exposed and naive rats that received saline, was regressed linearly 
against the number of rectal temperature measurements for each rat to determine if 
normothermic rats habituate to five repeated measurements of rectal temperatures spaced 
an hour apart.  
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2.3 Results 
 
Figure 2.1 shows that rats injected s.c. with Brewer’s yeast initially had a significant 
decrease in abdominal temperature (36.81 ± 0.35 °C) two hours after injection compared 
to rats injected with saline (37.56 ± 0.23 ºC). Following the brief period of hypothermia, 
the abdominal temperature of rats injected with Brewer’s yeast started to increase and 
peaked at 39.02 ± 0.3 °C eight hours after injection and remained significantly elevated 
for 72 hours compared to rats injected with saline (main effects of time (F (36, 1692) = 212.8, 
P < 0.0001), treatment (F (5, 47) = 149, P < 0.0001) and their interaction (F (180, 1692) = 29.71, 
P < 0.0001)).  
 
The difference in the body temperature between rats injected with Brewer’s yeast and rats 
injected with saline represents the amplitude of the fever. Greater fever amplitudes were 
noted at 18 hours after injection (the time at which fever is usually assessed in 
pharmacological antipyretic screening studies) with temperature values obtained from 
radiotelemeters implanted in the abdomen (mean difference 1.79 ºC and 95% confidence 
intervals 1.56 and 2.03 ºC), than with temperature values obtained from thermocouple 
probes inserted into the rectum (mean difference 1.56 ºC and 95% confidence intervals 
1.31 and 1.8 ºC).   
 
The rectal temperature and abdominal temperature values measured at 18 hours after 
injection were significantly correlated in rats that received saline (r = 0.79, P = 0.0003) 
and in rats that received Brewer’s yeast (r = 0.64, P = 0.01).  
 65 
 
Figure 2.1: Abdominal temperature (mean and SD) of rats injected subcutaneously with 
saline or 4 g/kg Brewer’s yeast in saline. Pre-exposed rats had rectal temperature 
measurements taken once a day on the two days before receiving an injection of Brewer’s 
yeast (n=7) or saline (n=8). Naive rats received the first rectal temperature measurement 
18 hours after receiving injections of either Brewer’s yeast (n=8) or saline (n=8). The 
arrow indicates the time of injection and dashed lines indicate the period during which 
rectal temperature measurements were taken (10:00-15:00 clock time on day 1 post-
injection). The black bars represent night time. Brewer’s yeast and no rectal probe 
represent rats that received an injection but no rectal temperature measurements (n = 6). 
No rectal probe represents the abdominal temperature when the rats that received saline 
were left undisturbed in their home cages; i.e. before exposure to rectal temperature 
measurements started. As there were no significant differences in the temperature profiles 
obtained for the naive and pre-exposed rats during the days when they were not disturbed, 
the data for both groups were combined to create one temperature profile for the no rectal 
probe data (n = 16). The original one-minute abdominal temperature recordings were 
averaged over two hours and the two-hourly means have been plotted. * Rectal probe pre-
exposed + Brewer’s yeast significantly different to Rectal probe pre-exposed + Saline 
(Tukey’s, P < 0.05). # Rectal probe naive + Brewer’s yeast significantly different to Rectal 
probe naive + Saline (Tukey’s, P < 0.01). 
 
Figure 2.2 shows the mean difference (bias) and limits of agreements of the rectal 
temperatures and abdominal temperatures measured at 18 hours after injection. The 
temperature values measured with the two methods differed in rats injected with Brewer’s 
yeast (mean difference 0.04 ± 0.23; 95% limits of agreement -0.4 to 0.48) and in rats 
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injected with saline (mean difference -0.2 ± 0.25; 95% limits of agreement -0.68 to 0.29). 
Thus, the agreement interval between the two methods identified that the temperature 
values recorded in rats using a thermocouple probe inserted into the rectum could either 
be 0.7 ºC greater or 0.5 ºC lower than those obtained with a radiotransmitter implanted 
into the abdomen. 
 
The average change in abdominal temperature, over the 5-hour period (10:00 – 15:00), 
of rats pre-exposed or naive to rectal temperature measurements and injected s.c. with 
Brewer’s yeast was not significantly different from the change in abdominal temperature 
of rats not exposed to rectal temperature measurements and injected with Brewer’s yeast 
(main effects of time (F (59, 1062) = 4.04, P < 0.0001), treatment (F (2, 18) = 2.63, P = 0.10) 
and their interaction (F (118, 1062) = 1, P = 0.49)) (Figure 2.3A). 
 
Rectal temperature measurement induced a significant increase in the abdominal 
temperature of rats injected s.c. with saline compared to when they did not receive rectal 
temperature measurements, i.e. when they were left undisturbed in their home cages 
(Figure 2.3B) (main effects of time (F (59, 1711) = 20.49, P < 0.0001), treatment (F (2, 29) = 
20.42, P < 0.0001) and their interaction (F (118, 1711) = 7.02, P < 0.0001)). After each rectal 
temperature measurement, the increase in abdominal temperature, of rats injected with 
saline that were pre-exposed or naive to rectal temperature measurements, occurred after 
a latent period of 5 - 10 minutes, peaked at 15 - 20 minutes with a mean maximum change 
of 0.66 ± 0.27 ºC, and resolved after 35 - 50 minutes. The regression slopes plotted for 
the maximum change in abdominal temperature, recorded after each rectal temperature 
measurement against number of rectal temperature measurements significantly deviated 
from zero in only three of the sixteen rats. Thus, for most rats, the maximum change in 
abdominal temperature induced by rectal temperature measurement did not decrease with 
repeated rectal temperature measurements taken at hourly intervals. 
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Figure 2.2: The mean difference (bias) and limits of agreements of the rectal 
temperatures and abdominal temperatures measured at 18 hours in (A) rats with a fever 
induced by Brewer’s yeast (n=15) or (B) rats injected with saline (n=16). Rats were 
housed at an ambient temperature of 22 ± 2 °C. Black dots represent individual animals. 
Upper limit of agreement is calculated as the mean difference between two methods plus 
1.96 (SD) of the difference. Lower limit of agreement is calculated as the mean difference 
between two methods minus 1.96 (SD) of the difference. 
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Figure 2.3: Change in abdominal temperature (mean and SD), shown in five-min 
intervals over five hours following rectal temperature measurement in (A) febrile rats 
injected s.c. with 4g/kg Brewer’s yeast in saline (n = 7 pre-exposed; n = 8 naive) and (B) 
normothermic rats injected s.c. with saline (n = 8 pre-exposed; n = 8 naive). Pre-exposed 
rats had rectal temperatures taken once a day on the two days before the experiment. 
Naive rats received their first rectal temperature measurement only at the beginning of 
the experiment (at time T0). T0 = 10:00 clock time and T5 = 15:00 clock time. The black 
arrows indicate the time of handling and rectal temperature measurements. Brewer’s 
yeast and no rectal probe represent rats that received an injection but no rectal temperature 
 69 
measurements (n = 6). No rectal probe (Figure 2.3B) represents the change in abdominal 
temperature when the rats that received saline were left undisturbed in their home cages; 
i.e. before exposure to rectal temperature measurements started. As there were no 
significant differences in the temperature profiles obtained for the naive and pre-exposed 
rats during the days when they were not disturbed, the data for both groups were 
combined to create one temperature profile for the no rectal probe data (n = 16). * Rectal 
probe pre-exposed + Saline significantly different to no rectal probe (Tukey’s, P < 0.05). 
# Rectal probe naive + Saline significantly different to no rectal probe (Tukey’s, P < 0.05). 
$ Rectal probe pre-exposed + saline significantly different to Rectal probe naive + saline 
(Tukey’s, P < 0.05). No significant differences were observed between the febrile groups.  
 
2.4 Discussion 
 
This study has shown that the procedure of measuring rectal temperature is associated 
with an increase in abdominal temperature (0.66 ± 0.27 ºC) i.e. stress-induced 
hyperthermia, in normothermic rats, and that it is muted in rats during the plateau phase 
of fever (Figure 2.3). In normothermic rats, the stress-induced hyperthermia had a rapid 
onset (within 5 - 10 minutes), peaked at 15 - 20 min and lasted for 35 - 50 minutes after 
each rectal temperature measurement (Figure 2.3B). The exposure of rats to the procedure 
of rectal temperature measurement on two occasions before the start of the experiment 
did not significantly reduce the magnitude or duration of the stress-induced hyperthermia 
(Figure 2.3B). Similarly, five repeated measurements of rectal temperatures undertaken 
on the day of the experiment had no significant effects on the magnitude and duration of 
the stress-induced hyperthermia. The difference in temperature between rats injected with 
saline vs rats injected with Brewer’s yeast, i.e. the amplitude of the fever, was smaller 
when temperature was measured using a thermocouple probe inserted into the rectum, 
than when temperature was measured using intra-abdominally implanted radiotelemeters. 
There was a significant positive linear association between temperatures recorded using 
a thermocouple probe inserted into the rectum and temperatures recorded using intra-
abdominally implanted radiotelemeters in normothermic and febrile rats. Overall, the 
agreement interval between the two methods identified that the temperature values 
recorded in rats using a thermocouple probe inserted into the rectum could either be 0.7 
ºC greater or 0.5 ºC lower than those obtained with a radiotransmitter implanted into the 
abdomen (Figure 2.2). Thus, the two methods of temperature measurement may yield 
qualitatively similar results but quantitatively different results. 
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The results obtained in this study showed that there is a clear and reproducible increase 
in body temperature (stress-induced hyperthermia) that developed after rectal temperature 
measurement in normothermic rats. Stress-induced hyperthermia is a well-established 
physiological response of various species of animals to different stressful events such as: 
restraint, frustration (Shibata and Nagasaka, 1982, Hashimoto et al., 2001, Parrott and 
Lloyd, 1995), cage-switching (Long et al., 1990c, Morimoto et al., 1991), exposure to an 
open field (Butterweck et al., 2003, Grundmann et al., 2006, Kluger et al., 1987, Rowsey 
et al., 2001), tail-suspension (Liu et al., 2003), capture (Meyer et al., 2008), and rectal 
temperature measurement (Bae et al., 2007, Dallmann et al., 2006, Poole and Stephenson, 
1977, Hale et al., 2003). While hyperthermia appears to be a common physiological 
response in all of these stress paradigms, the magnitude of the stress-related increase in 
body temperature appears to be dependent on the intensity, modality and duration of the 
stressful stimulus and may vary across species [for review see Bouwknecht et al. (2007), 
Vinkers et al. (2008)]. The magnitude and duration of the hyperthermia noted in 
normothermic rats in the present study (between 0.5-1.5 ºC) is consistent with those 
reported in other studies that used rectal probes for measuring temperature (Bae et al., 
2007, Poole and Stephenson, 1977). 
 
The findings from this study have important implications for the use of thermocouple 
probes to measure rectal temperature in pharmacological antipyretic screening studies.  
In these studies, rats are usually injected with either Brewer’s yeast or saline and 18 hours 
after they are injected with the antipyretic agent being tested (Hassan et al., 2015a, Keri 
et al., 2010, Pingsusaen et al., 2015). The efficacy of the antipyretic agent is determined 
by comparing the rectal temperatures of the treated febrile rats and their normothermic 
controls. Similar body temperature measurements in the treated febrile rats and 
normothermic controls would indicate that the antipyretic agent being tested is indeed 
effective. Results from this study show that rectal temperature measured using a 
thermocouple probe underestimated the amplitude of fever and that normothermic rats 
injected with saline have a significant increase in abdominal temperature for 5 - 50 
minutes after each rectal temperature measurement; maximum change of 0.66 ± 0.27 ºC 
occurred 15 - 20 min after the measurement (Figure 2.3B). Thus, measurement of rectal 
temperatures, which report a smaller fever amplitude, coupled with a stress-induced 
increase in body temperature in control rats may potentially lead to investigators 
erroneously reporting a positive effect of the antipyretic agent under investigation, 
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especially if the rectal temperature measurements are taken at intervals of less than 60 
min as has been reported in some studies [for example see (Josa et al., 2001, Liu et al., 
2016, Pingsusaen et al., 2015, Zakaria et al., 2006)]. The majority of the pharmacological 
antipyretic screening studies however record rectal temperatures in 60 min intervals. As 
shown in our study, the hyperthermic response resolves between 40 - 50 min after rectal 
temperature measurement, hence values measured at hourly intervals are less likely to 
reflect the stress-induced hyperthermia, induced by the rectal temperature measurement. 
A study investigating the neuroendocrinological responses of hyperthermia in stressed 
mice also showed that corticosterone levels returned to pre-stress levels 60 min after 
stress induction (Veening et al., 2004). However, stress induced by rectal temperature 
measurement is also associated with a concomitant increase in concentrations of the pro-
inflammatory cytokines IL-1β and IL-6. Therefore, it is important to note that, even if the 
stress-induced hyperthermia resolves within 60 min, the basic biochemical make-up and 
physiological responses of a stressed rat will be different from those of an undisturbed 
rat. These changes could impact on results, particularly in studies investigating the 
pathophysiological mechanisms mediating fever or the potential effects of various 
antipyretic agents.  
 
Subjecting the rats to rectal temperature measurements on two previous occasions in an 
attempt to alleviate stress-induced hyperthermia, as is commonly done in other studies 
(Souza et al., 2002, Tomazetti et al., 2005), did not change the magnitude or duration of 
the hyperthermia induced by the rectal temperature measurements. Similarly, repeating 
the procedure five times, at 60 min intervals, on the day of the experiment did not 
significantly alter the magnitude or duration of the hyperthermia noted following each 
rectal temperature measurement. Although an effective duration of habituation to the 
procedure of rectal temperature measurement was not strictly investigated in this study, 
two days before the experiment may be too short a period to pre-expose the rats and 
habituate them to the procedure. Others have similarly reported no reduction in the 
hyperthermic response of rats pre-exposed to rectal temperature measurement 15 times 
over a period of five days (Bae et al., 2007). 
 
While the hyperthermic response to rectal temperature measurement is prominent, long-
lasting and reproducible in normothermic rats (Figure 2.3B) it appears muted in rats 
during the plateau phase of fever induced by s.c. administration of Brewer’s yeast (Figure 
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2.3A). Results obtained from studies using other stressful events, such as cage-switching 
and exposure to an open field, have reported conflicting findings regarding the possible 
involvement of prostaglandins, the terminal mediators of fever, in mediating stress-
induced hyperthermia (Kluger et al., 1987, Singer et al., 1986, Morimoto et al., 1991, 
Lecci et al., 1990, Parrott and Lloyd, 1995, Vinkers et al., 2009). If prostaglandins are 
indeed involved in mediating stress-induced hyperthermia then the absence of 
hyperthermia following rectal temperature measurement in febrile rats might be related 
to saturation of prostaglandin receptors. Alternatively, it has also been previously 
proposed that the absence of stress-induced hyperthermia in febrile rats may be related to 
a ceiling effect i.e. a maximally reachable temperature above which no further rise is 
possible (Vinkers et al., 2009). However, because rats injected with Brewer’s yeast in this 
study had earlier attained higher temperatures i.e. at the peak of the fever and additionally 
showed an ability to raise their temperature during the plateau phase (Figure 2.1 and 
2.3B), it is unlikely that a ceiling effect for body temperature contributed to the absence 
of the hyperthermia observed in our study.  
 
The proposed sources of heat production associated with stress-induced hyperthermia in 
rats include: (1) increased non-shivering thermogenesis in brown adipose tissue (BAT), 
(2) cutaneous vasoconstriction to reduce heat loss (mediated by sympathetic outflow 
especially to the tail), and (3) activation of the hypothalamic-pituitary-adrenal (HPA) axis 
to increase production of thermogenic hormones (Bi, 2014, Morrison, 2016b, Morrison, 
2016a, Oka et al., 2001). In this study, rats were housed in a sub-thermoneutral 
environment (22 ± 2 °C). Rats housed in sub-thermoneutral environments use 
sympathetic activation of cutaneous vasoconstriction and BAT thermogenesis activated 
through the preoptic area, DMH and the medullary raphe to maintain normal core body 
temperatures (Ootsuka and McAllen, 2006, Nakamura and Morrison, 2008, Rathner et 
al., 2001, Morrison, 2016b, Morrison, 2016a). The same heat generating mechanisms and 
brain regions are also employed in maintaining the febrile state during infection-induced 
fever.  
 
The “law of initial values” postulated by Wilder in 1931 (Wilder, 1931), states that the 
direction and magnitude of a physiological response depends, to a great extent, on the 
initial (pre-stimulus) values. Thus, the existence of elevated initial (pre-stimulus) values 
may constrain further increases in a physiological response and therefore lessen the 
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magnitude of the response observed when a stimulus is applied. As illustrated in Figure 
2.4, stress-induced hyperthermia, exposure to cold and infection-induced fever share 
common descending pathways and effectors for thermogenesis (DiMicco et al., 2006, 
Zaretskaia et al., 2002, Zaretskaia et al., 2003, Cerri and Morrison, 2006, Kataoka et al., 
2014, Nakamura, 2011, Nakamura et al., 2005a, Sarkar et al., 2007). Applying the law of 
initial values to the findings of the present study, the absence of the stress-induced 
hyperthermia in the febrile rats may be related to a pre-existent background activation of 
heat generating mechanisms for cold defence and maintenance of fever. 
 
In the comparison of rectal thermometry and biotelemetry, the agreement interval 
between the two methods showed that rectal temperature recorded using a thermocouple 
probe could either be as much as 0.7 ºC greater or 0.5 ºC lower than temperatures obtained 
with a radiotransmitter implanted into the abdomen (Figure 2.2). Others have reported 
mean differences in excess of 1 ºC in normothermic rats (Dilsaver et al., 1992). The 
accuracy of temperatures recorded using a thermocouple probe inserted into the rectum 
is heavily dependent on the probe insertion depth. Temperatures measured closer to the 
anal opening (further away for the liver) are lower and a less accurate representation of 
core body temperature (Dilsaver et al., 1992). Faecal material, involuntary/reflexive 
smooth muscle movements in the colon and at times slight movements of the rat itself 
may change the depth of the probe during measurement. Thus, the accuracy of the rectal 
temperature measurements recorded using a thermocouple probe is contingent on the 
technique and consistency of the researcher. These factors are however difficult to 
standardize because not all animals cooperate or respond in the same way every time. In 
this regard, although surgically implanted radiotelemeters are more expensive than 
thermocouple probes, they appear to be a more reliable method of core body temperature 
measurement in rodents, particularly in studies measuring temperature responses over a 
prolonged period of time (Clement et al., 1989). 
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Figure 2.4: Neural pathways mediating thermogenesis induced by stress, fever and cold 
exposure. Stress activates the medial amygdala, which in turn activates the dorsomedial 
hypothalamus (DMH) and paraventricular nucleus (PVN). Fever and cold exposure both 
activate the preoptic area (POA) of the hypothalamus, which in turn activates the DMH 
(and partly raphe nuclei, not shown). The DMH activates the raphe nuclei in the medulla 
oblongata to stimulate sympathetic premotor neurons in the spinal cord and increase 
brown adipose tissue (BAT) metabolism, cutaneous vasoconstriction and shivering. The 
DMH also activates the hypothalamic-pituitary adrenal (HPA) axis and stimulates the 
release of thermogenic hormones such as the glucocorticoids (e.g. corticosterone) and the 
catecholamines (e.g. adrenaline). Hormones of the adrenal gland then activate BAT 
thermogenesis, metabolism and cutaneous vasoconstriction leading to an increase in core 
body temperature. 
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In conclusion, the findings from this study show that the procedure of rectal temperature 
measurement induces a clear hyperthermic response in normothermic rats, but not in rats 
during the plateau phase of fever. These findings are important particularly for antipyretic 
screening studies where conclusions are drawn based on comparisons of temperature 
responses of febrile rats and their normothermic controls. The use of rectal thermometry 
in these studies may affect the reliability of results especially if short-spaced, intermittent 
rectal temperature measurements are used. 
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3. CHAPTER THREE 
 
 
 
 
 
 
 
Pyrogenic models used during antipyretic testing: A characterisation of the 
fever, sickness behaviour and inflammatory mediators associated with 
Brewer’s yeast administration 
 
 
 
 
 
 
 
 
 
 
Data and ideas from this chapter have been published as a scientific paper: Dangarembizi, R., 
Erlwanger, K H., Rummel, C., Roth, J., Madziva, M T and Harden, L M. Brewer’s yeast: a potent 
inducer of fever and sickness behaviour through activation of inflammatory mediators in the 
brain. Brain Behaviour and Immunity 68; 211-223. 
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3.1 Introduction 
 
For almost a century, Saccharomyces cerevisiae (S. cerevisiae) (commonly known as Brewer’s 
or Baker’s yeast) has remained the standard pyrogen for inducing pyrexia in pharmacological, 
especially ethnopharmacological, studies screening antipyretics in rats (Nicolle, 1925, 
Tomazetti et al., 2005, Loux et al., 1972, Aouey et al., 2016, Abotsi et al., 2016, Liu et al., 
2016). Pharmacological antipyretic testing guidelines in rats recommend that the test drug or 
the standard drug be administered 18 hours after subcutaneous injection of yeast and rectal 
temperatures be recorded at time intervals of 30 – 60 min, for five hours thereafter (Thangaraj, 
2016, Vogel, 2002). Although Brewer’s yeast is used extensively in antipyretic testing 
protocols in rats, the sickness response to this pyrogen has not been fully characterised. Results 
from Chapter 2 support the reports in current literature [see section 1.6.2.1 for review of 
literature] which show that Brewer’s yeast induces fever, but there is very little information 
available describing the characteristics of the fever and sickness behaviour across the range of 
Brewer’s yeast doses that are commonly used. 
 
In addition to the fever and sickness behaviour not being fully characterised, the spatiotemporal 
inflammatory profile associated with yeast administration has also not been fully described. 
Thus, it is unclear which inflammatory mediators are present around the recommended 
antipyretic administration time point of 18 hours after administration of Brewer’s yeast. As 
outlined in Chapter 1 (section 1.5), reported mechanisms of action of antipyretics include: (1) 
inhibiting the enzyme cyclooxygenase (COX) and reducing the levels of PGE2 within the 
hypothalamus, (2) reducing pro-inflammatory mediators, and (3) enhancing anti-inflammatory 
signals (Aronoff and Neilson, 2001). The activation of transcription factors controls the 
expression of immune response genes that ultimately leads to the synthesis and release of the 
inflammatory mediators regulating fever [for review see Rummel (2016)]. The most important 
inflammatory transcription factors implicated in mediating the inflammatory response 
associated with fever include: nuclear factor (NF)-kB, signal transducer and activator of 
transcription (STAT)3 and NF-IL6 [for review see Rummel (2016)]. Thus, collectively 
characterizing the fever-curve and the spatiotemporal profile of inflammatory mediators 
induced following yeast administration would provide valuable insight for studies using 
Brewer’s yeast to screen antipyretics and determine their mechanism of action. 
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Thus, I have chosen to characterise the sickness response across a range of Brewer’s yeast 
doses and to determine the spatiotemporal activation of inflammatory mediators in the 
periphery and key brain regions implicated in mediating fever, namely the hypothalamus and 
OVLT. Results obtained in my study show that Brewer’s yeast administration has the capacity 
to induce fever, lethargy, anorexia and growth-stunting lasting at least six days. Eighteen hours 
after injection corresponded to the plateau phase of the fever where the core body temperature 
of rats receiving the high and medium doses of Brewer’s yeast was consistently greater than 
the core body temperature of rats that received saline. The time-course of the inflammatory 
changes showed a marked increase in the synthesis of pro-inflammatory cytokines, key 
prostaglandin-synthesizing enzymes and transcription factors in the periphery and brain 
between 2 and 18 hours after Brewer’s yeast administration. 
 
3.2 Methods 
 
3.2.1 Animals 
 
Male Sprague Dawley rats were purchased from the National Health Laboratory Service 
(Johannesburg, South Africa) and housed in the Central Animal Service Unit of the University 
of the Witwatersrand, Johannesburg. The rats were housed individually in acrylic cages lined 
with wood shavings in a temperature-controlled room (22 ± 2 °C) on a 12h:12h light/dark cycle 
(lights on at 06:00 clock time). The rats had access to rodent pellets (Epol, Johannesburg, South 
Africa) and water ad libitum. Rats were allowed to acclimate to their environment for seven 
days before surgery.  On the day of injection of the pyrogen, rats had a body mass of between 
250 and 300 g. All experiments were performed in accordance with the principles of the Animal 
Ethics and Control Committee of the University of the Witwatersrand and were approved by 
its Animal Ethics Screening Committee (ethics clearance number 2014/10/C; see Appendix A). 
 
3.2.2 Pyrogen administration  
 
Rats received a single subcutaneous (s.c.) injection of Brewer’s yeast (Sigma Aldrich, St Louis, 
USA: Lot number SLBC 5519V) reconstituted in a vehicle of 0.9% sterile, non-pyrogenic 
saline (Sabax, Johannesburg, South Africa) to a final concentration of 20% (w/v). The yeast 
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solution was injected in the dorsum of the neck at a volume of 20 ml/kg (4 g yeast/kg body 
weight), 10 ml/kg (2 g yeast /kg body weight) or 2 ml/kg (0.4 g yeast /kg body weight). The 
high (4 g/kg) and intermediate (2 g/kg) doses of Brewer’s yeast are commonly used for 
inducing fever in young rats (~200-250 g) in pharmacological studies (Keri et al., 2010).  
 
3.2.3 Body temperature and cage activity 
 
As previously described by Hopwood et al. (2009), core body temperature and cage activity of 
rats were recorded using sterile, wax-coated temperature-sensitive radiotelemeters (TA10TA-
F40, Data Sciences, St Paul, MN, USA). The radiotelemeters had been implanted intra-
abdominally, with rats under general anaesthesia induced by an intramuscular (i.m.) injection 
of ketamine hydrochloride (80 mg/kg, Anaket-V, Bayer, South Africa) and xylazine (20 mg/kg, 
Chanazine, Bayer, South Africa). After surgery, the rats received a single i.m. injection of an 
analgesic (Temgesic®; Schering-Plough, Johannesburg, South Africa), and were given a week 
to recover from the surgery. The radiotelemeters were calibrated in a water bath at 35 ºC and 
39 ºC by the manufacturer (Data Sciences, St Paul, MN, USA) to an accuracy of 0.1 °C.   
 
3.2.4 Body mass and food intake 
 
 
Body mass and food intake were measured daily, using an electronic scale (Diamond, US) 
accurate to 1 g, two hours before the beginning of the dark phase of the circadian cycle. To 
measure food intake, 200 g of standard rat chow were given to each rat and the daily intake 
was the difference between the initial weight of food at the start (200 g) and the food remaining 
after 24 hours. 
 
3.2.5 IL-6 and TNF-a bioassays 
 
To determine the level of TNF-α in plasma, a bioassay based on the dose-dependent cytotoxic 
effect of TNF on a mouse fibrosarcoma cell line WEHI 164 subclone 13 (Espevik and Nissen-
Meyer, 1986) was performed. Serial dilutions of plasma samples or a murine TNF-α standard 
were incubated for 24 hours in 96 microtitre wells seeded with 50 000 actinomycin D-treated 
WEHI cells. Cell viability after 24 hours was measured using the dimethyl tetrazolium bromide 
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(MTT) assay [as previously described by (Holt et al., 1991)]. The detection limit of the assay, 
after factoring in the dilution of samples, was 6 pg/ml.  
 
IL-6 bioactivity was determined using a bioassay that is based on the dose-dependent growth 
stimulation of IL-6 on the B9 hybridoma cell line (Aarden et al., 1987). Serial dilutions of 
plasma samples or different concentrations of the human IL-6 standard (89/548; National 
Institute of Biological Standards and Control, UK) were incubated for 72 hours in wells that 
had been seeded with 5000 B9 cells. According to the National Institute of Biological Standards 
and Control, one microgram of the IL-6 standard is equivalent to 100 000 international units 
(IU). Viable cells in each cell were measured using the MTT assay. The detection limit of the 
assay, after factoring in the dilution of samples, was 3 IU for IL-6/ml.  
 
The levels of TNF-α and IL-6 determined in this study are not a reflection of the absolute 
concentrations of the cytokines but rather their bioactivity according to established 
international standards. The specificity of the assays was confirmed by neutralizing some 
stimulated microcultures with one microgram of TNF binding protein or 10 µL of antiserum 
against rat-IL-6 (Ross et al., 2003, Harden et al., 2011).   
 
3.2.6 Tissue preparation 
 
Coronal brain sections (20 µm) were cut at -20 °C on a cryostat (2800 Frigocut-E, Cambridge 
Instruments, West Germany) and thaw mounted onto poly-L-lysine-coated glass slides. Brain 
sections used in this study were prepared from areas encompassing the vascular organ of the 
lamina terminalis (OVLT) according to the stereotactic atlas of the rat brain (Paxinos and 
Watson, 1998). Twelve sections were collected per rat. The same brains used for 
immunohistochemistry were also used for RT-PCR and to do so, 35 consecutive, frozen, 30 
µm sections of the hypothalamus were thaw-mounted on glass slides and the hypothalamus 
was carefully dissected out and used for RNA extraction. Sections were stored at – 55 ºC until 
processing. 
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3.2.7 Immunohistochemistry 
 
3.2.7.1 General procedure 
 
Frozen brain sections were air dried for 10 min and fixed in 2% paraformaldehyde (PFA; 
Merck, Darmstadt, Germany) followed by three 5-min washes with phosphate-buffered saline 
(PBS). The sections were then blocked with 10% Normal Donkey Serum (NDS; Biozol, 
Germany) and 0.3% Triton X-100 (0.1% for NF-IL6 and NF-kB, and 0.3% for COX-2 and 
STAT3). Following this, sections were incubated with primary antibody solutions overnight at 
4 °C (details of antibodies are as described in Table 3.1). The specificity of the respective 
antibodies has previously been tested (Damm et al., 2011, Fuchs et al., 2013, Rummel et al., 
2006, Rummel et al., 2011). After three successive 5-min washes with PBS, sections were 
incubated with secondary antibodies conjugated with fluorescent dyes (Cy3 and Alexa-488) 
for 2 hours at room temperature. This was followed by nuclear staining with 4,6-diamidino-2-
phenylindole (DAPI) stain (1:8000) to clearly visualize the nucleus and to demonstrate the 
nuclear localization of immunoreactive protein (Mobitec GmbH, Göttingen, Germany) and 
three final 5-min washes with PBS after which sections were cover-slipped with glass 
coverslips and glycerol/PBS solution (Citifluor, Ltd, London, UK). Sections were stored at 4 
°C pending microscopic analysis. 
 
3.2.7.2 Colocalization 
 
Double immunohistochemistry was performed to determine the contribution of endothelial 
cells to the NF-IL6, STAT3 and COX-2 immunoreactive cell population. The antibodies for 
NF-IL6, STAT3 or COX-2 were mixed with the cell marker antibody (dilutions given in Table 
3.1) before the first incubation (20 – 22 hours). NF-IL6 and STAT3 was visualized with Cy3-
conjugated anti-rabbit IgG, COX-2 was visualized with Cy3-conjugated anti-goat IgG, 
endothelial cell markers with Alexa-488-conjugated anti-rabbit or anti-sheep IgG as secondary 
antibodies (1:500 dilution each). In control experiments, the sections were incubated with the 
primary antibody mixture in which one of the primary antibodies was substituted with non-
immunized animal IgG (goat IgG for COX-2, rabbit IgG for NF-IL6). Inappropriate cross-
reaction between antibodies was confirmed to be negligible. 
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Table 3.1: Antibodies used for immunohistochemistry 
Antibody Dilution Catalog number 
Primary antibodies   
NF-IL6 rabbit polyclonal IgG 1: 6000 sc-150-G Santa Cruz Biotechnology, Santa Cruz, CA 
vWF rabbit polyclonal IgG 1:5000 008202 Dako Deutschland, GmbH, Hamburg, Germany 
vWF sheep polyclonal IgG 1:2000 SARTW-IG Affinity Biologicals, Ancaster, Ontario, 
Canada 
COX-2 goat polyclonal IgG 1:2000 sc-1747 Santa Cruz Biotechnology, Santa Cruz, CA 
STAT-3-rabbit polyclonal IgG 1:3000 sc-482 Santa Cruz Biotechnology, Santa Cruz, CA 
NF-kB-rabbit polyclonal IgG 1:500 sc-109 Santa Cruz Biotechnology, Santa Cruz, CA 
Secondary antibodies   
Cy3-conjugated anti-rabbit IgG 1:600 711-165-152 Jackson Immuno Research West Grove, PA 
Cy3-conjugated anti-goat IgG 1:600 705-165-147 Jackson Immuno Research West Grove, PA 
Alexa 488-conjugated anti-
rabbit IgG 
1:500 AZA11055 MobiTec GmbH, Göttingen, Germany 
Alexa 488-conjugated anti-
sheep IgG 
1:500 AZA11015 MobiTec GmbH, Göttingen, Germany 
vWF = von Willebrand factor, NF-IL6 = nuclear factor for IL-6, NF-kB = nuclear factor kappa-
light-chain-enhancer of activated B cells, IgG = immunoglobulin G, STAT-3 = signal 
transducer and activator of transcription-3 
 
3.2.8 Microscopic analysis 
 
Processed sections were analysed using a light/fluorescent microscope (Olympus BX50, 
Olympus Optical, Hamburg, Germany). The microscope was equipped with filter sets to allow 
detection of the fluorescent conjugates used (Cy3, Alexa 488 and DAPI). All images were 
taken using a black and white Spot Insight camera (Diagnostic Instruments, Visitron Systems, 
Puchheim, Germany) using the Metamorph 5.05 software. Metamorph 5.05 was also used to 
combine individual images into the red/green/blue (RGB) colour figure plates (staining was 
performed for all animals at the same time and for quantification purposes all images were 
processed the same way using Adobe Photoshop CC 2017 (Adobe Systems Incorporated, San 
Jose, CA, USA). 
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3.2.9 Real-time PCR 
 
RNA extraction from hypothalamic tissue was done using TRIzol (Invitrogen, CA, USA) 
according to the manufacturer’s instructions. RNA (1 µg) was transcribed in a 10 µL reaction 
mix comprising of 50U murine leukemia virus (MLV) reverse transcriptase, 50 mM random 
hexamers and 10 mM dNTP mix (Applied Biosystems, Foster City, CA, USA). Qualitative 
PCR was thereafter performed in duplicate using a preoptimised primer/probe mixture 
(Taqman Gene Expression Assay; Applied Biosystems, Foster City, CA, USA) and Taqman 
Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA) using a StepOne RT-
PCR System (Applied Biosystems Foster City, CA, USA) (Damm et al., 2011). b-actin was 
used as the housekeeping gene for normalizing cDNA concentrations from the different sample 
reactions. Sample values were derived from comparison with a reference sample (from the 
same experiment and designated the value of 1). Samples value represented an x-fold 
difference from this reference (Damm et al., 2011). The assay IDs for the analysed genes are 
as follows: NF-IL6 (Rn00824635_s1), IkBa (Rn01473658_g1), SOCS3 (Rn00585674_s1), 
COX-2 (Rn00568225_m1), mPGES (Rn00572047_m1), TNF-a (Rn99999017_m1), IL-1β 
(Rn00580432_m1), and IL-6 (Rn01410330_m1); (Applied Biosystems, Foster City, CA, 
USA). 
 
3.2.10 Experimental procedures 
 
3.2.10.1 Experiment 1: Characterisation of fever and sickness behaviour 
 
Rats were assigned randomly to receive one of three different doses of 20% (w/v) Brewer’s 
yeast solution (20 ml/kg = 4 g/kg (n = 9), 10 ml/kg = 2 g/kg (n = 5) or 2 ml/kg = 0.4 g/kg (n = 
6)) or saline (20 ml/kg of 0.9% (n = 6). Injections were administered at 16:00, two hours before 
lights off at 18:00. Core body temperatures, cage activity, food intake and body mass were 
monitored for 3 days before and 6 days after injection.  
 
3.2.10.2 Experiment 2: Spatiotemporal characterisation of inflammatory mediators 
 
Separate groups of rats were assigned randomly to receive one of two doses of Brewer’s yeast 
solution (4 g/kg or 2 g/kg) or saline, before brain tissue was collected under terminal 
87 
 
anaesthesia induced with an i.p. injection of 1 ml sodium pentobarbital (Euthanase, 200 mg/ml; 
Kyron Laboratories (Pty) Ltd., South Africa). Blood and brain samples were collected at: 2, 8, 
18 and 72 hours after injection; with five to seven rats euthanased per time point for each of 
the intervention groups. These four time points were chosen to represent four different phases 
of the febrile response the early phase (2 hours), the peak (8 hours), the plateau phase (18 hours) 
and defervescence (72 hours). Blood was collected by cardiac puncture into EDTA tubes after 
which the rats were transcardially perfused using ice cold saline (0.9%) for 2 min. Whole brains 
were recovered and quickly frozen on powdered dry-ice and stored at -80 °C (Damm et al., 
2011). 
 
3.2.11 Data analysis 
 
All data are expressed as mean and SD and were analysed using GraphPad Prism (version 7.0, 
GraphPad Software Inc, USA). Significance was set at P < 0.05. For statistical purposes, the 
original 5-min temperature recordings were averaged over successive two-hour periods. 
Abdominal temperature responses were plotted as abdominal temperature-time curves in one-
hour intervals. The 5-min nocturnal activity counts for each rat were summed for 12 hours 
(18:00 – 06:00) and the summed values were averaged for three nights before the day of 
injection, when the rats were undisturbed in their home cages. Change in nocturnal cage 
activity was then calculated as the difference between the night-time activity following 
injection and the average night-time activity in the three nights before injection, and expressed 
as a percentage of the average pre-injection activity.  
 
Food intake was calculated as grams of food consumed in 24 hours per 100 g of body mass and 
expressed as a percentage change from the mean daily food intake measured over three days 
before injection. Twenty-four-hour change in body mass (g) was determined by subtracting the 
body mass measured at 17:00 on each day after the injection from the body mass measured 
immediately before the injection and expressed as the change in body mass (g) per 100 g of rat 
body mass.  
 
The two-hourly temperature means and changes in nocturnal cage activity, food intake and 
body mass were analysed by two-way repeated measures analysis of variance (ANOVA) with 
intervention and time as main effects. Tukey’s multiple comparisons post hoc test was used to 
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detect differences when the ANOVA detected significant main effects or interactions. To 
determine whether the change in cage activity, food intake and body mass on each of the six 
days after injection was significantly different from pre-injection values, a one-sample t-test 
was performed for each of the experimental groups.  
 
Cytokine levels and relative mRNA expression were compared by two-way ANOVA with 
treatment and time as main effects. Tukey’s multiple comparisons post hoc test was used to 
detect differences when the ANOVA detected significant main effects or interactions. Where 
cytokine levels were undetectable, samples were assigned a value equivalent to the detection 
limit of the assay. Plasma cytokine data that were not normally distributed were log-
transformed prior to statistical analysis. The data presented are non-transformed means and 
SD, but the associated significance values were derived from log-transformed data.  
 
3.3 Results 
 
3.3.1 Experiment 1 - Brewer’s yeast induces fever, lethargy, anorexia and body mass 
stunting 
 
3.3.1.1 Body temperature and nocturnal activity 
 
Figure 3.1 shows the core body temperature over six days for rats that received s.c. injections 
of Brewer’s yeast or saline. The main effects of time (F (72, 1584) = 121.10, P < 0.0001), treatment 
(F (3, 22) = 54.02, P < 0.0001) and interaction (F (216, 1584) = 13.83, P < 0.0001) were significant 
such that rats injected with Brewer’s yeast developed a fever while rats injected with saline did 
not. The core body temperature of rats injected with the high dose of Brewer’s yeast (4 g/kg) 
initially decreased to 36.44 ± 0.60 °C. The decrease in core body temperature lasted for 3 hours 
and was followed by a fever, which peaked at 39.17 ± 0.23 °C ~ 8 hours after injection. Core 
body temperature of rats injected with the medium (2 g/kg) or low (0.4 g/kg) doses of Brewer’s 
yeast started to increase after a latent period of ~ 3 hours and peaked at ~ 8 hours after injection 
at 39.16 ± 0.20 °C and 38.66 ± 0.30 °C respectively. The duration of the fever was dependent 
on the dose of yeast injected. Fever induced by the 0.4 g/kg dose of yeast persisted for the first 
night and day after injection (P < 0.05, Tukey), while fever induced by the medium dose (2 
g/kg) and high dose (4 g/kg) persisted for five (P < 0.05, Tukey) and six (P < 0.05, Tukey) days 
respectively, including the first two nights. 
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Figure 3.1: Core body temperature (mean and SD) of rats over six days after subcutaneous 
injection of (A) 4 g/kg Brewer’s yeast (n = 9), (B) 2 g/kg Brewer’s yeast (n = 5) and (C) 0.4 
g/kg Brewer’s yeast (n = 6) or saline (n = 6). Core body temperatures were plotted in one-hour 
intervals.  The black arrow indicates injection time and black bars indicate lights off (18:00-
06:00 clock time).*significantly different from saline (P < 0.05, Tukey). 
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Figure 3.2 shows that s.c. injection of Brewer’s yeast and saline both induced a significant 
decrease in nocturnal cage activity, but the decrease following Brewer’s yeast injection was 
significantly greater, on the first night after injection, than that following the saline injection, 
and lasted longer (main effects of time (F (5, 110) = 54.63, P < 0.0001), treatment (F (3, 22) = 74.76, 
P < 0.0001) and interaction (F (15, 110) = 7.53, P < 0.0001). Rats receiving the high and medium 
dose of Brewer’s yeast decreased nocturnal cage activity by ~ 80% on the first night after 
injection.  
 
 
Figure 3.2: Change in nocturnal activity (mean and SD) of rats over six days after 
subcutaneous injection of either 4 g/kg Brewer’s yeast (n = 9), 2 g/kg Brewer’s yeast (n = 5), 
0.4 g/kg Brewer’s yeast (n = 6), or saline (n = 6). *Indicates differences between 4 g/kg 
Brewer’s yeast and saline (P < 0.0001, Tukey); # indicates differences between 2 g/kg Brewer’s 
yeast and saline (P < 0.001, Tukey); ^ indicates differences between 0.4 g/kg Brewer’s yeast 
and saline (P < 0.0001, Tukey); + indicates differences between 4 g/kg and 0.4 g/kg Brewer’s 
yeast (P < 0.05, Tukey); & indicates differences between 2 g/kg and 0.4 g/kg Brewer’s yeast 
(P < 0.01, Tukey). One sample t test performed on each experimental group at each time point 
indicated that the decrease in cage activity: (i) never returned to pre-injection values for rats 
that received 4 g/kg or 2 g/kg Brewer’s yeast; (ii) returned to pre-injection values on night 4 
post injection for rats injected with 0.4 g/kg Brewer’s yeast; and (iii) for rats injected with 
saline was only reduced compared to pre-injection values on the first night after injection. 
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From the third night onwards rats injected with the high or medium dose of Brewer’s yeast 
gradually became more active, but activity never fully recovered to pre-injection levels, as by 
the end of the sixth night they remained less active than before the injections (t = 6.1, P = 
0.0003 high dose; t = 6.9, P = 0.002 medium dose). Rats receiving a s.c. injection of the low 
dose of Brewer’s yeast decreased nocturnal cage activity by approximately 60% on the first 
night after injection, which was significantly less than the decrease in nocturnal activity for rats 
that received the high dose of Brewer’s yeast (P < 0.05, Tukey).  Unlike that noted for the high 
and medium doses of Brewer’s yeast, activity recovered, from its initial decrease, such that, 
from the fourth night after injection rats that received the low dose of Brewer’s yeast had 
nocturnal activity levels similar to those before the injections (t = 0.57, P = 0.59).    
3.3.1.2 Food intake and body mass 
 
For the three days before receiving an injection the average daily food consumption of the rats 
per 100 g of body mass was 9.5 ± 0.3 g. Figure 3.3A shows that s.c. injection of Brewer’s yeast 
induced a significant dose-dependent decrease in the food intake compared to rats injected with 
saline (main effects of time (F (5, 110) = 60.70, P < 0.0001), treatment (F (3, 22) = 56.93, P < 
0.0001) and interaction (F (15, 110) = 15, P < 0.0001)). Rats receiving the high, medium or low 
dose of Brewer’s yeast decreased food intake by approximately 60%, 50% and 25%, 
respectively, on the first night after injection. Food intake recovered after its initial decrease 
for rats injected with the high dose of Brewer’s yeast but remained slightly (~ 8%) reduced on 
the sixth day after injection (t = 2.5, P = 0.04).  Rats receiving the medium or lower dose of 
Brewer’s yeast had a faster recovery in food intake after the initial decrease, such that, from 
the fourth day after injection, they were consuming similar amounts of food compared to before 
the injections (t = 2.5, P = 0.07 medium dose; t = 0.16, P = 0.9 low dose). 
 
Figure 3.3B shows that the dose-dependent decrease in food intake following s.c. injection of 
Brewer’s yeast was associated with a dose-dependent loss of body mass (main effects of time 
(F (5, 110) = 18.19, P < 0.0001), treatment (F (3, 22) = 24.95, P < 0.0001) and interaction (F (15, 110) 
= 3.45, P < 0.0001). The body mass of rats injected with the high or medium dose of Brewer’s 
yeast fell progressively for two days and then gradually increased, but remained stunted on the 
sixth day after injection (P < 0.01, Tukey). Over the entire six-day period following injection, 
rats injected with the low dose of Brewer’s yeast gained a similar amount of body mass to that 
noted for rats injected with saline (P > 0.05, Tukey).  
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Figure 3.3: Change in food intake (A) and body mass (B) (mean and SD) of rats over six days 
after subcutaneous injection of either 4 g/kg Brewer’s yeast (n = 9), 2 g/kg Brewer’s yeast (n 
= 5), 0.4 g/kg Brewer’s yeast (n = 6), or saline (n = 6). Food intake was calculated as grams of 
food consumed in 24 hours/100 g of body mass and was expressed as a percentage change from 
average daily food intake measured over three days before injection. Change in body mass was 
determined by subtracting the body mass measured on each day after the injection from the 
body mass measured at the same time immediately before the injection and expressed as the 
change in body mass (g) per 100 g of rat body mass.  * indicates differences between 4 g/kg 
and saline (P < 0.05, Tukey); # indicates differences between 2 g/kg Brewer’s yeast and saline 
(P < 0.01, Tukey); ^ indicates differences between 0.4 g/kg Brewer’s yeast and saline (P < 
0.0001, Tukey); $ indicates differences between 4 g/kg and 2 g/kg Brewer’s yeast (P < 0.05, 
Tukey); + indicates differences between 4 g/kg and 0.4 g/kg Brewer’s yeast (P < 0.05, Tukey); 
& indicates differences between 2 g/kg and 0.4 g/kg Brewer’s yeast (P < 0.05, Tukey). One 
sample t test performed on each experimental group at each time point indicated that the 
decrease in food intake: (1) never returned to pre-injection values for rats that received 4 g/kg 
Brewer’s yeast; (2) returned to pre-injection values on night 4 post injection for rats injected 
with 2 g/kg or 0.4 g/kg Brewer’s yeast. 
 
3.3.2 Experiment 2 – Brewer’s yeast induces an inflammatory response in the periphery 
and the brain 
 
3.3.2.1 Plasma levels of pro-inflammatory cytokines 
 
Plasma was collected at 2, 8, 18 and 72 hours after s.c. administration of Brewers’ yeast or 
saline. Figure 3.4A shows that s.c. injection of Brewer’s yeast induced a significant dose-
dependent increase in plasma levels of TNF-a compared to rats injected with saline (main 
effects of time (F (3, 57) = 46.23, P < 0.0001), treatment (F (2, 57) = 98.67, P < 0.0001) and 
interaction (F (6, 57) = 36.93, P < 0.0001)). Rats injected with the high dose (4 g/kg) of Brewer’s 
yeast had significantly elevated plasma levels of TNF-a at 2 hours and 8 hours compared to 
rats injected with the medium dose (2 g/kg) or saline (P < 0.0001, Tukey). Plasma levels of 
TNF-α were significantly elevated at 2 hours in rats injected with the medium dose (2 g/kg) of 
Brewer’s yeast compared to rats injected with saline.  
 
94 
 
 
Figure 3.4: Blood plasma levels (mean and SD) of bioactive TNF-a (A) and IL-6 (B) at 2, 8, 
18 or 72 hours after subcutaneous injection of either 4 g/kg Brewer’s yeast, 2 g/kg Brewer’s 
yeast or saline. Sample size per intervention group per time point = 5 - 7 rats.* Indicates 
differences between 4 g/kg Brewer’s yeast and saline (P <0.01, Tukey); # indicates differences 
between 2 g/kg Brewer’s yeast and saline (P < 0.05, Tukey); $ indicates differences between 4 
g/kg and 2 g/kg Brewer’s yeast (P < 0.05, Tukey); nd = not detectable. 
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Figure 3.4B shows that s.c. injection of Brewer’s yeast induced a significant dose-dependent 
increase in plasma levels of IL-6 compared to rats injected with saline (main effects of time (F 
(3, 57) = 6.60, P = 0.0007), treatment (F (2, 57) = 77, P < 0.0001) and interaction (F (6, 57) = 2.92, P 
= 0.0148)). Plasma levels of IL-6 were significantly increased at all time points (2, 8, 18 and 
72 hours) in rats injected with the medium and high doses of Brewer’s yeast when compared 
to rats injected with saline (P < 0.05, Tukey). At 8 hours after injection, rats that received the 
high dose of Brewer’s yeast had significantly greater levels of plasma IL-6 than rats that 
received the medium dose of Brewer’s yeast (P = 0.04, Tukey). 
 
3.3.2.2  Activation of NF-IL6, STAT3, NF-kB and COX-2 in the brain 
 
Figure 3.5 shows representative photomicrographs of immunohistochemical detection of 
nuclear factor interleukin-6 (NF-IL6) in the OVLT of rats injected s.c. with the high dose of 
Brewer’s yeast or saline. NF-IL6 immunoreactivity, which colocalised with the DNA marker 
DAPI, appeared in this sensory circumventricular organ as early as 2 hours after injection, was 
strongest at 8 hours and then decreased to reach basal levels by 72 hours after rats were injected 
with Brewer’s yeast. Rats injected with saline did not show nuclear NF-IL6 immunoreactivity 
in the OVLT at any time points. The nuclear NF-IL6 signals were closely associated with blood 
vessels in the OVLT as shown by an additional colocalisation with von Willebrand factor 
(vWF). Nuclear NF-IL6 immunoreactivity was also observed in blood vessels and parenchymal 
cells of the cortex, ependymal cells, the choroid plexus and the median eminence of rats 
injected with Brewer’s yeast (images not shown).   
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Figure 3.5: Nuclear NF-IL6 immunoreactivity in the OVLT at 2, 8, 18 and 72 hours after 
subcutaneous injection of either 4 g/kg Brewer’s yeast or saline. (A) Schematic overview of 
the rat brain showing the position of the OVLT. The white arrowheads show the co-localization 
of red NF-IL6 signals with the nuclear DAPI stain (blue) that indicates the nuclear localization 
of the signals, which appeared at 2 hours (C), peaked at 8 hours (D) and decreased at 18 hours 
(E) and reached basal levels at 72 hours (F) after injection with Brewer’s yeast. Subcutaneous 
injection of rats with saline was not associated with nuclear NF-IL6 immunoreactivity (B). The 
locations of areas used for high magnification are indicated by a dashed square in the 
overviews. Blood vessels were stained with von Willebrand factor (green). Scale bars: in B 
represents 100 µm and applies to 20 x magnification micrographs (B-E); in b represents 25 µm 
and applies to 40 x magnification inserts (b-e).  
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Figure 3.6A and 3.6B shows representative high-magnification photomicrographs of 
immunohistochemical detection of signal transducer and activator of transcription 3 (STAT3) 
activation in the OVLT of rats injected with the high dose of Brewer’s yeast or saline. The 
strongest STAT3 immunoreactivity that colocalised with the DNA marker DAPI, appeared in 
the OVLT at 2 hours after injection and could still be detected at 18 hours, but not 72 hours, 
after rats were injected with Brewer’s yeast. Rats injected with saline did not show nuclear 
STAT3 immunoreactivity in the OVLT at any of the four time points. The nuclear STAT3 
signals were closely associated with blood vessels in the OVLT as shown by an additional 
colocalisation with vWF. Nuclear STAT3 immunoreactivity was also observed in blood vessels 
of the cortex (images not shown). Figure 3.6C and 3.6D shows representative high 
magnification photomicrographs of immunohistochemical detection of nuclear factor-κB (NF-
κB) in the cortex of rats injected with the high dose of Brewer’s yeast or saline. The strongest 
NF-kB staining, which colocalised with the nucleic acid marker DAPI, appeared in the cortex 
at 2 hours after injection, but was not detected at 8, 18 and 72 hours after injection of Brewer’s 
yeast.  
 
 
Figure 3.6: Nuclear STAT-3 immunoreactivity in the OVLT (B) (red shown with white 
arrowheads) and nuclear NF-kB immunoreactivity in the cerebral cortex (D) (red shown with 
white arrowheads) of rats 2 hours after subcutaneous injection of either 4 g/kg Brewer’s yeast 
or saline. Co-localization of red NF-IL6 signals with the nuclear DAPI stain (blue) indicates 
the nuclear localization of the STAT-3 and NF-kB signals (red). Blood vessels were stained 
with von Willebrand factor (green). The nuclear STAT-3 and NF-kB staining was associated 
with blood vessels, as shown by co-localization with von Willebrand factor (green). 
Subcutaneous injection of rats with saline was not associated with nuclear STAT-3 (A) or NF-
kB (C) immunoreactivity. Scale bar = 10 µm and applies to all micrographs (A-D) which were 
taken at 100x magnification. 
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The nuclear NF-kB signals were closely associated with blood vessels in the cortex as shown 
by an additional colocalisation with vWF. No nuclear NF-kB signals were observed in the 
OVLT at any of the four time points in rats injected with Brewer’s yeast. 
 
Figure 3.7 shows representative high-magnification photomicrographs of 
immunohistochemical detection of the enzyme COX-2 in the OVLT of rats injected with the 
high dose of Brewer’s yeast or saline. Weak signals of nuclear COX-2 immunoreactivity were 
detected at 2 hours, strong signals at 8 hours and 18 hours, and no signals were detected at 72 
hours after Brewer’s yeast injection.  
 
 
 
Figure 3.7: Perinuclear COX-2 immunoreactivity (red) in the OVLT at 8 hours (B) and 18 
hours (D) after subcutaneous injection of either 4 g/kg Brewer’s yeast or saline (A and C). Co-
localization of red COX-2 signals with the nuclear DAPI stain (blue) indicates the perinuclear 
localization of the COX-2 signals (red). COX-2 staining (red) was associated with blood 
vessels as shown by co-localization with von Willebrand factor (green) (white arrowheads in 
inserts b and d). Subcutaneous injection of rats with saline was not associated with COX-2 
immunoreactivity (A) and (C) (also see inserts a and c). Scale bar = 25 µm and applies to all 
micrographs (A - D) which were taken at 100 x magnification. 
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The nuclear COX-2 signals co-localised with small and large blood vessels in the OVLT as 
shown by an additional co-localisation with vWF (Figure 3.7B and 3.7D). Nuclear COX-2 
immunoreactivity was also detected in the walls of large vessels with large lumens in the 
subarachnoid space, lateral to the optic chiasm (images not shown). No nuclear COX-2 signals 
were observed in blood vessels in the OVLT at any time point in rats injected with saline.  
 
3.3.2.3 Relative mRNA expression of inflammatory mediators in the hypothalamus  
 
Figure 3.8 shows the increase in hypothalamic mRNA expression of pro-inflammatory target 
genes and regulatory proteins of transcription factors following Brewer’s yeast injection. 
Figure 3.8A shows that there was a dose-dependent increase in NF-IL6 mRNA expression in 
the hypothalamus of rats injected with Brewer’s yeast (10 ml/kg or 20 ml/kg of a 20% solution) 
compared to rats injected with saline (main effects of time (F (3, 57) = 40.40, P < 0.0001), 
treatment (F (2, 57) = 46.26, P < 0.0001) and interaction (F (6, 57) = 3.07, P = 0.0114)). Rats injected 
with the high dose of Brewer’s yeast had significantly greater hypothalamic NF-IL6 mRNA 
expression at 2, 8 and 18 hours compared to rats injected with the medium dose or saline (P < 
0.05, Tukey). The upregulation of NF-IL6 mRNA in the hypothalamus was significantly 
greater in rats injected with the medium dose compared to rats injected with saline at 2 and 8 
hours (P < 0.05, Tukey). 
 
Figure 3.8B shows that there was a dose-dependent increase in the mRNA expression of the 
NF-kB regulator IkBα in the hypothalamus of rats injected with Brewer’s yeast (4g/kg or 2 
g/kg) compared to rats injected with saline (main effects of time (F (3, 57) = 38.55, P < 0.0001), 
treatment (F (2, 57) = 54.62, P < 0.0001) and interaction (F (6, 57) = 8.84, P < 0.0001)).  Rats 
injected with the high or medium dose of Brewer’s yeast had significantly greater hypothalamic 
IkBα mRNA expression at 2, 8 and 18 hours compared to rats injected with the saline (P < 
0.05, Tukey). The upregulation of IkBα mRNA in the hypothalamus was significantly greater 
in rats injected with the high dose of Brewer’s yeast compared to rats injected with medium 
dose of Brewer’s yeast at 2 hours (P < 0.001, Tukey). 
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Figure 3.8: Relative mRNA expression (mean and SD) of transcription factors (A - C), pro-
inflammatory cytokines (D - F) and rate limiting enzymes for PGE2 synthesis (G - H) in the 
rat hypothalamus at 2, 8, 18 and 72 hours after subcutaneous injection of either 4 g/kg Brewer’s 
yeast, 2 g/kg  Brewer’s yeast or 0.9% saline. Sample size per intervention group per time point 
= 5 - 7 rats. * Indicates differences between 4 g/kg and saline (P < 0.05, Tukey); # indicates 
differences between 2 g/kg and saline (P < 0.05, Tukey); $ indicates differences between 4 g/kg 
and 2 g/kg (P < 0.05, Tukey).  
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Figure 3.8C shows that there was a dose-dependent increase in suppressor of cytokine 
signalling 3 (SOCS3) mRNA expression in the hypothalamus of rats injected with Brewer’s 
yeast (4 g/kg or 2 g/kg) compared to rats injected with saline (main effects of time (F (3, 57) = 
80.61, P < 0.0001), treatment (F (2, 57) = 109.10, P < 0.0001) and their interaction (F (6, 57) = 
21.51, P < 0.0001)). Rats injected with the high or medium dose of Brewer’s yeast had 
significantly greater hypothalamic SOCS3 mRNA expression at 2, 8 and 18 hours compared 
to rats injected with the saline (P < 0.05, Tukey). The upregulation of SOCS3 mRNA in the 
hypothalamus was significantly greater in rats injected with the high dose of Brewer’s yeast 
compared to rats injected with medium dose of Brewer’s yeast at 8 and 18 hours (P < 0.05, 
Tukey). 
 
Figure 3.8D and 3.8F shows that there was a dose-dependent increase in TNF-α and IL-1b 
mRNA expression in the hypothalamus of rats injected with Brewer’s yeast (4 g/kg or 2 g/kg) 
compared to rats injected with saline (TNF-α: main effects of time (F (3, 57) = 51.94, P < 0.0001), 
treatment (F (2, 57) = 6.82, P = 0.0022) and interaction (F(6, 57) = 11.19, P < 0.0001) and 
interaction (F(6, 57) = 21.51, P < 0.0001); IL-1b: main effects of time (F(3, 57) = 28.90, P < 
0.0001), treatment  (F(2, 57) = 19.71, P < 0.0001) and interaction (F(6, 57) = 5.31, P = 0.0002)).   
 
Rats injected with the high or medium dose of Brewer’s yeast had significantly greater 
hypothalamic TNF-α and IL-1b mRNA expression at 8 hours compared to rats injected with 
the saline (P < 0.05, Tukey). The upregulation of TNF-α and IL-1b mRNA in the hypothalamus 
was significantly greater in rats injected with the high dose of Brewer’s yeast compared to rats 
injected with medium dose of Brewer’s yeast at 8 hours (P < 0.05, Tukey). 
 
Figure 3.8E shows that there was an increase in IL-6 mRNA expression in the hypothalamus 
of rats injected with Brewer’s yeast (4 g/kg or 2 g/kg) compared to rats injected with saline 
(main effects of time (F (3, 57) = 5.34, P = 0.0026), treatment (F (2, 57) = 12.51, P < 0.0001) and 
interaction (F (6, 57) = 2.99, P = 0.0132)). Rats injected with the high or medium dose of Brewer’s 
yeast had significantly greater hypothalamic IL-6 mRNA expression at 2, 8 and 18 hours 
compared to rats injected with the saline (P < 0.05, Tukey). There were no significant 
differences in the upregulation of IL-6 mRNA in the hypothalamus between rats injected with 
the high dose of Brewer’s yeast compared to rats injected with medium dose of Brewer’s yeast 
(P > 0.05, Tukey). 
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Figure 3.8G shows that there was an increase in COX-2 mRNA expression in the hypothalamus 
of rats injected with Brewer’s yeast (4 g/kg or 2 g/kg) compared to rats injected with saline 
(main effects of time (F (3, 57) = 3.46, P = 0.0221), treatment (F (2, 57) = 4.87, P = 0.0111) and 
their interaction (F (6, 57) = 2.28, P = 0.0485). Rats injected with the high or medium dose of 
Brewer’s yeast had significantly greater hypothalamic COX-2 mRNA expression at 8 hours 
compared to rats injected with the saline (P < 0.05, Tukey). There were no significant 
differences in the upregulation of COX-2 mRNA in the hypothalamus between rats injected 
with the high dose of Brewer’s yeast compared to rats injected with medium dose of Brewer’s 
yeast (P > 0.05, Tukey). 
 
Figure 3.8H shows that there was a dose-dependent increase in mPGES mRNA expression in 
the hypothalamus of rats injected with Brewer’s yeast (4 g/kg or 2 g/kg) compared to rats 
injected with saline (main effects of time (F (3, 57) = 250.40, P < 0.0001), treatment (F (2, 57) = 
130.40, P < 0.0001) and their interaction (F (6, 57) = 76.69, P < 0.0001)). Rats injected with the 
high or medium dose of Brewer’s yeast had significantly greater hypothalamic mPGES mRNA 
expression at 8 and 18 hours compared to rats injected with the saline (P < 0.05, Tukey). The 
upregulation of mPGES mRNA in the hypothalamus was significantly greater in rats injected 
with the high dose of Brewer’s yeast compared to rats injected with medium dose of Brewer’s 
yeast at 8 hours (P < 0.0001, Tukey). 
 
3.4 Discussion 
 
The results from this study show that s.c. administration of Brewer’s yeast dose-dependently 
induces fever, lethargy, anorexia and body mass stunting that is accompanied by pronounced 
inflammation in the periphery and the brain. To my knowledge this is the first report that fever 
and sickness behaviour induced by Brewer’s yeast administration coincides with increased 
concentrations of circulating pro-inflammatory cytokines (IL-6 and TNF-a) (Figure 3.4), and 
enhanced mRNA and protein expression of key transcription factors and regulators (NF-IL6, 
STAT3, NF-kB and SOCS3) involved in the activation or suppression of immune response 
genes in the brain (Figures 3.5 – 3.8). There was a pronounced increase in the mRNA 
expression of pro-inflammatory cytokines (TNF-α, IL-1β and IL-6) and the rate-limiting 
enzymes for prostaglandin synthesis (COX-2 and mPGES) in the hypothalamus primarily 
around the peak of fever, which occurred eight hours after s.c. administration of Brewer’s yeast 
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(Figure 3.1 and 3.8). Moreover, nuclear immunoreactivity for NF-IL6, STAT3 and COX-2 was 
associated with blood vessels in the OVLT. Thus, the OVLT appears to be an important 
communication pathway between the periphery and the brain during yeast-induced infections. 
 
The fever and sickness behaviour observed were dose-dependent in that the high (4 g/kg) and 
medium dose of Brewer’s yeast (2 g/kg) induced responses of greater magnitude and longer 
duration than did the lower dose (0.4 g/kg) (Figure 3.1 – 3.3). The fevers arising from injection 
of the medium and high doses of Brewer’s yeast were not significantly different (time to onset 
~3 hours, time to peak = 8 hours and duration 5-6 days after injection). Similarly, the lethargy 
induced by the high and medium dose was sufficiently intense for the rats to almost cease 
moving around their cages for 48 hours after injection. The rats failed to reach pre-injection 
activity levels over the six-day period of observation. In line with a decrease in food intake, I 
observed a comparable decrease in body mass between rats injected with the high dose and 
those injected with the medium dose of Brewer’s yeast. For both doses, the decrease in body 
mass ultimately resulted in stunting, with the body mass failing to reach pre-injection values 
over the six-day period of observation. From these findings, it appears that the sickness 
response to injection of the medium dose is very similar to that induced by the high dose. Thus, 
for purposes of screening for the efficacy of antipyretic drugs against the sickness response 
induced by Brewer’s yeast, injecting the high dose proffers no advantage over the medium 
dose. From observations made in my study, injection of the high dose is associated with other 
undesirable responses such as; the development of an initial hypothermia before fever, 
excessive inflammation around the head and neck region on the first night and day after 
injection, and a later development of an abscess: all of which do not occur when one injects the 
medium or the low dose.   
 
The short-lived hypothermia that develops after injection of the high dose of Brewer’s yeast is 
similar to that which occurs when one injects high, septic doses of bacterial endotoxin (Derijk 
and Berkenbosch, 1994, Leon, 2004, Ueno et al., 1982). Despite earlier arguments that 
hypothermia is a nonspecific, non-beneficial, unregulated secondary response to an infectious 
agent, recent studies have shown that the hypothermia is a tightly regulated, adaptive response, 
which occurs during systemic inflammation to increase chances of survival (Derijk et al., 
1994b, Romanovsky and Szekely, 1998, Leon, 2004). Research has shown that following 
infection, the development of hypothermia is mediated through deliberate metabolic 
depression, peripheral vasodilation and cold-seeking behaviour (Corrigan, et al., 2014, 
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Romanovsky and Szekely, 1998). Environmental conditions, in particular ambient 
temperatures are also believed to determine whether rodents challenged with high doses of a 
pyrogen develop hypothermia or a fever (Derijk et al., 1994a, Rudaya et al., 2005, Liu et al., 
2012). My experiments were carried out at sub-thermoneutral temperatures (22 ± 2 ºC) and this 
may also explain the development of the hypothermia in rats injected with the high dose of 
Brewer’s yeast. 
 
Published pharmacological antipyretic drug testing guidelines recommend that the test 
compound or the standard drug be administered 18 hours after injection of yeast and 
temperatures be recorded at time intervals of 30 – 60 min for five hours thereafter (Thangaraj, 
2016, Vogel, 2002). In this study, Brewer’s yeast was injected two hours before lights off and 
18 - 23 hours after injection corresponded to the plateau phase of the fever. During the plateau 
phase of the fever, abdominal temperature of rats receiving the high and medium doses of 
Brewer’s yeast was consistently greater (1 - 1.5 ºC) than the abdominal temperature of rats that 
received saline. The increased body temperature noted during the plateau phase of the fever 
supports the recommendation of antipyretic administration taking place 18 hours after Brewer’s 
yeast administration and shows that screening for antipyretic effects can continue beyond 23 
hours. However, it is important to note that the fever was prominent only during the lights-on 
phase and masked during the lights-off phase due to the nychthemeral temperature rhythm of 
rats. 
 
In addition to fully characterizing the yeast-induced fever-curve and sickness behaviours across 
a range of Brewer’s yeast doses commonly used in antipyretic screening in rats, I also 
characterised the spatiotemporal activation of inflammatory mediators in the periphery and 
brain. The time-course of the inflammatory changes showed a marked increase in the synthesis 
of pro-inflammatory cytokines, key prostaglandin-synthesizing enzymes and inflammatory 
transcription factors in the periphery and brain between 2 and 18 hours after Brewer’s yeast 
administration. Overall, the most pronounced increase in inflammatory mediators was noted 
eight hours after Brewer’s yeast injection, with a muted response at 18 hours (Figures 3.4 and 
3.8). Thus, studies wanting to explore the mechanism of action of antipyretics may consider 
administering the antipyretic drug at 8 hours after Brewer’s yeast administration as it 
corresponds to a time when there are higher levels of inflammatory markers in the periphery 
and in the brain. 
105 
 
 
The fever, lethargy, anorexia and body mass stunting induced by s.c. administration of 
Brewer’s yeast was accompanied by an increase in plasma levels and hypothalamic mRNA 
expression of the pro-inflammatory cytokines IL-6 and TNF-a (Figure 3.4 and 3.8). A key role 
for peripherally-released and centrally-released IL-6 in mediating fever has been suggested 
based on the findings that injecting recombinant IL-6 into the brains of rats induces fever 
(Harden et al., 2008, LeMay et al., 1990, Dinarello et al., 1991b) and that neutralizing the action 
of IL-6 in the periphery, using a species-specific IL-6 antiserum, completely prevented fever 
from occurring following localized administration of LPS (Cartmell et al., 2000, Harden et al., 
2006, Rummel et al., 2006). In this study, increased plasma concentrations of bioactive IL-6 
and increased hypothalamic IL-6 mRNA expression were observed from as early as 2 hours 
injection of the medium and high doses of Brewer’s yeast, suggesting that IL-6 may be 
involved in the onset of Brewer’s yeast induced fever. Although hypothalamic expression of 
IL-6 mRNA had returned to basal levels by 72 hours after injection, circulating levels of IL-6 
were still significantly higher in rats injected with Brewer’s yeast suggesting that IL-6 maybe 
responsible for the maintenance of fever beyond 72 hours.  
 
In line with the increase in IL-6 an increase in plasma concentrations and hypothalamic mRNA 
expression of TNF-α was also noted. TNF-α production mirrored the peak of the fever 
response. Findings supporting a pyrogenic action for peripherally and centrally-released TNF-
α include reports that LPS-induced fever in rabbits and guinea-pigs is attenuated when the 
action of TNF-α is inhibited (Kawasaki et al., 1989, Mabika and Laburn, 1999, Roth et al., 
1998) and injecting recombinant TNF-α into the brains of rabbits and mice induces fever 
(Sundgren-Andersson et al., 1998, Kapas et al., 1992).  
 
The synthesis of the pro-inflammatory cytokines and prostaglandins proposed to be involved 
in mediating fever and sickness behaviour occurs via activation of inflammatory transcription 
factors, such as NF-IL6, STAT3 and NF-kB [for review see Rummel (2016)]. Following 
activation, transcription factors translocate from the cytoplasm into the nucleus where they 
regulate the expression of inflammatory target genes identified as important mediators of fever 
and sickness behaviour [for review see Roth and Blatteis (2014), Pecchi et al. (2009)]. Using 
immunohistochemical staining and real-time PCR, I examined the mRNA expression, 
activation and translocation of the transcription factors in the brains of rats injected with 
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Brewer’s yeast. While the signals were observed in several structures in the brain namely the 
cerebral cortex, choroid plexus, ependymal cells and median eminence, the main areas of focus 
for my study were the hypothalamus and the OVLT. The OVLT expresses low basal levels of 
nuclear NF-IL6 and STAT3 (Nadeau et al., 2005, Rummel et al., 2004), but activation and 
nuclear translocation of these transcription factors increases dramatically during inflammation 
induced by LPS administration (Damm et al., 2011, Rummel et al., 2004, Voss et al., 2007, 
Rummel et al., 2005). Immunohistochemical staining for nuclear translocation and activation 
of transcription factors in this sensory CVO therefore serves as a useful tool for investigating 
yeast-related inflammatory signalling between the periphery and the brain.  
 
A clear, time-dependent activation of NF-IL6 was observed in the OVLT following injection 
of Brewer’s yeast (see Figure 3.5). Others, using different inflammatory stimuli, have reported 
similar findings (Damm et al., 2011, Damm et al., 2012, Straccia et al., 2013). The 
spatiotemporal appearance of NF-IL6 in Brewer’s yeast-induced inflammation is similar to the 
activation resulting from LPS administration i.e. an early onset (in this case 2 hours), and a late 
peak at 8 hours (Damm et al., 2011). The activation of STAT3 was also observed in endothelial 
cells of the OVLT (see Figure 3.6) following Brewer’s yeast administration. Immunoreactive 
STAT3 signals were closely associated with blood vessels and STAT3 activation showed an 
early onset (peak at 2 hours) although it remained significantly high for up to 18 hours after 
injection. STAT3 activation has been implicated in the expression of SOCS3, which mediates 
feedback inhibition of cytokine signalling pathways (Alexander, 2002). Hypothalamic mRNA 
expression of SOCS3 was increased between 2 and 18 hours after s.c. administration of 
Brewer’s yeast (Figure 3.8).   
 
Endothelial STAT3 activation has been shown to play an indispensable role in COX-2 
induction and PG synthesis and specific deletion of endothelial STAT3 attenuated the COX-2 
production and the febrile response induced by a moderate immune challenge to LPS 
(Eskilsson et al., 2014). The appearance of COX-2 immunoreactivity in the blood vessels 
preceded the development of the fever, suggesting that this enzyme is involved in PGE2 
synthesis during the early phases of Brewer’s yeast induced fever. Although I did not stain for 
PGE2 synthase in the blood vessels to ascertain that the product of COX-2 activity (PGH2) is 
indeed converted to PGE2, I used RT-PCR to show the upregulation of mPGES gene expression 
in the hypothalamus. In the absence of the inflammatory stimulus, mPGES synthase expression 
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in the hypothalamus was minimal, but a dramatic (40-fold) increase was observed 
corresponding to the peak of Brewer’s yeast induced fever (see Figure 3.8H). 
 
Although there was no NF-kB immunoreactivity observed in the OVLT, it is interesting to note 
that the expression of its regulatory inhibitory molecule IkBα, which usually matches its 
activation patterns (Quan et al., 1997), was significantly raised in the hypothalamus and peaked 
at the earliest time-point (2 hours). NF-kB activation in the OVLT has been shown to occur as 
early as 30 min after peripheral injection of IL-1β (Nadjar et al., 2003) and thus it is possible 
that the earliest time point used in this study (2 hours) was rather late to detect its nuclear 
translocation in the OVLT. NF-kB translocation was however observed in blood vessels of the 
cortex (see Figure 3.6D). 
 
Overall the cascade of cytokine release in the periphery explains the activation of inflammatory 
transcription factors in the brain following Brewer’s yeast administration. To varying degrees 
the activation of NF-IL6, STAT3 and NF-kB in the hypothalamus and OVLT appear to be 
involved in the initiation and maintenance, and SOCS3 in the termination of the brain 
inflammatory and sickness response to yeast. The sickness response to Brewer’s yeast 
remained long after the levels of cytokines and rate limiting enzymes for PGE2 synthesis (e.g. 
COX-2) had returned to basal levels. There is a possibility that direct neural afferents (e.g. 
vagal and other cutaneous afferents) could be responsible for sending immunosensory 
information from the periphery to the brain without need for humoral signals [see Romanovsky 
(2000), Quan and Banks (2007) and Dantzer et al. (2000)]. The abscess formed on the site of 
Brewer’s yeast injection, could therefore act as a reservoir for immunosensory signals carried 
by neural afferents to the brain. It is also possible that other variants of the COX enzyme e.g. 
COX-1 and COX-3 could possibly be involved in mediating the longer-lasting aspects of the 
Brewer’s yeast-induced sickness response (Chandrasekharan et al., 2002). 
 
In conclusion, from the results obtained in this study, I have established that Brewer’s yeast 
induces a high magnitude and long-lasting sickness response that is characterised by an initial 
hypothermia (at high doses), fever, anorexia, lethargy and growth-stunting. The recommended 
18th hour post yeast injection is an appropriate time point for measuring effects of a drug on 
thermal responses as it corresponds with the plateau phase of fever when temperatures are 
consistently increased and not changing. Mechanistically however, there are more 
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inflammatory mediators present in blood and in the brain at 8 hours and this time point may be 
a more appropriate one to intervene for studies investigating the mechanisms of action of the 
antipyretic drugs. At the recommended dose of 4 g/kg, Brewer’s yeast injection is associated 
with the development of an abscess and excessive inflammation. Injection of the medium dose 
induces a sickness response of similar magnitude to that induced by the high dose. In the next 
chapter I therefore I explore the possibility of using zymosan (a cell wall component of 
Brewer’s yeast) as an alternative pyrogen for antipyretic drug testing and elucidation of the 
mechanism of action of test drugs.  
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4. CHAPTER FOUR 
 
 
 
 
Pyrogenic models used during antipyretic testing: The potential use of 
zymosan to induce fever and sickness behaviour during antipyretic testing 
 
 
 
 
 
 
 
 
 
Data and ideas from this chapter have been written up as a scientific paper and submitted to 
Acta Physiologica. Dangarembizi, R., Rummel, C., Roth, J., Erlwanger, K H., Madziva, M T 
and Harden, L M. Zymosan: an inducer of fever and sickness behaviour through activation of 
inflammatory mediators in the brain.  
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4.1 Introduction 
 
As outlined in Chapter 1 and Chapter 3 of this thesis, Saccharomyces cerevisiae (Brewer’s 
yeast) has, for close to a century, remained the recommended pyrogen for inducing fever in 
pharmacological, especially ethnopharmacological, studies screening antipyretics in rats 
(Vogel, 2002, Thangaraj, 2016). However, the large volumes and doses of live yeast 
administered to rats in these pharmacological studies are associated with the development of 
an abscess (Todd, 1986), a prolonged sickness response e.g. lethargy, anorexia and body mass 
stunting (see Figures 3.1 - 3.3 earlier in this thesis). As mentioned earlier in the introductory 
chapter, the animal research ethics welfare principle of refinement, states that procedures and 
techniques used for collecting data on experimental animals should cause minimal suffering 
and pain (Fenwick et al., 2009). Owing to the animal welfare challenges associated with using 
live yeast as a pyrogen, there is a need to find an alternative pyrogen that can induce reasonably 
long fevers that allow for pharmacological manipulations without causing unnecessary pain 
and suffering to the experimental animals. LPS, a bacterial pyrogen has been suggested as an 
alternative pyrogen but no studies have explored the possibility of using zymosan as an 
alternative for simulating fungal infections in rodents.  
 
Zymosan, an immunogenic cell wall extract of S. cerevisiae, is made up of mainly b-glucans 
and mannans and has been shown to stimulate an immune response through activation of toll 
like receptor 2/6 (TLR2/6) and Dectin 1 (Brown et al., 2003, Gantner et al., 2003, Dillon et al., 
2006). Owing to its immunostimulatory effects, zymosan has been used to induce arthritis 
(Frasnelli et al., 2005, Gegout et al., 1994, Keystone et al., 1977), pleurisy (Utsunomiya et al., 
1998, Tarayre et al., 1989), peritonitis (Cash et al., 2009, Sakashita et al., 2000), oedema (Erdő 
et al., 1993), shock (Asmuth et al., 1990b, Volman et al., 2005) and other inflammatory diseases 
in experimental animals.  
 
Intra-articular injection of zymosan at doses between of 4 - 10 mg/kg has been shown to induce 
fever, anorexia and lethargy, albeit short-lived (lasting only up to 4 hours), (Gegout et al., 1994, 
Kanashiro et al., 2009). While these studies may provide empirical evidence that zymosan 
administration can successfully induce fever and sickness behaviour, the low doses of zymosan 
used in these studies induce very short-lived fevers that are undesirable for antipyretic 
screening. Intraperitoneal injection of greater doses of zymosan (500 - 1000 mg/kg) on the 
other hand induced hypothermia, shock, multiple organ failure and increased mortality 
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(Fantuzzi et al., 1997, Volman et al., 2005). Thus, in order to test the suitability of zymosan as 
an alternative/additional pyrogen in antipyretic drug testing, there remains a need to identify a 
dose and route of administration that will induce reasonably long, stable fevers and 
inflammation. 
 
As discussed previously in Chapter 3, the knowledge of the inflammatory mediators activated 
by an experimental pyrogen is important for determining the efficacy and mechanism of action 
of antipyretic drugs. Previous studies have reported that zymosan-induced inflammation is 
mediated by pro-inflammatory cytokines such as interleukin (IL)-1b, IL-6 and tumor necrosis 
factor (TNF)-a (Fantuzzi et al., 1997, Bastos-Pereira et al., 2014) which ultimately induce 
prostaglandin E2 (PGE2) synthesis in the brain (Lima et al., 2016). Using in vitro techniques, 
others further showed that zymosan could activate neuroglial cells cultured from the febrigenic 
regions of the brain, the OVLT and the MnPO, to release IL-6 and TNF-a (Bastos-Pereira et 
al., 2014). Although these studies provide the first evidence that these mediators are stimulated 
during zymosan-induced inflammation, a spatiotemporal description of their activation would 
be more valuable for determination of mechanisms during antipyretic screening. Additionally, 
there are no studies describing the activation of the prominent inflammatory transcription 
factors (NF-kB, NF-IL6 and STAT-3), their target genes or rate-limiting enzymes for PGE2 
synthesis (COX-2 and mPGES) in the brain after zymosan administration. Thus, our 
knowledge of the inflammatory pathways subserving the zymosan-induced sickness response 
remains incomplete.  
 
I therefore carried out this study to determine if subcutaneous injection of zymosan can 
successfully induce fever and a sickness response that can be used in pharmacological 
antipyretic drug testing. I also sought to investigate the neuroinflammatory pathways and 
mediators that are activated during the zymosan-induced sickness response. I monitored body 
temperature, nocturnal cage activity, food intake and body mass gain as indicators of sickness. 
To establish if zymosan activates the same suite of inflammatory mediators as Brewer’s yeast, 
I measured circulating levels of cytokines and assessed the activation of the key inflammatory 
transcription factors NF-kB, NF-IL6 and STAT-3 in the OVLT. I also measured the expression 
of the target genes for these transcription factors (cytokines, COX-2, mPGES and other 
inflammatory regulators) in the hypothalamus. My results show that subcutaneous injection of 
300 mg/kg zymosan induced fever, lethargy, anorexia and growth-stunting. The sickness 
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response was accompanied by an increase in circulating levels of pro-inflammatory cytokines, 
activation of inflammatory transcription factors and an increase in the expression of cytokines 
and key prostaglandin-synthesizing enzymes in the brain. 
 
4.2 Methods 
 
4.2.1 Animals 
 
Male Sprague Dawley rats were purchased from the National Health Laboratory Service 
(Johannesburg, South Africa) and housed in the Central Animal Service Unit of the University 
of the Witwatersrand Johannesburg under conditions previously described in section 3.2.1. On 
the day of injection of the pyrogen, rats had a body mass of between 250 and 300 g. All 
experiments were performed in accordance with the guidelines of the Animal Ethics and 
Control Committee of the University of the Witwatersrand and were approved by its Animal 
Ethics Screening Committee (ethics number 2014/10/C see Appendix 1). 
 
4.2.2 Pyrogen administration 
 
Rats received a single subcutaneous (s.c.) injection of Zymosan A from Saccharomyces 
cerevisiae (Sigma Aldrich, St Louis, USA: Lot number BCBP2641V) reconstituted in a vehicle 
of 0.9% sterile, non-pyrogenic saline (Sabax, Johannesburg, South Africa). To make the 
zymosan solution, 3 g of powdered zymosan was dissolved with 100 ml of saline and vortexed 
until there were no lumps. The zymosan was incubated in a water bath at 37°C for 10 mins 
before being ultrasonicated for a further 2 minutes, in 30-second bouts. The zymosan solution 
was injected in the dorsum of the neck at a dose of either 300 mg/kg or 30 mg/kg.  
 
 
4.2.3 Body temperature and cage activity 
 
As previously described by Hopwood et al. (2009), core body temperature and cage activity of 
rats was measured using sterile, wax-coated temperature-sensitive radiotelemeters (TA10TA-
F40, Data Sciences, St Paul, MN, USA), that had been implanted intra-abdominally, with rats 
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under general anaesthesia (as described fully in section 3.2.3). The rats were given a week to 
recover from surgery. 
 
4.2.4  Body mass and food intake 
 
Body mass and food intake were measured daily, using an electronic scale (Diamond, US) 
accurate to 1 g, two hours before the beginning of the dark phase of the circadian cycle. To 
measure food intake, 200 g of standard rat chow were given to each rat and the daily intake 
was the difference between the initial weight of food at the start (200 g) and the food remaining 
after 24 hours. 
 
4.2.5 IL-6 and TNF-a bioassays 
 
To determine the level of IL-6 and TNF-α in plasma, a bioassay based on the dose-dependent 
growth stimulation of IL-6 on the B9 hybridoma cell line (Aarden et al., 1987) and on the 
cytotoxic effect of TNF on a mouse fibrosarcoma cell line WEHI 164 subclone 13 (Espevik 
and Nissen-Meyer, 1986) was performed as previously described in section 3.2.5. 
 
4.2.6 Tissue preparation, immunohistochemistry and RT-PCR 
 
Coronal brain sections were prepared from areas encompassing the vascular organ of the 
lamina terminalis (OVLT) as described fully in section 3.2.6. Double immunohistochemistry 
was performed as described in section 3.2.7 to measure activation of NF-IL6, STAT3 and 
COX-2, and to determine the contribution of endothelial cells to the immunoreactive cell 
population. Details of primary and secondary antibody dilutions are as described in Table 3.1. 
Processed sections were analysed using fluorescence microscopy as described previously in 
section 3.2.8. 
 
Hypothalamic mRNA expression of NF-IL6, IkBa, SOCS3, COX-2, mPGES, TNF-a, IL-1β, 
and IL-6 was measured using RT-PCR. The procedure for RT-PCR and the assay IDs for the 
genes assayed in this study are as described in section 3.2.9. 
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4.2.7 Experimental procedures 
 
4.2.7.1 Experiment 1: Characterisation of fever and sickness behaviour 
 
Rats were assigned randomly to receive one of three treatments; 300 mg/kg zymosan (n=8), 30 
mg/kg zymosan (n=7) or saline (n=7). All substances were injected at a volume of 10 ml/kg 
body weight. I administered the injections at 17:00, one hour before lights off at 18:00. Core 
body temperature, cage activity, food intake and body mass of the rats were monitored for three 
days before and one day after the s.c. injection of zymosan.  
 
4.2.7.2 Experiment 2: Spatiotemporal characterisation of inflammatory mediators 
 
Separate groups of rats were randomly assigned to receive 300 mg/kg zymosan or saline, before 
brain tissue was collected under terminal anaesthesia induced with an i.p. injection of 1 ml 
sodium pentobarbital (Euthanase, 200 mg/ml; Kyron Laboratories (Pty) Ltd., South Africa). 
Blood and brain samples were collected at: 2, 8 and 18 hours after injection; with five to seven 
rats euthanased per time point for each of the intervention groups. These three time points were 
chosen to represent three different phases of the febrile response; the early phase (2 hours), the 
early plateau phase (8 hours) and the late plateau phase (18 hours). Blood was collected by 
cardiac puncture into EDTA tubes after which the rats were transcardially perfused using ice 
cold saline (0.9%) for 2 min. Whole brains were recovered and quickly frozen on powdered 
dry-ice and stored at -80 °C. 
 
4.2.8 Data analysis  
 
All data are expressed as mean and standard deviation (SD) and were analysed using GraphPad 
Prism (version 7.0, GraphPad Software Inc, USA). Significance was set at P < 0.05. For 
statistical purposes, the original five-minute temperature recordings were averaged over 
successive two-hour periods. The two-hour temperature means were analysed by two-way 
analysis of variance (ANOVA) with treatment and time as main effects. A Bonferroni post hoc 
test was used to identify differences between groups whenever the ANOVA detected 
significant main effects or interactions. Abdominal temperature responses were plotted as 
abdominal temperature-time curves in 30-min intervals. The five-minute nocturnal activity 
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counts for each rat were summed for 12 hours (18:00 – 06:00) and the summed values were 
averaged for three nights before the day of injection, when the rats were undisturbed in their 
home cages. Change in nocturnal cage activity after injection was calculated as the difference 
between the night-time activity following injection (18:00 – 06:00) and the average night-time 
activity in the three nights before injection, when the rats were undisturbed in their home cages, 
and expressed as a percentage of the average pre-injection activity. Food intake post injection 
was calculated as grams of food consumed in 24 hours per 100 g of body mass and expressed 
as a percentage change from the mean daily food intake measured over three days before 
injection.  
 
Twenty-four-hour change in body mass (g) was determined by subtracting the body mass 
measured at 24 hours after the injection from the body mass measured immediately before the 
injection and expressed as the change in body mass (g) per 100 g of rat body mass. Changes in 
nocturnal cage activity, food intake and body mass were analysed by one-way analysis of 
variance (ANOVA) followed by the Bonferroni post hoc test. To determine whether the change 
in cage activity, food intake and body mass after injection was significantly different from pre-
injection values, a one-sample t-test was performed for each of the experimental groups. 
Cytokine levels and relative mRNA expression across treatments at each of the 3 time points 
(2, 8 and 18 hours after injection) were compared by two-way ANOVA with treatment and 
time as main effects. We used a Bonferroni post hoc test to identify differences between groups 
when the ANOVA detected significant main effects or interactions. Where cytokine levels were 
undetectable, samples were assigned a value equivalent to the detection limit of the assay. 
Plasma cytokine data that were not normally distributed were log-transformed prior to 
statistical analysis. The data presented are non-transformed means and SD, but the associated 
significance values were derived from log-transformed data. 
4.3 Results 
 
4.3.1 Experiment 1 - Zymosan induces fever, lethargy, anorexia and body mass stunting 
4.3.1.1 Body temperature and nocturnal activity 
 
Figure 4.1 shows the core body temperature recorded over one day for rats that received s.c. 
injections of either 300 mg/kg zymosan, 30 mg/kg zymosan or saline. The main effects of time 
(F (13, 247) = 95.25, P < 0.0001), treatment (F (2, 19) = 124.40, P < 0.0001) and interaction (F (26, 
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247) = 40.41, P < 0.0001) were significant such that rats injected with zymosan developed a 
fever while rats injected with saline did not. Body temperatures of rats injected with the high 
dose of zymosan (300 mg/kg) started to increase after a latent period of ~ 2 hours and peaked 
(Tmax 38.95 ± 0.23 °C) ~9 hours after injection.  
 
Figure 4.1: Core body temperature (mean and SD) of rats over one day following subcutaneous 
injection of either 300 mg/kg zymosan (n = 8), 30 mg/kg zymosan (n = 7) or saline (n = 7). 
Core body temperatures plotted in 30-minute intervals. The black arrow indicates injection 
time and black bars indicate lights off (18:00 - 06:00 clock time).* indicates differences 
between 300 mg/kg zymosan and saline (P < 0.01, Bonferroni), # indicates differences between 
30 mg/kg zymosan and saline (P < 0.05, Bonferroni). $ indicates differences between 300 
mg/kg zymosan and 30 mg/kg zymosan (P < 0.01, Bonferroni).  
 
The body temperature of rats injected with the lower dose (30 mg/kg) doses of zymosan started 
to increase after a latent period of ~ 4 hours and peaked (Tmax 38.56 ± 0.25 °C) ~6 hours after 
injection. Fever induced by the 300 mg/kg dose of zymosan persisted for the first night and day 
after injection (P < 0.01, Bonferroni), while fever induced by the lower dose (30 mg/kg) 
persisted for 18 hours after injection (P < 0.05, Bonferroni). The increase in body temperature 
induced by the high dose of zymosan was greater than that induced by the lower dose (P < 0.01, 
Bonferroni). 
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Figure 4.2 shows that s.c. injection of zymosan and saline both induced a significant decrease 
in nocturnal cage activity over 12 hours after injection, but the decrease following zymosan 
injection (300 mg/kg; 59.4 ± 10.6% and 30 mg/kg; 37.9 ± 13.1%) was significantly greater 
than that following saline injection (7.3 ± 6.6%) (one-way ANOVA, F (2, 19) = 46.58, P < 
0.0001). The magnitude of the decrease in nocturnal cage activity was dependent on the dose 
of zymosan injected as rats that had received 300 mg/kg decreased nocturnal cage activity by 
~ 20% more than rats that had received 30 mg/kg (P < 0.01, Bonferonni). The mean change in 
nocturnal cage activity of rats receiving the vehicle was not significantly different from zero (t 
= 1.65, P = 0.15). Injection of saline therefore did not have any effect on nocturnal cage activity 
of rats.  
 
 
 
Figure 4.2: Percentage change in nocturnal cage activity (mean and SD) of rats over 12 hours 
(18:00 – 06:00) after subcutaneous injection of either 300 mg/kg zymosan (n = 8), 30 mg/kg 
zymosan (n = 7) or saline (n = 7). * indicates differences between 300 mg/kg zymosan and 
saline (P < 0.0001, Bonferroni), # indicates differences between 30 mg/kg zymosan compared 
to saline (P < 0.0001, Bonferroni), $ indicates differences between 300 mg/kg and 30 mg/kg 
zymosan (P < 0.01, Bonferroni). A one sample t test indicated that cage activity decreased 
significantly from pre-injection values in all groups (300 mg/kg t = 15.9 and P < 0.0001; 30 
mg/kg t = 7.7 and P = 0.0003; saline t = 2.9 and P = 0.0274).  
 
4.3.1.2 Food intake and body mass 
 
For the three days before receiving an injection of zymosan or saline, the average daily food 
consumption of the rats per 100 g of body mass was 7.5 ± 0.3 g. Figure 4.3A shows that s.c. 
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injection of 300 mg/kg zymosan induced a significant decrease (37.9 ± 7.7%) in 24-hour food 
intake of rats compared to injection of saline (one-way ANOVA, (F (2, 19) = 45.09, P < 0.0001). 
The food intake of rats that had received 30 mg/kg zymosan or saline was significantly different 
to the food intake of rats that had received 300 mg/kg, but it was not significantly different to 
pre-injection values (t = 0.79, P = 0.46 and t = 0.67, P = 0.52). Thus, the decrease in food intake 
induced by zymosan injection was dependent on the dose administered.  
 
Figure 4.3B shows that the decrease in food intake following s.c. injection of the 300 mg/kg of 
zymosan was associated with a significant loss of body mass (one-way ANOVA, F (2, 19) = 
12.54, P = 0.0003). Over the 24 hour period after injection there was no significant change in 
the body mass of rats that received 30 mg/kg zymosan (t = 1.2, P = 0.287), while rats that 
received saline significantly gained (1.1 ± 0.8 g) body mass (t = 3.3, P = 0.0156). Thus, the 
loss of body mass induced by zymosan injection was dependent on the dose administered. 
 
4.3.2 Experiment 2 – Zymosan induces an inflammatory response in the periphery and 
the brain 
4.3.2.1 Plasma levels of pro-inflammatory cytokines 
 
Blood plasma was collected at 2, 8 and 18 hours after s.c. administration of 300 mg/kg zymosan 
or saline. Figure 4.4A shows that rats injected with zymosan had significantly elevated plasma 
levels of TNF-a at 2 hours after injection compared to rats injected with saline (main effects 
of time (F (2, 23) = 20.42, P < 0.0001), treatment (F (1, 23) = 30.64, P < 0.0001) and interaction (F 
(2, 23) = 20.42, P < 0.0001)). Figure 4.4B shows that rats injected with zymosan had significantly 
elevated plasma levels of IL-6 at 2, 8 and 18 hours compared to rats injected with saline (main 
effects of time (F (2, 23) = 2.43, P = 0.11), treatment (F (1, 23) = 189.70, P < 0.0001) and interaction 
(F (2, 23) = 0.69, P = 0.69)).  
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Figure 4.3: Change in food intake (A) and body mass (B) (mean and SD) of rats 24 hours after 
subcutaneous injection of either 300 mg/kg zymosan (n = 8), 30 mg/kg zymosan (n = 7) or 
saline (n = 7). * indicates differences between 300 mg/kg zymosan and saline (P < 0.001, 
Bonferroni), $ indicates differences between 300 mg/kg and 30 mg/kg zymosan (P < 0.01, 
Bonferroni). A one sample t test indicated that food intake decreased significantly from pre-
injection values in rats receiving 300 mg/kg zymosan (t = 13.9 and P < 0.0001), but not in rats 
receiving 30 mg/kg zymosan (t = 0.8 and P = 0.46) or saline (t = 0.7 and P = 0.52). A one 
sample t test indicated a significant loss of body mass from pre-injection values in rats receiving 
300 mg/kg zymosan (t = 4.8 and P = 0.0019), but not in rats receiving 30 mg/kg zymosan (t = 
1.2 and P = 0.287); rats receiving saline significantly gained body mass (t = 3.3 and P = 0.0156). 
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Figure 4.4: Blood plasma levels of bioactive TNF-a (A) and IL-6 (B) at 2, 8 or 18 hours after 
subcutaneous injection of either 300 mg/kg zymosan or saline. Sample size per intervention 
group per time point = 4 – 6 rats. * Indicates significant differences between 300 mg/kg 
zymosan and saline (P < 0.0001, Bonferroni); nd = not detectable.  
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4.3.2.2 Activation of NF-IL6, STAT3 and COX-2 in the brain 
 
Figure 4.5 shows representative photomicrographs of immunohistochemical detection of NF-
IL6 in the OVLT of rats injected s.c. with 300 mg/kg zymosan or saline. NF-IL6 
immunoreactivity, which colocalised with the DNA marker DAPI, appeared in this sensory 
circumventricular organ as early as 2 hours after injection (Figure 4.5B), was strongest at 8 
hours (Figure 4.5C) and was still significantly detectable 18 hours after rats had been injected 
with zymosan (Figure 4.5D). Rats injected with saline did not show nuclear NF-IL6 
immunoreactivity in the OVLT at any of the three time points (Figure 4.5A). 
 
Figure 4.6 shows representative photomicrographs of immunohistochemical detection of 
STAT3 activation in the OVLT of rats injected with the 300 mg/kg zymosan or saline. The 
strongest STAT3 immunoreactivity, which colocalised with the nucleic acid marker DAPI, 
appeared in this sensory circumventricular organ between 2 hours and 18 hours after rats were 
injected with zymosan (Figure 4.6B - D). Rats injected with saline did not show nuclear STAT3 
immunoreactivity at any of the three time points (Figure 4.6A). The nuclear STAT3 signals 
were closely associated with blood vessels as shown by an additional colocalisation with vWF.  
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Figure 4.5: Nuclear NF-IL6 immunoreactivity in the OVLT at 2, 8 and 18 hours after 
subcutaneous injection of either 300 mg/kg zymosan or saline. (A) Schematic overview of the 
rat brain showing the position of the OVLT. The co-localisation of the red NF-IL6 signals with 
the nuclear DAPI stain (blue) indicates the nuclear localization of the signals, which appeared 
at 2, 8 and 18 hours (C - E). Blood vessels were stained with von Willebrand factor (green). 
NF-IL6 staining (red) was associated with blood vessels as shown by co-localization with von 
Willebrand factor (green) (white arrowheads in inserts c – e). Subcutaneous injection of rats 
with saline was not associated with nuclear NF-IL6 immunoreactivity (B). The locations of 
areas used for high magnification are indicated by a dashed square in the overviews.  Blood 
vessels were stained with von Willebrand factor (green). Scale bar in (B) represents 100 µm 
and applies to 20 x magnification micrographs (B - E). Scale bar in (b) represents 25 µm and 
applies to 40 x magnification inserts (b - e). 
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Figure 4.6: Nuclear STAT-3 immunoreactivity in the OVLT at 2, 8 and 18 hours after 
subcutaneous injection of either 300 mg/kg zymosan or saline. The co-localisation of the red 
STAT-3 signals with the nuclear DAPI stain (blue) indicates the nuclear localization of the 
signals, which appeared at 2, 8 and 18 hours (B - D). Blood vessels were stained with von 
Willebrand factor (green). STAT-3 staining (red) was associated with blood vessels as shown 
by co-localization with von Willebrand factor (green) (white arrowheads in inserts b – d).  
Subcutaneous injection of rats with saline was not associated with nuclear translocation of 
STAT-3 (A). The locations of areas used for high magnification are indicated by a dashed 
square in the overviews. Scale bar in (A) = 25 µm and applies to all micrographs (A - D) which 
were taken at 40 x magnification. Scale bar in (a) = 10 µm and applies to all inserts (a - d) 
which were taken at 100 x magnification. 
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Figure 4.7 shows representative high magnification photomicrographs of 
immunohistochemical detection of the enzyme COX-2 in the OVLT of rats injected with 300 
mg/kg. Typical perinuclear COX-2 immunoreactivity was detected in this sensory 
circumventricular organ between 2 hours and 18 hours after rats were injected with zymosan 
(Figure 7B - D). The perinuclear COX-2 signals colocalised with blood vessels as shown by 
an additional colocalisation with vWF (Figure 4.7B and D).  
 
 
 
Figure 4.7: Perinuclear COX-2 immunoreactivity at 2, 8 and 18 hours after subcutaneous 
injection of either 300 mg/kg zymosan or saline. The co-localisation of the red COX-2 signals 
with the nuclear DAPI stain (blue) indicates the perinuclear localization of the signals, which 
appeared at 2, 8 and 18 hours (B - D).  Blood vessels were stained with von Willebrand factor 
(green).  COX-2 staining (red) was associated with blood vessels as shown by co-localization 
with von Willebrand factor (green) (white arrowheads in inserts b – d). Subcutaneous injection 
of rats with saline was not associated with COX-2 immunoreactivity (A). The locations of areas 
used for high magnification are indicated by a dashed square in the overviews. Scale bar in (A) 
= 25 µm and applies to all micrographs (A - D) which were taken at 40 x magnification. Scale 
bar in (a) = 10 µm and applies to all inserts (a - d) which were taken at 100 x magnification. 
 
 
128 
 
Perinuclear COX-2 immunoreactivity was also detected in the walls of large vessels with large 
lumens in the subarachnoid space, lateral to the optic chiasm (images not shown). No 
perinuclear COX-2 signals were observed in blood vessels in the OVLT at any of the three 
time points in rats injected with saline (Figure 4.7A). 
4.3.2.3 Relative mRNA expression of inflammatory mediators in the hypothalamus 
 
Figure 4.8 shows the increase in hypothalamic-mRNA expression of pro-inflammatory target 
genes and regulatory proteins of transcription factors; following injection of 300 mg/kg 
zymosan or saline in rats. Figure 8A and 8B show that rats injected with zymosan had 
significantly greater mRNA expression of NF-IL6 and IkBα (the negative regulator of NF-kB) 
in the hypothalamus at 8 and 18 hours compared to rats injected with saline (NF-IL6: main 
effects of time (F (2, 23) = 3.54, P = 0.0458), treatment (F (1, 23) = 27.18, P < 0.0001) and 
interaction (F (2, 23) = 5.08, P = 0.0149); IkBα: main effects of time (F (2, 23) = 2.76, P = 0.0843), 
treatment (F (1, 23) = 17.12, P =0.0004) and interaction (F (2, 23) = 0.6661, P = 0.5233)). 
 
Figure 4.8C shows that there was a significant increase in SOCS3 mRNA expression in the 
hypothalamus of rats injected s.c. with zymosan (300 mg/kg) compared to rats injected with 
saline (main effects of time (F (2, 23) = 4.27, P < 0.0264), treatment (F (1, 23) = 147.20, P < 0.0001) 
and interaction (F (2, 23) = 4.422, P = 0.0237)). Rats injected with zymosan had significantly 
higher hypothalamic SOCS3 mRNA expression at 2, 8 and 18 hours compared to rats injected 
with the saline (P < 0.01, Bonferroni).  
 
Figure 8D, 8E and 8F shows that rats injected with zymosan had significantly greater 
hypothalamic TNF-α mRNA expression at 8 and 18 hours, IL-6 mRNA expression at 8 hours 
and IL-1b mRNA expression at 2, 8 and 18 hours compared to rats injected with the saline 
(TNF-α: main effects of time (F (2, 23) = 12.47, P = 0.0002), treatment (F (1, 23) = 31.38, P < 
0.0001) and interaction (F (2, 23) = 5.56, P = 0.0107); IL-6: main effects of time (F (2, 23) = 0.69, 
P = 0.5113), treatment (F (1, 23) = 8.18, P = 0.0089) and interaction (F (2, 23) = 1.34, P = 0.2807); 
IL-1b: main effects of time (F (2, 23) = 21.68, P < 0.0001), treatment (F (1, 23) = 153.70, P < 
0.0001) and interaction (F (2, 23) = 15.39, P < 0.0001)). 
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Figure 4.8: Relative mRNA expression (mean and SD) of transcription factors (A - C), pro-
inflammatory cytokines (D - F) and rate-limiting enzymes for PGE2 synthesis (G - H) in the 
rat hypothalamus at 2, 8 and 18 hours after subcutaneous injection of either 300 mg/kg zymosan 
or saline. Sample size per intervention group per time point = 4 – 6 rats. * Indicates significant 
differences between 300 mg/kg zymosan and saline (P < 0.05, Bonferroni).  
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Figure 4.8G shows that there was an increase in COX-2 mRNA expression in the hypothalamus 
of rats injected s.c. with zymosan (300 mg/kg) compared to rats injected with saline (main 
effects of time (F (2, 23) = 2.33, P = 0.1196), treatment (F (1, 23) = 42.29, P < 0.0001) and 
interaction (F (2, 23) = 1.80, P = 0.1879)). Rats injected with zymosan had significantly higher 
hypothalamic COX-2 mRNA expression at 2, 8 and 18 hours compared to rats injected with 
the saline (P < 0.05, Bonferroni).  
 
Figure 4.8H shows that there was a significant increase in mPGES mRNA expression in the 
hypothalamus of rats injected s.c. with zymosan (300 mg/kg) compared to rats injected with 
saline (main effects of time (F (2, 23) = 57.04, P < 0.0001), treatment (F (1, 23) = 265.50, P < 
0.0001) and interaction (F (2, 23) = 57.22, P < 0.0001)). Rats injected with zymosan had 
significantly higher hypothalamic mPGES mRNA expression at 8 and 18 hours compared to 
rats injected with the saline (P < 0.0001, Bonferroni). 
 
4.4 Discussion 
 
The results obtained in this study show that subcutaneous administration of zymosan in rats 
induces a dose-dependent sickness response which includes fever, lethargy, anorexia and 
growth stunting (Figure 4.1 – 4.3). The fever and sickness behaviour are accompanied by an 
increase in circulating levels of IL-6 and TNF-a (Figure 4.4) and subsequent activation of pro-
inflammatory transcription factors (NF-IL6 and STAT-3) in the OVLT between 2 and 18 hours 
(Figure 4.5 – 4.6). Zymosan administration also induced an increase in hypothalamic 
expression of genes encoding pro-inflammatory cytokines (IL-1b, TNF-a and IL-6), regulators 
of inflammatory transcription factors (IkBa and SOCS3) and rate-limiting enzymes for 
prostaglandin synthesis (COX-2 and mPGES) (Figure 4.7 – 4.8).  
 
The characteristics of the thermal response to zymosan administration are dependent on the 
dose of zymosan injected. In this study, s.c. injection of 300 mg/kg of zymosan induced fever 
with an earlier onset and greater magnitude (time to onset ~2 hours; time to peak = 9 hours and 
an amplitude of 2 at 18 hours after injection) compared to s.c. injection of 30 mg/kg. My results 
show that s.c. injection of a moderately high dose (300 mg/kg) of zymosan could be used 
experimentally for inducing, non-septic and non-hypothermic thermal responses characterised 
by reasonably long fevers that allow for pharmacological manipulations and antipyretic drug 
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testing without inducing prolonged suffering and sickness in the rats. In the first 24 hours after 
injection, the febrile response induced by administration of zymosan was comparable to that 
induced by 2-4 g/kg Brewer’s yeast (see Figure 3.1). As was observed in Brewer’s yeast 
induced fever (Figure 3.1), 18 hours after injection corresponds with the plateau phase of the 
fever when temperatures are consistently 1.5 - 2 °C above that of normothermic rats. Thus, for 
zymosan-induced fever at a dose of 300 mg/kg, the 18-hour time point is also an appropriate 
time point for injecting antipyretics and determining their efficacy in attenuating fever.  
 
In addition to fever, zymosan dose-dependently induced lethargy (Figure 4.2), anorexia and 
growth-stunting (Figure 4.3). The reduction in activity (~60%) and food intake (~40%) induced 
24 hours after zymosan administration is comparable to that induced by the medium and low 
doses of Brewer’s yeast (see Figures 3.2 - 3.3). Sickness behaviour was prominent during the 
night period, when the rats are usually active and consume most of their food. Thus, if one 
intends to measure the efficacy of a drug against zymosan-induced sickness behaviour, they 
may consider injecting the pharmacological drug before the night phase. The observation that 
zymosan administration is associated with sickness behaviour is consistent with the findings 
of other researchers who also reported anorexia (Cremeans-Smith and Newberry, 2003, 
Fantuzzi et al., 1997), lethargy (Hubschle et al., 2007) and weight loss (Hubschle et al., 2007, 
Volman et al., 2005) during zymosan-induced inflammation.  
 
The fever, lethargy, anorexia and body mass stunting induced by s.c. administration of 300 
mg/kg zymosan was accompanied by an increase in the blood plasma levels and hypothalamic 
mRNA expression of the pro-inflammatory cytokines IL-6 and TNF-α (Figure 4.4 and 4.8). 
Circulating levels of TNF-α were significantly increased 2 hours after zymosan administration 
suggesting that TNF-α release, which precedes fever, may mediate the early rise in temperature 
during zymosan-induced fever. Early TNF-α release during zymosan-induced inflammation 
has similarly been reported by other researchers (Asmuth et al., 1990b, Fantuzzi et al., 1997, 
Utsunomiya et al., 1998) and inhibition of TNF-α activity blocked the earlier part of zymosan-
induced fever as opposed to the latter (Bastos-Pereira et al., 2014, Kanashiro et al., 2015). 
 
I also observed elevated plasma levels of IL-6 during the early phase (2 hours), as well during 
the mid-to-late plateau phase (8 and 18 hours) after zymosan injection. The timing of IL-6 
increase suggests that IL-6 may be involved in both early development and the maintenance of 
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zymosan-induced fever, as has similarly been noted in Brewer’s yeast-induced fever (see 
Figure 3.4). An early (3 hours) increase in IL-6 has been reported in rats injected 
intraperitoneally with zymosan (Bastos-Pereira et al., 2014). Additionally, inhibition of IL-6 
activity attenuated zymosan-induced fever (Bastos-Pereira et al., 2014, Kanashiro et al., 2015). 
These data, together with my current findings, support the involvement of IL-6 in mediating 
zymosan-induced fever. 
 
Zymosan-induced fever and sickness behaviour are mediated by prostaglandins (Lima et al., 
2016) and zymosan has been shown to activate the production of cytokines (TNF-α and IL-6) 
by neuroglial cells cultured from the OVLT and MnPO (Bastos-Pereira et al., 2014). As 
discussed in Chapter 1 and 3, production of PGE2 and central cytokines occurs via activation 
of inflammatory transcription factors. To my knowledge, my results provide the first, in vivo, 
experimental evidence that zymosan administration induces a time-dependent activation of the 
pro-inflammatory transcription factors NF-IL6 and STAT3 in the OVLT and their target genes 
in the hypothalamus (Figure 4.5 - 4.8). These findings align with the current theories describing 
the development of fever in which humoral immune signals are believed to activate the brain 
to synthesize inflammatory molecules that then act locally to induce fever and sickness 
behaviour (Rummel, 2016, Saper and Breder, 1994). 
 
The activation and nuclear translocation of NF-IL6 in the OVLT observed in this study 
occurred in the early and the mid-to-late plateau phases of zymosan-induced fever (Figure 4.5). 
Additionally, the strongest activation of NF-IL6 in the OVLT occurred just before the highest 
temperatures were achieved; 8 hours after injection (see Figure 4.5 and Figure 4.1). The late 
induction of NF-IL6 (strongest immunoreactivity at 8 hours) is similar to the induction pattern 
reported for Brewer’s yeast (see Figure 3.5) and supports the hypothesis that NF-IL6 may be 
more active during the latter, than earlier phase of the zymosan induced-acute phase response. 
Overall, the activation of NF-IL6 in the OVLT by zymosan carries an important functional 
significance because, as discussed in Chapter 1, this sensory CVO lies close to and has 
numerous neural connections with the febrigenic zones of the hypothalamus. The OVLT may 
therefore be an important port of entry for immune signals originating in the periphery in 
zymosan-induced sickness responses.  
 
Some researchers have argued that there is transcriptional synergism between NF-IL6 and NF-
kB and that the two transcription factors co-regulate gene expression (Matsusaka et al., 1993, 
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Santos et al., 2011). Previous studies have also shown that zymosan activates the NF-kB 
pathway by binding to TLR2/TLR6 and Dectin 1 (de Hooge et al., 2004b). Although I did not 
perform immunohistochemical staining of NF-kB in this study, I measured the expression of 
its regulatory protein, IkBa, whose upregulation is an established and accepted indicator of 
NF-kB activation (Quan et al., 1997). I noted a late expression of hypothalamic IkBa (8 and 
18 hours), which confirms earlier reports given from cell culture studies that the zymosan-
induced inflammatory response may be mediated by both the NF-IL6 and NF-kB pathways 
(Santos et al., 2011). 
 
In addition to evidence showing the activation of NF-IL6 and NF-kB, I also observed an early 
activation of STAT3 associated with blood vessels in the brains of rats injected with zymosan 
(Figure 3.6). These findings suggest that in addition to stimulating NF-kB and NF-IL6 
signalling pathways, zymosan may also induce neuroinflammation through activation of the 
JAK/STAT signalling pathway. The involvement of STAT3 in the zymosan-induced sickness 
response could be further confirmed by the increase in the expression of the STAT3 regulator 
(SOCS3) observed in the hypothalamus.  
 
The activation and nuclear translocation of NF-IL6 and STAT3 in the brain induces the 
transcription of inflammatory genes including cytokines and rate-limiting enzymes for PGE2 
synthesis (COX-2 and mPGES) (Damm et al., 2012, Matsusaka et al., 1993, Schneiders et al., 
2015, Rummel et al., 2011). NF-IL6 and STAT3 have been shown to play a role in the 
regulation of transcription of genes encoding the pro-inflammatory cytokines, IL-6 and IL-1b  
(Zhang et al., 1994, Zhang and Rom, 1993, Rummel et al., 2011). The transcriptional regulation 
of these genes in the hypothalamus following zymosan administration is, for the first time, 
shown in this study. I observed an upregulation in the expression of genes encoding TNF-a, 
IL-6 and IL-1b in the hypothalamus. Given the numerous physiological functions of the 
hypothalamus i.e. control of thermoregulation, feeding, drinking, sleep, an activation of 
inflammatory mediators in the hypothalamus is of functional significance as it may explain the 
behavioural shift that occurs during the zymosan-induced sickness response. 
 
Zymosan-induced sickness is ultimately mediated by prostaglandins as has been shown in 
studies where; (1) systemic injection of zymosan was associated with an increase in PGE2, (2) 
stimulation of macrophages with zymosan induced the production of PGD2, PGE2, PGF2 and 
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PGI2, and (3) the administration of prostaglandin-synthesis inhibitors such as indomethacin 
blocked the sickness response induced by zymosan injection (Lima et al., 2016). 
Prostaglandins, particularly PGE2, are produced in the brain and act as the terminal mediators 
of infection-induced neuroinflammation (Ivanov and Romanovsky, 2004). The activation of 
COX-2 in cerebrovascular cells (see Figure 4.7) and the upregulation of COX-2 and mPGES 
genes in the hypothalamus of rats injected with zymosan provide further evidence to confirm 
the involvement of PGE2 in mediating zymosan-induced sickness.  
 
Overall, the mechanisms underlying the zymosan-induced sickness response are similar to 
those mediating Brewer’s yeast-induced sickness. Zymosan, like Brewer’s yeast, induces the 
production of the peripheral cytokines TNF-a and IL-6. At the doses given in this study, the 
degree of increase of the pro-inflammatory cytokines was much lesser when zymosan was 
administered than when yeast was administered (see Figures 3.4 and 4.4). Except for IL-1b and 
COX-2, the degree of increase in the expression of hypothalamic genes (NF-IL6, IkBa, 
SOCS3, TNF-a, IL-6 and mPGES) was much lower when zymosan was administered than 
when yeast was administered (see Figures 3.8 and 4.8). A typical example is that of mPGES 
whose expression increased almost 40-fold in Brewer’s yeast-induced sickness but only about 
10-fold in zymosan-induced sickness. These results confirm the potency of the dose of live 
yeast that is currently being administered during antipyretic screening while affirming the 
suitability of using zymosan as an alternative pyrogen to induce a full suite of inflammatory 
mediators at a moderate degree. 
 
In conclusion, the results obtained from this study show that s.c. administration of zymosan 
induces a reasonably long-lasting fever that is accompanied by sickness behaviour. 
Administration of zymosan, like Brewer’s yeast, is associated with an increase in the levels of 
peripheral cytokines (IL-6 and TNF-a), activation of inflammatory transcription factors (NF-
IL6, NF-kB and STAT3), and an upregulation of their target genes (central cytokines and 
inducible enzymes) in the hypothalamus. The ability of zymosan to induce peripheral and 
central inflammatory mediators supports its suitability as an experimental pyrogen. In 
zymosan-induced sickness, just as in Brewer’s yeast-induced sickness, the 18-hour time point 
is more appropriate for assessing the efficacy of a pharmacological agent against fever while 
both the 8-hour and 18-hour time points appear suitable for determination of mechanisms of 
action. 
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Since the pre-antibiotic era, and even now after the discovery of antibiotics, antipyretic 
drugs remain useful for reducing elevated body temperatures associated with infectious 
diseases such as malaria and influenza, and even in non-infectious, autoimmune and auto-
inflammatory disorders. Fever control using antipyretic drugs has also proven important 
in vulnerable populations such as children with the risk of developing febrile seizures, 
critically ill patients and in patients with cardiovascular complications. The most 
commonly used assay for detecting antipyretic potential of drugs has not changed much 
over the past century. The recommended antipyretic drug testing assay entails inducing 
fever in rats by subcutaneous injection of 2 – 4 g/kg of Brewer’s yeast solution. A test 
drug is then injected 18 hours after the injection of the pyrogen and thereafter rectal 
temperatures are measured at hourly intervals, for five hours to determine the efficacy of 
the test drug in attenuating fever. Surprisingly, although this recommended protocol is 
extensively accepted and commonly used for testing antipyretics particularly in 
pharmacognostic studies, there is no clear scientific evidence provided to support the 
pyrogen used for inducing fever and the method used for measuring temperature. 
 
The general aim of my thesis was to validate specific aspects of the currently 
recommended anti-pyretic testing protocol and to provide experimental evidence to 
support the basis of its continued use. I also sought to establish avenues to improve the 
current published protocol to ensure accuracy and reliability of results (Thangaraj, 2016, 
Vogel, 2002). More specifically, my first objective was to examine the method commonly 
used for measuring temperature during antipyretic screening and in this study, I 
investigated the effects of rectal temperature measurement on the thermal profiles of 
normothermic and febrile rats (Chapter 2). I further compared temperatures recorded 
using rectal thermocouple probes with temperatures measured using intra-abdominally 
implanted radiotelemeters. My second objective was to characterise the fever, sickness 
behaviour and inflammatory response induced by Brewer’s yeast, the pyrogen that is 
recommended for inducing fever during antipyretic screening (Chapter 3). Having 
characterised the sickness response to Brewer’s yeast and having established the 
limitations associated with injecting the current recommended doses, my last objective 
was to investigate if zymosan (a cell wall moiety of Brewer’s yeast) could be used as an 
alternative experimental pyrogen during antipyretic screening (Chapter 4). My major 
findings are discussed below in the context of current literature.  
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5.1 Protocol for testing antipyretic drugs 
5.1.1 Measuring body temperature 
 
As discussed in Chapter 1, a good thermometry method is one which has a high level of 
sensitivity and accuracy; one that is associated with minimum distress and measurement-
related artefacts. As outlined above, the protocol for testing antipyretic drugs entails the 
use of a thermocouple probe to measure rectal temperature at hourly intervals after the 
injection of the test antipyretic drugs. There are a number of reasons that could explain 
why the use of rectal thermometry is very common in antipyretic testing particularly in 
ethnopharmacological studies. Firstly, rectal thermometry has relatively low set-up and 
maintenance costs when compared to other methods such as biotelemetry. Secondly, as 
shown in Chapter 2, core body temperatures measured using rectal thermometry are 
qualitatively comparable to those measured using biotelemetry. Although I observed a 
linear association between values measured using the two methods, the agreement 
interval of the two methods shows that temperatures measured using thermocouple probes 
can be greater (up to 0.7 ºC) or lower (up to 0.5 ºC) than those obtained with a 
radiotransmitter. Additionally, rectal thermometry underestimated the amplitude of the 
fever at 18 hours by approximately 0.4 ºC. Thus, rectal thermometry and biotelemetry 
may yield qualitatively similar results but rectal thermometry may underestimate or 
overestimate core body temperatures. The difference between temperatures measured 
using the two methods is likely caused by differences in the depth of probe insertion. In 
this study, even though I used and maintained an insertion depth of 40 mm (reportedly 
used successfully in studies done using the same size of rats as were used in this study), 
I still observed differences between temperatures measured using rectal thermometry 
with those recorded using radiotransmitters. The accuracy of rectal thermometry depends 
not only on the techniques of the researcher, but so too on the cooperation of the animal, 
which is difficult to standardize. 
 
Although it is a recommended, popular method for measurement of thermal responses in 
pharmacological studies, my results show that rectal temperature measurement is 
associated with stress-related increases in temperature. The stress-induced hyperthermia 
is clear, consistent and reproducible in normothermic rats, but muted in febrile rats. The 
difference in the thermal responses of normothermic vs febrile rats to stress has 
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significant implications that researchers in pharmacological studies need to consider. 
Usually, the antipyretic efficacy of a drug is determined by the index of similarity or 
difference between febrile rats treated with the test drug and the normothermic untreated 
controls. Due to the stress-related increase in temperature in normothermic rats, coupled 
with no change in their febrile counterparts, there is a higher likelihood of statistical non-
significance which may be erroneously mistaken to be positive drug effects. However, it 
is important to note that the experiments in Chapter 2 were carried out at temperatures 
below the thermoneutral zone of rats and the thermal responses to stress could have been 
different had they been done at thermoneutral temperatures.  
 
Some may argue that the stress-induced hyperthermia resolves within one hour and that 
since common practice in pharmacological studies is to measure rectal temperatures once 
every hour, then stress-induced hyperthermia is unlikely to affect the accuracy of the 
results. However, from the literature reviewed in my thesis, I observed that it is also 
common for researchers to take rectal temperature measurements at even shorter intervals 
e.g. 30 minutes [for example see (Josa et al., 2001, Liu et al., 2016, Pingsusaen et al., 
2015, Zakaria et al., 2006)]. At these shorter intervals, the reported thermal responses 
reported are likely to reflect the hyperthermia. Additionally, the procedure of rectal 
temperature measurement is also associated with other physiological changes such as an 
increase in cytokines and circulating hormones with longer lasting effects that may 
influence physiological responses long after the hyperthermia has subsided (Veening et 
al., 2004). Thus, although a rat’s temperature may have decreased back to normal after 
an hour, its biochemical make-up and physiological state may still be different to that of 
an unstressed rat. 
 
Another equally important observation I made regarding the use of rectal thermometry 
was that the protocol commonly employed for “habituating” rats to the procedure does 
not alleviate or blunt the development of stress-induced hyperthermia. One plausible 
explanation for the lack of adaptation could be that stress-induced hyperthermia is part of 
the non-adaptive sympathetically driven stress responses. Other researchers have shown 
little-to-no adaptation in the heart rate and catecholamine levels in response to repeated 
exposure to psychosocial stress (Schommer et al., 2003). Future studies could possibly 
investigate effective protocols for habituating rats to the procedure of rectal temperature 
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measurement and establish if rats can be conditioned to a point where they blunt the 
stress-related hyperthermia. 
 
In summary, although it potentially yields similar results to biotelemetry, the procedure 
of rectal temperature measurement is associated with a number of technical challenges 
which include stress-induced hyperthermia, a lack of clearly defined habituation 
protocols and difficulties in the standardization of measurements and techniques. These 
challenges have negative implications on the accuracy of thermal responses reported 
during antipyretic drug-testing. Thus, when compared with rectal thermometry, 
surgically-implanted radiotelemeters appear to be a more reliable and better tool for 
accurate, repeated temperature measurement during antipyretic screening. 
 
5.1.2 Pyrogen and timing of anti-pyretic drug administration 
 
As important as it is to choose a good method for measuring temperature during 
antipyretic drug testing, it is equally important to consider the efficacy of the pyrogen 
selected for inducing fever. As previously discussed in Chapter 1, the success of an 
experimental pyrogen lies in its ability to induce reasonably uniform, reproducible fevers 
that last long enough to allow pharmacological manipulations. My results show that when 
injected subcutaneously, Brewer’s yeast is an immunogenic substance capable of 
inducing fever in rats. The immunogenicity of Brewer’s yeast therefore forms the basis 
for its long-standing use and recommendation as an experimental pyrogen. However, the 
dose recommended for inducing sickness during antipyretic testing (4g/kg) induces an 
initial short-lived hypothermia followed by a long-lasting fever. What is clear from my 
findings is that the hypothermia was reproducibly associated with injection of the high 
but not lower doses of Brewer’s yeast suggesting that it may be related to hyperactivation 
of the immune response as occurs during sepsis. Current guidelines for antipyretic 
screening do not specify the environmental temperatures at which the experiments should 
be conducted. However, previous studies have shown that the thermal response of rodents 
to a pyrogen varies with environmental temperatures. When injected under their 
thermoneutral zone, rats have been shown to decrease temperature prior to developing a 
fever (Rudaya et al., 2005). It is possible, therefore, that the short-lived hypothermia that 
developed in rats injected with the high dose of Brewer’s yeast could be the result of the 
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ambient temperature at which they were kept, which was below their thermoneutral zone. 
Future studies characterising the thermal response to Brewer’s yeast administration could 
explore if the same thermal profile observed in the findings in Chapter 3 would be 
observed if experiments were to be done at thermoneutral temperatures for rats.  
 
The basis for injecting the test drug at the 18-hour time point is not well explained in 
literature, but my findings in Chapters 2 and 3 show that the 18-hour time point falls 
within the plateau phase of Brewer’s yeast-induced fever. Provided the pyrogen is 
injected just before the dark phase of the light/dark cycle, temperatures will be 
consistently higher than that of normothermic rats at 18 hours after Brewer’s yeast 
administration. However, had the pyrogen been injected in the early part of the light phase 
cycle (morning), the 18-hour time point would occur during the night period when the 
temperatures of controls were naturally high due to the circadian rhythm of core 
temperature and thus the fever amplitudes would have been smaller. While fever 
amplitudes may better be monitored during the light phase, sickness symptoms such as 
lethargy and anorexia are best measured during the dark phase of the circadian cycle; 
when the rats are active and eating. Although at present they are not included in the 
current guidelines for antipyretic testing, these sickness symptoms may be useful 
measurable indices of sickness that can be incorporated in comprehensively testing the 
efficacy of drugs against the sickness response.  
 
Although the 18-hour time point appears to be a good time point for comparison of 
temperatures, my results show that inflammatory mediators were more prominent at 8 
hours. Thus researchers investigating the mechanism of action of pharmacological 
substances, could consider administering test drugs before or at 8 hours after 
administration of Brewer’s yeast. In this study the levels of inflammatory mediators were 
not monitored beyond 72 hours and therefore mediators responsible for maintenance of 
the fever and sickness behaviours beyond this time point remain to be elucidated. 
Additionally, other inflammatory markers, not investigated in this study could also be 
involved in mediating Brewer’s yeast induced fever and may also be important in testing 
the mechanisms of antipyretic drugs. Examples of other inflammatory mediators that 
have been implicated in meditating LPS-induced fever but their role in yeast-induced 
fever is still unexplored include leptin, COX-1/COX-3, neuropeptides and chemotactic 
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cytokines such as macrophage inflammatory proteins (Sachot et al., 2004, Harden et al., 
2006, Miñano et al., 1996). 
 
The welfare of the experimental animals is an important factor that may be overlooked 
by researchers when they choose protocols for antipyretic drug-testing. While Brewer’s 
yeast is cheap and has the immunogenic properties that qualify it as an experimental 
pyrogen, the high doses of live yeast required to induce fever often cause suffering and 
discomfort to the experimental animals. Firstly, the recommended high dose of Brewer’s 
yeast (4 g/kg) is injected as a large volume (20 ml/kg) slurry solution that requires large 
gauge (18G) hypodermic needles to inject and often requires two injection sites. Although 
the injection sites were on the nape of the neck, injection of the yeast was often 
accompanied by severe inflammation and swelling in the whole head region on the first 
day after injection. Secondly, after injection the yeast solution is encapsulated forming an 
abscess, which although probably aimed at preventing the spread of the pathogen, may 
have acted as a reservoir for slow release of PAMPs leading to the excessively prolonged 
sickness response. I also observed however that injecting rats with the medium dose 
induced a similarly excessive sickness response, the duration and magnitude of which 
was not much less than that induced by the high dose. The use of the medium dose of 
Brewer’s yeast therefore did not improve the protocol as far as animal welfare was 
concerned. The lowest dose used induced a very short-lived sickness response that was 
too short to allow for pharmacological testing. Owing to the animal welfare challenges 
associated with the excessive sickness induced by the high and medium doses of Brewer’s 
yeast I decided to investigate the possibility of using zymosan as an experimental pyrogen 
and to examine if this moiety of the yeast cell wall would induce the same suite of 
inflammatory mediators as does whole yeast. 
 
Subcutaneous administration of a moderately high (300 mg/kg) dose of zymosan induced 
reasonable fever and sickness behaviour that lasted long enough to allow for 
pharmacological intervention without inducing unnecessary suffering to the experimental 
animals. Zymosan administration was also associated with an increase in the same suite 
of inflammatory mediators in the periphery and the brain as those noted during Brewer’s 
yeast-induced sickness. Thus, current guidelines for antipyretic testing could consider 
incorporating zymosan as a pyrogen that can be used for inducing fever and sickness 
behaviours during antipyretic screening. In addition to inducing fever and sickness 
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behaviour, recent studies have also shown that zymosan-induced fever can be reduced by 
currently known antipyretics e.g. indomethacin and celecoxib (Bastos-Perreira et al., 
2017). The mechanisms underlying zymosan-induced fever therefore appear to be the 
same mediating most common febrile responses hence making it a suitable pyrogen for 
testing antipyretics. 
 
The current pharmacognostic protocol for antipyretic testing is based on a model of fungal 
infections and therefore may not provide a complete picture of the efficacy of test drugs 
against bacterial and viral infections. Because my study focused only on the most 
commonly recommended models for antipyretic drug testing, my characterisation was 
limited to Brewer’s yeast and its moiety zymosan and therefore did not include other 
bacterial or viral pyrogens. In Table 5.1, I have drawn a general comparison of the 
inflammatory response observed by other researchers during systemic and localised 
inflammation induced by LPS in rodents with what I observed in Brewer’s yeast and 
zymosan-induced sickness. Fever and sickness behaviours induced by the viral mimetic 
Poly I:C has also been shown to be mediated by the same inflammatory mediators and 
downstream pathways as LPS, Brewer’s yeast and zymosan (Field et al., 2010, Fortier et 
al., 2004).  These pyrogens appear to share common downstream mediators but the 
spatiotemporal appearance of these mediators may vary due to the activation of different 
upstream pathogen recognition receptors. For example, fungal pathogens interact with 
TLR 2, 6 and dectins, while bacteria and viruses interact with TLR4 and TLR3 
respectively. Current guidelines for testing antipyretics could incorporate other pyrogens 
of bacterial and viral origin e.g. LPS and Poly (I:C) respectively to complement Brewer’s 
yeast or zymosan in the determination of the efficacy of antipyretic drugs.  
 
In Chapter 3 and Chapter 4, I provide the measurable indices of sickness, both 
physiological and behavioural, associated with Brewer’s yeast and zymosan 
administration. These characteristics of the sickness response will help researchers to 
determine appropriate times for pharmacological interventions while the measurable 
physiological changes can act as a yardstick for determining the efficacy of test drugs. 
However, for one to successfully test an antipyretic drug there are a number of other 
important factors that they will have to consider which include: (1) the appropriate route 
of administration of the test drug; based on the physicochemical characteristics of the 
drug, (2) effective doses; based on the quantity and bioavailability of bioactive 
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compounds (normally requires rigorous chemical analyses) and (3) an appropriate time 
and frequency of administration which is dependent on the pharmacokinetics of the drug 
i.e. the rate of absorption, distribution and clearance. The determination of all these were 
outside the scope of this study’s objectives therefore I did not test any antipyretic drugs. 
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Table 5.1: Comparison of the inflammatory and sickness responses observed in rodents 
administered yeast, zymosan or LPS                                                                                                                                                                                                                                                                            
Response Brewer’s 
yeast 
(2-4 g/kg; 
s.c.) 
Zymosan 
(300 mg/kg; s.c.) 
Lipopolysaccharide 
(10 µg – 250 mg/kg; i.p or s.c) 
 References 
Fever ü ü ü (Harden et al., 2006, 
Schneiders et al., 2015) 
Lethargy ü ü ü (Harden et al., 2011, 
Schneiders et al., 2015) 
Anorexia and body mass 
stunting 
ü ü ü (Harden et al., 2006, 
Harden et al., 2011, 
Layé et al., 2000) 
Increased plasma IL-6 ü ü ü (Harden et al., 2011, 
Miller et al., 1997, 
Copeland et al., 2005) 
Increased plasma TNF-α ü ü ü (Roth et al., 2000, 
Copeland et al., 2005) 
Increased plasma IL-1β ? ? ü (Harden et al., 2011, 
Layé et al., 2000, 
Copeland et al., 2005) 
NF-kB activation in the 
OVLT 
ü ü ü (Rummel et al., 2006) 
STAT-3 activation in 
the OVLT 
ü ü ü (Rummel et al., 2006, 
Rummel et al., 2004, 
Harré et al., 2002) 
NF-IL6 activation in the 
OVLT 
ü ü ü (Schneiders et al., 2015, 
Damm et al., 2011) 
COX-2 activation in 
endothelial cells  
ü ü ü (Damm et al., 2011, 
Rummel et al., 2006) 
Upregulation of the 
expression of pro-
inflammatory cytokines 
(IL-1β, IL-6 and TNF-α) 
in the hypothalamus 
 
ü ü ü (Schneiders et al., 2015, 
Damm et al., 2011) 
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Upregulation of the 
expression of inducible 
enzymes (COX-2 and 
mPGES) in the 
hypothalamus 
 
ü ü ü (Schneiders et al., 2015, 
Rummel et al., 2006, 
Damm et al., 2011) 
Upregulation of the 
expression of regulators 
for transcription factors 
(SOCS3 and IkBa) 
ü ü ü (Schneiders et al., 2015, 
Rummel et al., 2006) 
 
Based on the findings obtained in this experiments described in this thesis, Table 5.2 
summarises the recommendations that could be incorporated into the current protocol in 
order to improve animal welfare and more importantly improve accuracy and reliability 
of findings during antipyretic drug-testing.  
5.2 Clinical relevance and recommendations  	
Saccharomyces cerevisiae is a ubiquitous yeast and has for a long time been regarded as 
safe and non-pathogenic. A growing body of evidence has however implicated S. 
cerevisiae as a causative agent for invasive fungal infections particularly in 
immunocompromised and postoperative patients suggesting that virulent and pathogenic 
strains of the yeast may be emerging (Aucott et al., 1990, Cimolai et al., 1987, Clemons 
et al., 1994, Muñoz et al., 2005). Thus, an understanding of yeast-immune interaction 
mechanisms and a knowledge of the sickness response associated with yeast infection 
would be useful in the development of therapeutic targets and management strategies for 
S. cerevisiae infections. My results provide the first experimental evidence of the 
involvement of some neuroinflammatory signalling pathways and mediators in the S. 
cerevisiae-induced sickness response. The lengthy febrile response and body mass-
stunting which are characteristic of Brewer’s yeast-induced sickness described in this 
study, could also serve as useful, measurable clinical indicators during diagnosis and 
treatment of S. cerevisiae infections. 
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Table 5.2: Recommended modifications to the current protocol for antipyretic testing 
 Current 
recommended  
protocol  
Recommended 
modifications and 
rationale 
Future work 
Animals Male or female 
young rats 
Male rats-  thermal 
responses in female rats 
may be affected by the 
oestrous cycle  
Comparison of 
thermal responses of 
males and females 
to consider effects 
of the oestrous cycle  
Pyrogen 2 – 4 g/kg Use of zymosan as 
alternative pyrogen since 
high doses of Brewer’s 
yeast are associated with 
animal welfare challenges; 
Development of 
protocols that utilise 
other pyrogens e.g. 
of bacterial or viral 
origin during 
antipyretic testing 
Route and site of 
administration 
Subcutaneous; 
Dorsum of neck 
Maintain- good success rate 
and reproducibility 
 
Time of injection Not specified Injection of Brewer’s yeast 
or zymosan just before dark 
phase so that the plateau 
phase (18 hours) falls 
during day 
 
 
Method of 
temperature 
measurement 
Rectal 
thermometry 
Biotelemetry since rectal 
thermometry is associated 
with stress-induced 
hyperthermia and technical 
limitations which affect 
accuracy, reliability and 
reproducibility or results. 
Determination of 
the effective 
habituation 
protocols for rectal 
thermometry 
Time and 
intervals of 
temperature 
measurement 
18 hours after 
pyrogen 
injection; hourly  
Plateau phase – 18 - 23 
hours (or beyond) for 
Brewer’s yeast and 9-18 
hours for zymosan. 
Temperatures are 
consistently high and do not 
change much during this 
phase  
 
Assessment of 
thermal responses in 
the thermoneutral 
environment  
Measurement of 
inflammatory 
mediators 
Not included Measurement of cytokines, 
transcription factors and 
hypothalamic gene 
expression to determine the 
mechanisms of action of 
test drugs 
Determination of 
other inflammatory 
mediators e.g. 
COX-1, COX-3, 
leptin 
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Measurement of 
sickness 
behaviours  
Not included Inclusion of sickness 
behaviours during 
antipyretic testing because 
these are a part of the 
sickness response and are 
often a cause of discomfort 
in patients. NB: Cage 
activity and food intake 
should be monitored during 
the dark phase.   
 
 
The individual contribution of each cytokine or signalling pathway to the febrile response 
or sickness behaviours induced by Brewer’s yeast was beyond the scope of my thesis and 
therefore was not thoroughly investigated. The studies I undertook sought to investigate 
the mediators that are activated during Brewer’s yeast-induced sickness, as a starting 
point in delineating the signalling pathways and mechanisms subserving the Brewer’s 
yeast-induced sickness response. However, the use of cytokine specific antisera and 
antagonists, if employed in future studies, may shed light on the contribution of each 
cytokine to the Brewer’s yeast-induced sickness response. Additionally, more clinical 
studies measuring blood cytokines in patients clinically confirmed to have S. cerevisiae 
infections may also assist us to further understand the involvement of these mediators 
during S. cerevisiae infection. 
 
In conclusion, I have provided the experimental evidence and explained the deficiencies 
of the current protocol used during antipyretic screening in pharmacognostic studies. I 
have highlighted the shortcomings of using rectal thermometry and have shown instead 
the reliability and reproducibility offered by biotelemetry. My results also clearly show 
the lengthy, excessive sickness response associated with injecting the large, 
recommended doses of Brewer’s yeast. To circumvent the animal welfare challenges 
associated with Brewer’s yeast administration, I have demonstrated that zymosan could 
be a useful alternative pyrogen to induce fever and sickness behaviour. My findings also 
provide the first experimental evidence of the involvement of inflammatory mediators in 
the S. cerevisiae-induced sickness response, an important first step towards the 
delineation of the mechanisms underlying S. cerevisiae infections.  
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